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Abstract 
Estradiol is the most potent estrogen in humans. It is known to be involved in development and 
proliferation of estrogen dependent diseases such as breast cancer and endometriosis. The last 
step of its biosynthesis is catalyzed by 17β-hydroxysteroid dehydrogenase type 1 (17β- HSD1) 
which consequently is a promising target for the treatment of these diseases. Recently, we 
reported on bicyclic substituted hydroxyphenylmethanones (BSHs) as potent inhibitors of 17β-
HSD1. Our goal in this study was to obtain a suitable candidate for proof of principle (PoP) 
study in an animal disease model for endometriosis. At a first stage, we focused on rational 
structural modifications in this compound class with the aim of gaining more insight into its 
structure-activity relationship (SAR). At a second stage, supplementary substituents were added 
to the most active core to enhance activity towards both human and rodent 17β-HSD1 enzymes. 
Thus, the most potent nonsteroidal inhibitors of h17β-HSD1 described so far have been 
discovered. Furthermore, a successful strategy was applied to improve the metabolic stability in 
human liver microsomes (S9 fraction). Compound II.43, one of the most interesting h17β-HSD1 
inhibitors in this study, showed a very good metabolic stability towards both phase I and II in 
human liver microsomes (S9 fraction), with 72 % remaining after 60 min. In addition, inhibition 
of rodent 17β-HSD1 was significantly improved. Compound II.47 could be considered a 
possible candidate for a PoP study (63 % inhibition of rat 17β-HSD1 @ 250 nM). 
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Zusammenfassung 
Estradiol ist das potenteste Estrogen beim Menschen. Es ist bekanntermaßen an Entstehung und 
Fortschreiten Estrogen-abhängiger Erkrankungen wie Brustkrebs und Endometriose beteiligt. 
Der letzte Schritt seiner Biosynthese wird durch 17β-Hydroxysteroid Dehydrogenase Typ 1 
(17β-HSD1) katalysiert. Daher ist dieses Enzym ein vielversprechendes Target für die 
Behandlung dieser Erkrankungen. Kürzlich berichteten wir über bicyclisch substituierte 
Hydroxyphenylmethanone (BSHs), die potente Inhibitoren der 17β-HSD1 darstellen. Das Ziel 
der vorliegenden Studie bestand darin, einen Wirkstoff-Kandidaten zu erhalten, der für die 
Indikation Endometriose eine proof of principle- (PoP-)Studie in einem Krankheitsmodell am 
Tier (Nager) ermöglicht. Dazu wurden zunächst rationale Strukturmodifikationen durchgeführt, 
die das Ziel hatten,  die Struktur-Wirkbeziehungen (SAR) dieser Wirkstoffklasse zu beleuchten. 
Aus den resultierenden Verbindungen wurde anschließend diejenige mit den interessantesten 
biologischen Eigenschaften ausgewählt, um durch Einfügen weiterer Substituenten die 
Hemmaktivität sowohl gegenüber der humanen als auch gegenüber Nager-17β-HSD1 weiter zu 
steigern. Aus diesen Arbeiten gingen die potentesten nichtsteroidalen Inhibitoren der humanen 
17β-HSD1 hervor, die bisher beschrieben wurden. Darüber hinaus wurde erfolgreich eine 
Strategie zur Verbesserung der metabolischen Stabilität in humanen Lebermikrosomen (S9-
Fraktion) angewandt. Verbindung II.43, eine der interessantesten Verbindungen der Studie, zeigt 
eine sehr hohe metabolische Stabilität: Nach 60 minütiger Inkubation liegen 72 % der 
Verbindung unverändert vor. Auch die Hemmung des Nager-Enzyms konnte signifikant 
verbessert werden. Verbindung II.47 kann als möglicher Kandidat für eine PoP-Studie an der 
Ratte angesehen werden (63 % Hemmung der Ratten-17β-HSD1 bei 250 nM). 
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1 Introduction  
1.1 Sex steroid hormones 
1.1.1 General 
Sex steroids are steroid hormones that interact with vertebrate androgen or estrogen 
receptors.
1
 A large proportion of androgens and estrogens in men and women are synthesized 
locally in peripheral tissues at their site of action from the inactive adrenal precursors 
dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) (fig. 1).
2
  
 
 
Figure 1. Schematic representation of the role of adrenal and ovarian sources of sex steroids in 
women. After menopause, the secretion of estradiol by the ovaries ceases and the sex steroids are 
synthesized locally in peripheral target intracrine tissues (taken from
2
) 
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Approximately 50 % of androgens in adult men and all active sex steroids in 
postmenopausal women are biosynthesized in target tissues by an intracrine mechanism. This 
means, that synthesis of active steroids occurs in peripheral target tissues in the same cells where 
steroid action is exerted without releasing in the extracellular space (fig. 2).
3
 
 
 
 
Figure 2. Schematic representation of endocrine, paracrine, autocrine and intracrine secretion 
(taken from
4
) 
 
 In peripheral intracrine tissues, DHEA-S is providing a large reservoir of substrate for 
conversion into estrogens and/or androgens as, in both women and adult men, plasma DHEA-S 
levels are much higher than those of estradiol and testosterone.
4
  
In the higher mammals, the target tissues of estrogens and androgens are able to adjust the 
formation and metabolism of sex steroids according to local requirements. This refers to almost 
all active sex steroids that are synthesized locally in peripheral tissues. This situation is very 
different in lower primates, where the exclusive sources of estrogens and androgens are the 
ovaries and testes.
3
 
Sex steroid hormone signaling regulates the development, growth, and functioning of the 
breast and the prostate and plays also a role in the development and progression of cancer in 
these organs.
5
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1.1.2 Estrogens 
Estrogens are steroid hormones that have estrane as backbone. Structurally, they differ from 
other steroid hormones by the aromatic A ring.
6
 The most potent naturally occurring member of 
this group is 17β-estradiol (E2). Its metabolites estrone (E1) and estriol (E3) have less affinity for 
the estrogen receptors and are weaker agonists.
7
 
The biosynthesis of estrogens, and all other hormones with steroidal structure, starts from 
cholesterol and involves cytochrome P450 enzymes.The transfer of cholesterol from the cytosol 
to the inner membrane of mitochondrion, where the cytochrome P450 enzymes are located, is the 
rate-limiting step in steroid production.
8
 
The final step of estrogen biosynthesis is the aromatization by a P450 aromatase 
monooxygenase enzyme complex, which catalyzis the conversion of androstendione (A4) and 
testosterone (T) into E1 and E2, respectively (fig. 3).
8
  
Cholesterol
O
O
O
OH
HO
O
HO
OH
Aromatazation
NADPH
Androstenedione (A4) Estrone (E1)
Testosterone (T) 17-estradiol (E2)
Aromatazation
NADPH
 
Figure 3: Schematic representation the conversion of Androstendione (A4) and Testosterone (T) 
into Estrone (E1) and 17β-estradiol (E2), respectively (taken from8) 
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Estrogens are subjected to a high first-pass effect of about 90%. The glucuronide or sulfated 
conjugates are excreted via the bile and partially hydrolyzed in the colon by bacteria, which 
allows re-absorption, so that estrogens are subjected to enterohepatic circulation.
6
 
Another possibility for metabolism consists in the hydroxylation and partial subsequent 
methylation to form catechols or methoxylated estrogens. Some of these derivatives such as 4-
hydroxyestrone and 16α-hydroxyestradiol are carcinogenic.8 
The multifaceted effects of estrogens include promoting the growth of female sex organs 
and the expression of the female secondary sex characteristics e.g. by increasing the 
subcutaneous fat depots.
6
 They also cause cyclic changes in the uterine mucosa and the viscosity 
of the cervical mucus and prepare the tissue for gestagen action by increasing the number of 
progesterone receptors. 
Estrogens appear to play an essential role in maintaining bone, as they display  
antiresorptive effects by inducing apoptosis of osteoclasts.
9
 In young men estrogens are required 
for epiphyseal closure and maintaining bone mass.
10
 
 
1.2 Estrogen-dependent diseases 
1.2.1 Breast cancer 
1.2.1.1 General 
Breast cancer is the most common cancer in women; the largest percentage of new cancer 
cases and cancer deaths in females are attributed to this tumor localization.
11
 But also the 
mammary gland of men can be affected, as the number of 520 cancer cases in Germany in 2008 
illustrates.
11
 Breast cancer mainly affects postmenopausal women, and the probability for the 
occurrence of the disease increases with endogenous estradiol concentrations.
12
 Other risk factors 
include postmenopausal obesity and intake of exogenous hormones.
13
 
Estrogens are well recognized to play an important role in the growth of hormone-dependent 
breast cancers.
14, 15
 There are two breast cancer categories: Estrogen receptor positive (ER
+
) and 
estrogen receptor-negative (ER
-
) tumors. Approximately 50% of breast cancers in 
premenopausal women and 75% of postmenopausal women are ER
+
,
16
 This can be explained by 
the fact that increased estradiol formation and consequently an increased activation of the ER can 
promote tumor growth.
17
 
In the following, the influence of estrogens is illustrated in hormone-dependent tumors. 
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Although the serum estradiol levels in postmenopausal women are lower than those of 
premenopausal women,
18, 19
 the intratumoral estradiol levels in pre- and postmenopausal patients 
are comparable.
19
 In postmenopausal women, high intratumoral estradiol (E2) levels are assumed 
to be maintained by intratumoral biosynthesis of estrogens.
20-22
 
This can take place via two different pathways.
23-25
 In the first one, androstendione (A4) is 
aromatized into estrone (E1) and then catalyzed by 17β-hydroxysteroid dehydrogenase type 1 
(17β-HSD1) into estradiol (E2; aromatase pathway).26-28 In the second pathway, estrone sulfate 
(E1S) is converted into E1 and then transformed into E2 by 17β-HSD1 (sulfatase pathway).29 
Both the intratumoral estradiol levels as well as the mRNA expression of the enzymes 
aromatase and sulfatase do not significantly differ between pre-and postmenopausal women, 
whereas both the mRNA expression of 17β-HSD1 and the ratio estradiol / estrone in the tumor 
tissue of postmenopausal women are higher.
29
 These results suggest that 17β-HSD1 influences 
the intratumoral estradiol synthesis,
29
 a supposition which is confirmed by the fact that increased 
17β-HSD1 expression is associated with a worse prognosis and a shorter response time.30 
 
 1.2.1.2 Treatment options 
The surgical removal of the primary tumor represents a frequently applied treatment of 
breast cancer, where in some cases a mastectomy is essential. A radio and / or chemotherapy 
treatment is often carried out prior to surgical removal of the tumor, as it would reduce the tumor 
to an operable size or to prevent recurrences after surgery.
31, 32
 
For estrogen-dependent breast cancer endocrine therapies represent the treatment of 
choice,
33, 34
 aiming at suppression of estrogen action by influencing the hormonal system.
34
 On 
one hand, this is possible by the inhibition of estrogen biosynthesis, on the other hand by 
blockage of the estrogen receptors. 
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Applied endocrine therapeutics: 
 Aromatase inhibitors (e.g. anastrozole): 
Suppression of estrogen formation by inhibiting the last step of E1 biosynthesis. 
 GnRH-analogues (gonadotropin-releasing hormone analogs such as buserelin): 
Complete suppression of estrogen formation in the organism by disrupting a central 
feedback mechanism,
35
 that controls the biosynthesis. 
 SERMs (selective estrogen receptor modulators such as tamoxifen) 
Preventing estrogen binding to the receptor, act as tissue-specific agonists or antagonists 
at the receptor. 
 Pure antiestrogens (e.g. fulvestrant): 
Preventing estrogen action at the receptor in the whole organism 
 
1.2.2 Endometriosis 
1.2.2.1 General 
Endometriosis is one of the most common causes of pelvic pain and infertility in women. It 
is defined as an ectopic occurrence of endometrial glands and stroma. So endometrial tissue 
grows outside the uterus, especially on the ovaries, the fallopian tubes and into the abdominal 
cavity. However, there is no correlation between the location and size of lesions and severity of 
symptoms. Endometriosis causes adhesions and scars. There may be severe pain, heavy bleeding 
and damage to the reproductive organs, which can ultimately lead to infertility. The etiology of 
endometriosis is still poorly understood. The most widely accepted theory  states that normal 
endometrial cells pass through retrograde menstruation into the peritoneal cavity and develop 
there after transplantation of endometriosis (transplantation theory of Sampson).
36
 
In contrast to normal endometrium, aromatase is expressed aberrantly in endometriosis and 
is stimulated by prostaglandin E2 (PGE2).
37
 Deficient expression of 17β- hydroxysteroid type 2 
(17β-HSD2), an enzyme which inactivates E2 to E1, is another abnormality in endometriosis. 
Since endometriosis is an estrogen-dependent disorder, 17β-HSD2 deficiency and aromatase 
expression are of paramount importance in the endometriosis pathophysiology.
37
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E2 enhances the cell proliferation and infestation of endometric tissues while both cytokines 
and prostaglandins mediate pain and infertility. E2 in women is either directly produced by the 
ovary or in extra-ovarian sites (skin and adipose tissue).
37
 
In the endometric tissue of both pre- and postmenopausal women, E2 is produced locally 
from androstendione (A) of adrenal and ovarian origins in two steps. Firstly, androstendione (A) 
is converted to E1 by aromatase and subsequently, E1 is further converted to E2 in the peripheral 
tissues by 17β-HSD1. Thus, in the postmenopausal period or during ovarian suppression, the 
major source for circulating E2 is extra-ovarian aromatase (fig. 4).
37
 
 
Figure 4. Extra-ovarian estrogen formation in women (taken from 
37
) 
 
In response to progesterone during the secretory phase, estradiol is normally deactivated in 
epithelial cells of the eutopic endometrium by conversion to E1 by 17β-HSD2.  Despite high 
levels of progesterone during the secretory phase, 17β-HSD2 expression is absent in 
endometriosis. This is indicative of selective progesterone resistance in this tissue.
37
 The local 
concentration of E2 in endometriotic tissue is thus increased due to this lack of 17β-HSD2 (fig. 
5).
37
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Figure 5. Defective inactivation of estradiol (E2) in endometriosis (taken from 
37
) 
 
1.2.2.2 Treatment options 
Endometriosis can be treated surgically by laparoscopy, but this usually provides only a 
temporary removal of endometriotic lesions, since the probability of relapse is very high. 
As drug treatment COX inhibitors are often used, as they reduce the inflammatory process 
of endometriosis,
38
 while helping to relieve pain. 
Another option for the treatment of endometriosis is the suppression of estrogen biosynthesis 
and lowering the E2 production, similar to the treatment of estrogen-dependent  breast cancer , 
the application of oral contraceptives, androgens and GnRH analogues used there to inhibit the 
growth of endometriotic lesions, affecting hormone balances in the whole organism and thereby 
exerting undesirable side effects such as weight gain and acne.
39
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1.2.3 Disadvantages of existing therapies 
Systemic reduction in estrogen concentration leads to a shift of the natural hormone balance 
throughout the body and can therefore lead to many well-known, unwanted and sometimes 
serious side effects. In addition to these side effects the applied therapies show other limitations: 
SERM may function by their tissue-specific cancers in other tissues such as the 
endometrium, where tamoxifen acts as an estrogen receptor agonist.
40, 41
 With antiestrogens and 
with aromatase inhibitors a frequent development of resistance is observed .
42
 Furthermore, 
aromatase inhibitors may be used only in postmenopausal women because they cause a strong 
stimulation of the ovaries through a hypothalamic / pituitary feedback mechanism in 
premenopausal women.
43
 
 
 
1.3 Hydroxysteroid dehydrogenases (HSDs) 
1.3.1 General 
Hydroxysteroid dehydrogenases (HSDs) belong to the oxidoreductases, which are 
responsible for the mutual reaction of ketones and their corresponding secondary alcohols. HSDs 
are NADPH or NAD
+
-dependent enzymes whichcatalyse the regio- and stereoselective 
oxidoreduction at different positions of their steroidal substrates (3α, 3β, 11β, 17β, 20α, 20β-
position). They are involved in the metabolism of various steroidal compounds.
44, 45
 
Several enzymes, namely 3β-hydroxysteroid dehydrogenase/Δ5- Δ4 isomerase (3β-HSD), 
17β-HSD are involved in the synthesis of the most potent natural estrogen E2 (fig. 6).4 
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Figure 6. Main biosynthetic and inactivating pathways of androgens and estrogens in humans 
(taken from 
4
) 
 
1.3.2 17β-HSDs 
1.3.2.1 General 
At least 14 different 17β-HSDs have been already identified to date,46, 47 of which 12 
subtypes have been detected in human tissue (17β-HSD6 and 9 were only found in rodents).47 
They belong to the short chain dehydrogenase/reductase (SDR) family.
48
 The only exception is 
17β-HSD5 which is an aldo-ketoreductase (AKR).49 The different isoforms of 17β-HSD have a 
relatively low amino acid sequence identity (25-30%).
50
 They also differ in tissue distribution, 
subcellular localization and catalytic preference (oxidation or reduction using cofactor NAD(H) 
or NADP(H)). 
17β-HSDs are required for the synthesis and inactivation of all active androgens and 
estrogens. Thus they control the intracellular occupation of the respective steroid hormone 
receptors.
51, 52
 For most of the steroid hormones HSD enzyme pairs are known which regulate 
the local levels of the active forms and their inactive metabolites. HSD can therefore be 
considered a molecular switch that can modulate the function of steroid hormones before they 
bind to the receptor.
4, 53
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Taking into account the intracrine concept many promising therapeutic approaches have 
been investigated. The blockade of specific steroidogenic enzymes by means of potent and 
selective inhibitors came more and more into focus as a strategy for treatment of hormone-
dependent diseases. This approach has been successfully implemented in various enzymes, can 
also affect steroid hormone concentrations locally. Key enzymes which are involved in androgen 
and estrogen biosynthesis are e.g. aromatase
54, 55 and 5α-reductase56, 57. 
In recent years 17β-HSDs gained major interest as potential drug targets for the treatment of 
sex steroid hormone-dependent diseases. This is due to two advantages of the group of 17β-
HSDs: first, their tissue-specific expression; on the other hand, the fact that they often catalyze 
the last step in the biosynthesis steroid hormone. This leads to the assumption that the inhibition 
of these enzymes in comparison with the aforementioned approaches (for example, inhibition of 
the aromatase) should result in fewer side effects, since a smaller influence on the systemic 
steroid hormone concentration is expected. 
The physiological function of five of 17β-HSDs enzymes is not clear yet, while nine 
subtypes are involved in diseases (like EDD) (table 1).
58
 The nomenclature of 17β-HSD enzymes 
is based on the chronological order of discovery.
59
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Table 1: Human 17β-hydroxysteroid dehydrogenases (taken from58). 
Type Gene 
SDR or AKR 
nomenclature 
Function Disease-association 
1 HSD17B1 SDR28C1 Steroid (estrogen) synthesis Breast & prostate 
cancer, endometriosis 
2 HSD17B2 SDR9C2 Steroid (estrogen, androgen, 
progestin) inactivation 
Osteoporosis 
3 HSD17B3 SDR12C2 Steroid (androgen) synthesis Pseudohermaphroditism 
in males associated with 
obesity 
4 HSD17B4 SDR8C1 Fatty acidβ‐oxidation, steroid 
(estrogen, androgen) inactivation 
D‐specific Bifunctional 
Protein‐deficiency, 
prostate cancer 
5 AKR1C3 AKR1C3 Steroid (androgen, estrogen, 
prostaglandin) synthesis 
Breast & prostate cancer 
6 HSD17B6 SDR9C6 retinoid metabolism, 3α‐ 3β-
epimerase, steroid (androgen) 
inactivation? 
 
7 HSD17B7 SDR37C1 Cholesterol biosynthesis, steroid 
(estrogen) synthesis 
Breast cancer 
8 HSD17B8 SDR30C1 Fatty acid elongation, steroid 
inactivation, estrogens, 
androgens 
Polycystic kidney 
disease 
9 HSD17B9 SDR9C5-2 Retinoid metabolism  
10 HSD17B10 SDR5C1 Isoleucine, fatty acid, bile acid 
metabolism, steroid (estrogen, 
androgen) inactivation 
X‐linked mental 
retardation MHBD 
deficiency Alzheimer’s 
disease 
11 HSD17B11 SDR16C2 Steroid (estrogen, androgen) 
inactivation, lipids? 
 
12 HSD17B12 SDR12C1 Fatty acid elongation, steroid 
(estrogen) synthesis 
 
13 HSD17B13 SDR16C3 Not demonstrated  
14 HSD17B14 SDR47C1 Steroid (estrogen, androgen?) 
inactivation, fatty acid 
metabolism 
Breast cancer, 
prognostic marker 
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1.3.2.2 Cell metabolism and unidirectional steroid flux in living cells 
In principle, all members of the 17β-HSDs are able to catalyze both reaction directions 
(oxidation and reduction). However, intracellularly, they show a clear preference for one 
direction of catalysis and are thus divided into oxidative and reductive enzymes.
60
 This is due to 
the fact that concentrations of substrates (keto- and hydroxysteroids) are much lower (nanomolar 
range) than the ones of cofactors [NADP(H) and NAD(H)] which are in the micromolar range. 
Furthermore, the ratios between NADP
+
 and its reduced form NADPH (NADPH/NADP
+ 
>500) 
and NADH and its oxidized form NAD
+
 (NAD
+
/NADH >700) are homestatically maintained by 
glucose metabolism and O2 supply (Fig. 7).
61
  
 
 
 
Figure 7: Interplay between intermediary metabolism and 17β-HSDs reactions (taken 
From 
61
). 
 
 
Another reason for the determination of the direction of the 17β-HSD catalysis is its high 
binding affinity for the phosphorylated and non-phosphorylated nicotinamide adenine 
dinucleotide (NAD) cofactor.
61
 Structures and mutagenesis studies showed that in the N-terminal 
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region of the Rossmann folds, which represent the cosubstrate binding sites, of 17β-HSD1 and 
17β-HSD3 (reductive 17β-HSDs), a positively charged amino acid (Arg37 in 17β-HSD162, 
Arg80 in 17β-HSD363) forms an ionic interaction with the 2'-phosphate moiety of NADPH. This 
greatly increases the affinity for the phosphorylated cosubstrate. On the contrary, in 17β-HSD2 
and 17β-HSD4 (oxidative 17β-HSDs) this arginine is replaced by a negatively charged amino 
acid (17β-HSD2, Glu11664; 17β-HSD4, Asp4050), which is considered to be the reason for 
NAD(H) specificity (Fig. 8).
58
 
 
 
 
 
 
Figure 8: Important amino acidresidues for cofactor recognition by 17β-HSDs. (A) Reductive 
17β-HSD1: interaction of Arg37with NADPH (PDB file: 1A27); (B) Oxidative 17β-HSD4: 
interaction of Glu41with NAD+ (PDB file: 1ZBQ); NADPH, NAD+, Arg37 and Asp41 rendered 
as sticks and labelled. Figure rendered with MOE (www.chemcomp.com) (taken from 
58
). 
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 1.3.3 17β-HSD1 
1.3.3.1 17β-HSD1 as a promising drug target 
17β-HSD1 catalyzes the last step in the estrogen biosynthesis by conversion of the weak 
estrogen E1 to the most potent estrogen E2 (Fig. 9). The latter plays a crucial role in the 
development and progression of hormone-dependent breast cancer and endometriosis, as 
mentioned above. Substantially, estrogens exert their effect by activation of the estrogen 
receptors α and β (ERα and ERβ). 
 
17-HSD2, NAD+HO
O
HO
OH
17-HSD1, NAD(P)H
E1                                                                                            E2  
Figure 9. Interconversion of Estrone (E1) and Estradiol (E2). 
 
Selective inhibition of 17β-HSD1 is considered an attractive therapeutic target for treatment 
estrogen-dependent diseases due to high levels of 17β-HSD1 expression at mRNA and protein 
level as well as an increased E2/E1 ratio. Several studies have shown that in the tumors of 
patients with ER
+
 breast cancer, the 17β-HSD1/2 ratio is increased.29, 65, 66 
The high concentration of E2 in endometriotic tissues is due to changes in the expression 
pattern of steroidogenic enzymes.
37
 In comparison to normal tissues, both aromatase and 17β-
HSD1 are upregulated at mRNA level in endometriotic lesions, while 17β-HSD2 is down 
regulated.
67, 68
 Consequently, the inhibition of 17β-HSD1 for the treatment of this disorder, is an 
innovative approach. 
17β-HSD1 inhibitors must be selective towards both type 2 enzyme (which catalyzes the 
reverse reaction) and estrogene receptors α and β (ER α and β) to avoid systemically estrogenic 
response. 
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1.3.3.2 Structural design 
Human 17β-HSD1 belongs to SDR family and is active as a soluble cytosolic homodimer. 
The subunits of the homodimer have a molecular weight of 34.9 kDa and consist of 327 amino 
acids.
69
 Till now, there are 20 crystal structures of 17β-HSD1 available in the Protein Data Bank 
(PDB).
70
 Among all of these structures, no 17β-HSD1 crystal structure complexed with substrate 
E1 exists. The published crystal structures cover apoform, holoform, binary complexes with 
androgens or inhibitors and ternary complexes with cofactor, E2 or inhibitors. 
 
Figure 10. 3D structure of human 17β-HSD1 (PDB ID: 1A27) cocrystallized with E2 and 
NADP+. 
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1.3.3.3 Catalytic mechanism of 17β-HSD1 
Although different mechanisms of catalysis functions of 17β-HSD have been described, they 
all have of the following chemical mechanism in common: a reversible hydride or proton transfer 
from NADPH or hydroxysteroid to ketosteroid or to NAD +. 
In the postulated catalytic mechanism of 17β-HSD1, the Pro-S hydride of NADPH is 
transferred to the “α-face” of estrone at the C17 carbon. Subsequently, the resulting oxygen 
anion is protonated by the acidic hydroxyl group of tyrosine. Several studies evidenced that the 
catalytic tetrad (Asp 114, Ser142, Tyr155 and Lys159) and a water molecule form an H-bond 
network which is responsible for proton transfer and plays a critical role in the substrate 
stabilizing process Fig. 11.
71-74
  
 
 
 
Figure 11: Scheme of the possible catalytic mechanism for 17β-HSD1.73 
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1.3.3.4 Animal models for in vivo evaluation of 17β-HSD1 inhibitors 
In various animal models, the physiological role of the 17β-HSD1 and its inhibition has been 
investigated and confirmed as therapeutic approach for breast cancer. In lower mammals, the 
ovaries and not the peripheral target tissues (as in man and higher primates) are the primary 
sources of estrogens. To overcome the considerable interspecies differences between lower 
species and human in 17β-HSD1 tissue distribution and moderate sequence homology and 
identity of the orthologs, xenograft models were developed using nude mice.
17, 75-81
 
Recently, several animal models were established in order to gain insight into 
pathophysiological role of this enzyme in the development of estrogen-dependent diseases as 
well as with aim of testing 17β-HSD1 inhibitors in vivo. 
 
 
1.4 17β-HSD1 Inhibitors 
1.4.1 General 
During the last years, several publications and patents on 17β-HSD1 inhibitors and their 
progress have been published.
17, 58, 82-86
 This fact highlights the great potential of this target for 
drug research.  
17β-HSD1 inhibitors should be selective towards type 2 enzyme, non-estrogenic, and show 
acceptable ADME and toxicity parameter.
87
 Both steroidal and non-steroidal 17β-HSD1 
inhibitors are described to bind to the cofactor pocket and/or the steroid binding cleft. One 
exception are phytoestrogens which seem to interact with the dimer interface of 17β-HSD1.88 
 
 1.4.2 Steroidal 17β-HSD1 inhibitors 
The steroidal 17β-HSD1 inhibitors are based on the steroidal ring system (E1 and E2 core). 
In addition to variations at position 2, 6, 15, 16, and 17, the sterane skeleton was extended with 
an additional E-ring.
89-97
 The side chain derivatives at the C2, C15 and C16 positions showed the 
best biological results (Fig. 12). Steroidal inhibitors showed some drawback like insufficient cell 
membrane penetration (comp. IV) or estrogenicity (comp. V). 
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Figure 12: Examples for steroidal 17β-HSD1 inhibitors. 
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1.4.3 Non-steroidal 17β-HSD1 inhibitors 
Non-steroidal inhibitors (fig. 13)
98-117
 show advantages compared to steroidal ones such as 
selectivity and drug-likeness. Thiophenpyrimidinones represent a large class inhibitors of 17β-
HSD1. Generally, they can be divided into two generations. The first potent agents have been 
described by Messinger et al. and contained, in contrast to the second generation of three instead 
of four fused rings as a basic structure, which are two of the most active 17β-HSD1 inhibitors to 
date. Recently, coumarin derivatives were published as potent non-steroidal inhibitors of 17β-
HSD1.
118, 119
 
The most potent non-steroidal inhibitors so far were described by the Hartmann group. Four 
classes have been developed:  a) (Hydroxyphenyl)naphthols (e.g. IV), b) 
Bis(hydroxyphenyl)substituted arenes (e.g. V), c) Bicyclic substituted 
hydroxyphenylmethanones (e.g. VI) and d) Hydroxybenzothiazoles (e.g. VII). 
I, 94% inhibition @ 100 nM II, IC50 = 5 nM
O
O
O
HO
S
N
N
O
SH
O
S
N
N
O
OH
Br O
O
O
HO
OH
NH
S
O
O
S
OH
OH
F
SO
HO
OH
N
S
OH
HN
O
F
F
HO
III, IC50 = 270 nM
IV, IC50 = 15 nM V, IC50 = 8 nM VI, IC50 = 8 nM VII, IC50 = 13 nM  
Figure 13: Examples for non-steroidal 17β-HSD1 inhibitors described. 
Especially interesting are bicyclic substituted hydroxyphenylmethanones which showed very 
good inhibitory activity in both cell-free and cellular assays and good selectivity towards both 
type 2 enzyme and estrogen receptors α and β. 
OUTLINE 
21 
 
2 Outline  
2.1 Scientific goal 
Estrogens are an important factor in the development and progression of estrogen-dependent 
diseases (EDDs) such as breast cancer and endometriosis. Existing endocrine therapies in the 
treatment of EDDs are associated with numerous side effects due to the fact that the estrogenic 
activity in the whole body is radically lowered. 
17β-HSD1 is the enzyme that catalyses the last step in the biosynthesis of E2 from the weak 
precursor E1 and has been found strongly overexpressed in diseased tissues of patients affected 
by EDDs. Thus, inhibition of this enzyme is a promising novel strategy for the treatment of these 
diseases with the prospect of fewer side effects since systemic estrogen action should be less 
affected. 
The effectiveness of 17β-HSD1 inhibition to reduce the estrogen stimulated growth of human 
tumor cell lines has already been proven in various in vivo assays, but no 17β-HSD1 inhibitor 
has entered clinical trials yet, emphasizing the need for research in this field. 
There is, however, no suitable candidate for a PoP study in an animal (rodent) model for 
endometriosis. In part this is due to interspecies differences between human 17β-HSD1 and its 
rodent orthologs. As a result, many compounds which are highly active towards the human 
enzyme show no or only weak inhibition of murine or rat 17β-HSD1 
Accordingly, the main goal of the present thesis was the design, the synthesis and the 
biological evaluation of potent and selective non-steroidal inhibitors of both the human and 
rodent 17β-HSD1 enzymes. Suitable 17β-HSD1 inhibitors should display the following 
characteristics: 
- Potency against h17β-HSD1. 
- Activity against m/r 17β-HSD1. 
- Selectivity towards the type 2 enzyme. 
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- Selectivity towards ERα and β. 
- Favorable ADMET parameters. 
Inhibitor design should aim at the identification of a suitable candidate for a PoP study in an 
in vivo animal disease model for endometriosis  
 
2.2 Working strategy 
The class of bicyclic substituted hydroxyphenylmethanones (BSHs), which was described by 
our group previously, contains some of the most potent and selective non-steroidal inhibitors of 
human 17β-HSD1. In addition, several compounds show inhibition of the murine otholog which 
makes them valuable starting points in the search for a suitable PoP candidate. 
Interesting structure activity relationships (SARs) have been derived previously in this class 
of compounds and resulted in a conception concerning the interactions between the inhibitors 
and the target enzyme, derived using computational methods (molecular docking). The 
knowledge on SAR, however, was still fragmentary. 
A problem of the class of BSHs is the presence of phenolic OH- groups which preclude the 
use of many compounds in an in vivo study due their high liability towards phase II metabolism.   
Therefore, our objective in this thesis was – firstly - to obtain more insight in the SARs of 
BSHs by rational structural modifications. This procedure should also allow to estimate the 
validity of the docking results (Chapter 3.I).  
Subsequently, rational strategies were applied to elucidate drug metabolism and to obtain 
metabolically stable compounds (chapter 3.II). In addition, the designed compounds were 
consistently screened for their inhibitory activity towards rodent 17β-HSD1. Furthermore, the 
implementation of favorable in vitro ADME parameters (lipophilicity, solubility) was taken into 
account. 
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Figure 14: structure overview of the molecules described in this thesis 
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3 Results 
3.I Inhibition of 17β-HSD1: SAR of Bicyclic Substituted 
Hydroxyphenylmethanones and Discovery of New Potent 
Inhibitors with Thioether Linker 
This chapter is submitted to the European Journal of Medicinal Chemistry for publication. 
 
 
Abstract 
 
Estradiol is the most potent estrogen in humans. It is known to be involved in development and 
proliferation of estrogen dependent diseases such as breast cancer and endometriosis. The last 
step of its biosynthesis is catalyzed by 17β-hydroxysteroid dehydrogenase type 1 (17β- HSD1) 
which consequently is a promising target for the treatment of these diseases. Recently, we 
reported on bicyclic substituted hydroxyphenylmethanones as potent inhibitors of 17β-HSD1. 
The present study focuses on rational structural modifications in this compound class with the 
aim of gaining more insight into its structure-activity relationship (SAR). (4-Hydroxyphenyl)-(5-
(3-hydroxyphenylsulfanyl)-thiophen-2-yl)methanone (25) was discovered as a member of a 
novel potent class of human 17β-HSD1 inhibitors. Computational methods were used to 
elucidate its interactions with the target protein. The compound showed activity also towards the 
murine 17β-HSD1 enzyme and thus is a starting point for the design of compounds suitable for 
evaluation in an animal disease model. 
 
Introduction 
 
The important roles of estrogens and androgens in female and male development and 
reproduction are well known.
1
 They exert their effects by transactivation of the respective 
nuclear receptors,
2
 although also non-genomic effects are discussed.
3
 However, these steroidal 
sex hormones are also involved in the genesis and the progression of diseases. Estrogens are 
known to stimulate the progression of estrogen-dependent diseases (EDD) like endometriosis, 
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the majority of breast cancers, and uterine leiomyoma.
4-7
 Besides surgery, chemo- and 
immunotherapy, the inhibition of estrogen biosynthesis and the blockade of estrogen action, 
respectively, are today standard therapies for these diseases. These treatments (with aromatase 
inhibitors, GnRH-analogs, antiestrogens, selective estrogen receptor modulators (SERMs)), 
however, have a systemic mode of action, i.e. they reduce estrogen effects not only in the 
diseased tissue. As a result, they may lead to considerable side effects. A novel approach mainly 
aiming at lowering intracellular estrogen production in the diseased tissue could be a significant 
improvement for EDD therapy. Such an intracrine approach is presently being pursued using 
steroid sulfatase inhibitors in the treatment of hormone-dependent cancers
8
, and is already 
successfully applied in the treatment of androgen dependent diseases (ADD) by using 5α-
reductase inhibitors.
9
 
More recently, 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1, SDR28C1) has attracted 
attention as a potential target for the treatment of EDD. The enzyme catalyses the final step of 
estradiol (E2) biosynthesis which is the most potent estrogen in humans (fig. 1). 
 
17-HSD2, NAD+HO
O
HO
OH
17-HSD1, NAD(P)H
E1                                                                                            E2  
Figure 1. Interconversion of Estrone (E1) and Estradiol (E2). 
 
17β-HSD1 is described to be overexpressed at mRNA level in breast cancer tissue10-12 and 
endometriotic lesions.
13
 Since a more local mode of action can be anticipated compared to 
existing medical treatments, its selective inhibition is regarded as a promising strategy for the 
treatment of EDD, with the prospect of less side effects. No 17β-HSD1 inhibitor has entered 
clinical trials until now, but there is experimental evidence that inhibition of the enzyme is 
effective against estrone (E1) induced growth of human tumor cells in vitro and in vivo.
14-17
 The 
availability of compounds not only inhibiting the human enzyme but also 17β-HSD1 of another 
species would be a prerequisite for a proof of principle study concerning the applicability of 17β-
HSD1 inhibitors in the treatment of endometriosis. 
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17β-HSD2 can be considered as a functional counterpart of the type 1 enzyme as it de-activates 
E2 by transforming it to E1. Thus, it plays a protective role against too high E2 concentrations 
and should therefore not be inhibited by 17β-HSD1 inhibitors. 
Both steroidal
18, 19
 and non-steroidal
20-31
 17β-HSD1 inhibitors have been described in the past. 
Recently we reported on bicyclic substituted hydroxyphenylmethanones
32
 (general structure, fig. 
2) which combine low molecular weight with high inhibitory potency (high ligand efficiency) 
and show strong intracellular activity. The aim of the present study is to obtain more insight in 
the structure activity relationships (SARs) of this compound class by rational structural 
modifications. Moreover, the inhibitory activities of the synthesized compounds are used to 
verify previous docking results
32
 using a broader base of biological data. 
 
SO R1
HO
R1, R2: e.g. H, OH, O-alkyl, CN, hetaryl
R2
 
Figure 2. Bicyclic substituted hydroxyphenylmethanones: General structure. 
 
Design 
 
Starting point for the design of compounds 1-28 (chart 1) were our conceptions concerning the 
binding mode of bicyclic substituted hydroxyphenylmethanones (fig. 3)
32
: Previous molecular 
docking results suggest 
a) A hydrogen bond interaction of the hydroxy group of the benzoyl moiety with Asn152. 
b) A bifurcated H-bond between the carbonyl group and the hydroxyl groups of Ser142 and 
Tyr155 
c) Another bifurcated H-bond between the OH-group of the hydroxyphenyl moiety and the 
side chains of His221 and Glu282 
d) The close proximity of the side chains of Tyr218 and Ser222 to the inhibitor 
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Figure 3. Schematic H-bond interactions of bicyclic substituted hydroxyphenylmethanones with 
17β-HSD1.32 
 
In order to evaluate the structure activity relationships in this compound class, the different 
structural features mentioned above (a-c) were replaced by possible bioisosteres or other 
functional groups, see fig. 4 (modifications a-c). This procedure should also allow to estimate the 
validity of the docking results (fig. 3). In addition, attempts were made to establish additional 
interactions to Tyr218 and Ser222 by introducing a second linker function, between the 
heterocycle and the hydroxyphenyl moiety (modification d). 
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Figure 4. Design of potential inhibitors 1-28. 
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17-28
S
1-9
O
R2
S
10-16
O
R2
R1
R1 HN
X
Y
R2
 
 
Comd R1 R2 X Y Comd R1 R2 W Z 
1 H H - - 17 3-OH H CF2 - 
2 CH3 H - - 18 3-OH H C=S - 
3 Cl H - - 19 3-OH H CH2 - 
4 COOCH3 H - - 20 3-OH H C=CH2 - 
5 COOH H - - 21 3-OH 3-CH2OH C=O - 
6 NH2 OC2H5 - - 22 3-OH 4-CH2OH C=O - 
7 NHSO2CF3 OC2H5 - - 23 3-OH 3-OCH(CH3)2 C=O - 
8 NHCH(CH3)2 OC2H5 - - 24 3-OH 3-OCH2CH(CH3)2 C=O - 
9 NHC(S)NHCH3 OC2H5 - - 25 3-OH 3-OH C=O S 
10 - OC2H5 CH2 H 26 3-OH 3-OH C=O SO2 
11 - OC2H5 SO2 H 27 4-OH 3-OH C=O S 
12 - OC2H5 SO2 3-CN 28 4-OH 3-OH C=O SO2 
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Comd R1 R2 X Y Comd R1 R2 W Z 
13 - OC2H5 SO2 4-OCH3      
14 - OC2H5 CO H      
15 - OC2H5 CO CO2CH3      
16 - OC2H5 CO CO2H      
Chart 1: Overview on synthesized compounds 1-28. 
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Chemistry 
 
The synthesis of compounds 1-16 (scheme 1) started from 2-bromothiophene which – for the 
preparation of 1-5 – was coupled with phenylboronic acid in a Suzuki-reaction.33 Friedel-Crafts 
acylation of the resulting intermediate 1a
34
 with the appropriate benzoic acid chloride gave 
compounds 1-4.
35
 The intermediate 17c, which was the starting material for the syntheses 
according to scheme 2, was prepared in the same way. Saponification of the ester 4 led to the 
carbonic acid 5.  
For the synthesis of compounds 6-16, 2-bromothiophene was converted to the ketone 6b
36
 via 
Friedel-Crafts acylation with 3-nitrobenzoyl chloride. Reduction of the nitro-group with stannous 
chloride dihydrate gave amine 6a which was submitted to a Suzuki reaction with 3-
ethoxyphenylboronic acid. The resulting compound 6 was reacted with 2-bromopropane and 
benzyl bromide to give the secondary amines 8 and 10, respectively. In the synthesis of the 
former, copper(II)-oxide had to be added as a catalyst. The thiourea 9 was obtained by reaction 
of 6 with methylisothiocyanate. The reaction of 6 with sulfonic acid chlorides at room 
temperature yielded the corresponding sulfonic acid amides 7 and 11-13. For the analogous 
preparation of the carbonic acid amides 14 and 15, higher reaction temperatures had to be 
applied (pyridine, reflux, overnight). Hydrolysis of the ester 15 under basic conditions gave the 
carbonic acid 16. 
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cmpd R cmpd X R cmpd X R 
7 SO2CF3 10 CH2 H 13 SO2 4-OMe 
8 CH(CH3)2 11 SO2 H 14 CO H 
9 C(S)NHCH3 12 SO2 3-CN 15 CO COOMe 
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Scheme 1: a) method A, Cs2CO3, Pd(PPh3)4, DME/water (1:1), reflux, 18 h. b) method B, AlCl3, 
anhydrous CH2Cl2, 0
o
C, 0.5 h to rt, overnight. c) LiOH, MeOH/H2O (7:3). d) SnCl2·2H2O, CH3OH, 
reflux, 2 h. e) method D, RSO2Cl or RCOCl, Pyridine, rt or reflux, overnight (compounds 7, 11-15); 2-
bromopropane, CuO, KOH, DMF, reflux, 4 days (compound 8); CH3NCS, THF, Et3N, reflux, overnight 
(compound 9); (bromomethyl)benzene, K2CO3, acetone, rt, 10 h (compound 10). f) 10% NaOH, ethanol, 
reflux, 2 h. 
 
Starting point for the modifications of the carbonyl group between the aromatic moieties was 
compound 17c (scheme 2). The conversion to the CF2-group (compound 17a) with DAST could 
not be achieved directly but after formation of the thioketone 17b using Lawesson’s reagent.37 
From 17a and 17b the corresponding phenols 17 and 18 could be obtained by ether cleavage 
(BBr3, method C).
38
 Reduction of the keto function of compound 17c with stannous chloride 
dihydrate gave the methylene intermediate 19a, whereas Wittig reaction with 
methyltriphenylphosphonium bromide afforded the olefin 20a. Upon treatment with BBr3 in 
anhydrous CH2Cl2 (method C) both 19a and 20a underwent demethylation resulting in the final 
compounds 19 and 20, respectively. 
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Scheme 2: a) Lawesson´s reagent, toluene, reflux, 2 h. b) DAST, abs. CH2Cl2, rt, 3 h. c) method C, BBr3, CH2Cl2, -
78
o
C to rt, overnight. d) SnCl2·2H2O, acetic acid, HCl, reflux, overnight. e) methyltriphenylphosphonium bromide, 
n-BuLi, abs. THF, rt for 2.5 h then 65
o
C overnight.  
 
The first step in the synthesis of compounds 21-24 was a Friedel-Crafts acylation (method B) of 
2-bromothiophene with 3-methoxybenzoylchloride, leading to the benzoylated key intermediate 
21b
32
. The corresponding 4-methoxy isomer 27b, which was the starting material for one of the 
syntheses depicted in scheme 4, was synthesized accordingly. Compounds 21 and 22 were 
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prepared from 21b by Suzuki cross coupling reactions with the appropriate commercially 
available boronic acids, resulting in compounds 21a and 22a, and subsequent demethylation. The 
synthetic pathway leading from 21b to the final compounds 23 and 24 required the replacement 
of the methoxy- by a benzyloxy-group (compound 23c) which was accomplished via the 
phenolic intermediate 23d
32
. A subsequent Suzuki cross coupling reaction with 3-
hydroxyphenylboronic acid led to compound 23b which was alkylated using isopropyl- and 
isobutyl iodide to afford the ethers 23a and 24a, respectively. Selective debenzylation using BCl3 
instead of BBr3 (method C) yielded the final compounds 23 and 24 (scheme 3). 
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Scheme 3: a) method B, AlCl3, anhydrous CH2Cl2, 0 
o
C, 0.5 h to rt, overnight. b) method A, Cs2CO3, Pd(PPh3)4, 
DME/water (1:1), reflux, 18 h. c) method C, BBr3, CH2Cl2, -78
o
C to rt, overnight. d) R-I, Cs2CO3, acetone, reflux, 
overnight. e) method C, BCl3, CH2Cl2, -78
o
C to rt, overnight. 
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The synthesis of sulfides (25 and 27) and sulfones (26 and 28) is depicted in scheme 4.  The 
intermediates 21b and 27b were transformed to the sulfides 25a and 27a, respectively, using 3-
methoxybenzenethiol in aqueous dimethylformamide in the presence of potassium hydroxide and 
copper(II)-oxide as catalyst. The methoxy functions were cleaved with BBr3 according to 
method C to yield the hydroxylated compounds 25 and 27. The sulfones 26 and 28 were obtained 
from 25 and 27, respectively, by oxidation with hydrogen peroxide in acetic acid at room 
temperature. 
 
b
26, 3-OH
28, 4-OH
25, 3-OH
27, 4-OH
c
a
O
SH
25a, 3-OCH3
27a, 4-OCH3
S
Br
21b, 3-OCH3
27b, 4-OCH3
O
O
S
S
O
HO
S
S
O
HO
S
S
O
HO
HO
O
O
O
HO
 
 
Scheme 4: a) CuO, KOH, DMF, 135
o
C, 2 h. b) method C, BBr3, CH2Cl2, -78
o
C to rt, overnight. c) H2O2 (30%), 
acetic acid, rt, 4 days. 
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Biological results 
 
Inhibition of human 17β-HSD1 and selectivity towards human 17β-HSD2 
Human placental enzymes were used for both assays and were obtained according to described 
methods.
39-41
 In the h17β-HSD1 assay, incubations were run with cytosolic fractions, tritiated 
E1, cofactor and inhibitor. The separation of substrate and product was accomplished by HPLC. 
The h17β-HSD2 assay was performed similarly using tritiated E2 as substrate and a microsomal 
fraction. Activities are given as percent inhibition at 1 µM (tables 1-3). For the most active 
compounds IC50 values are reported (table 3). Compounds A-C identified in our previous work 
were used as reference compounds.
32
 
Modification a 
In the search for an appropriate replacement of the hydroxy-group at the benzoyl moiety several 
structural modifications starting from the reference compounds A and B were investigated.
30
 
Simple omission of the OH-group (modification a; fig. 4), i.e. replacement with H, led to the 
inactive compound 1 (table 1). Furthermore, different functionalities such as Me, Cl, CO2H, 
CO2CH3, and NH2 (compounds 2–6, respectively) were introduced. The substitutents were 
chosen considering the Craig plot (variation of the size, lipophilicity, and electronic properties)
42
 
as well as their ability to form hydrogen bond interactions with the target. Compounds 1-5 were 
inactive or showed only marginal inhibition of 17β-HSD1. The introduction of an amino group, 
which is at physiological pH the only hydrogen bond donor of the selection, led to the 
conservation of a residual activity (compound 6, 24% at 1 µM). These results demonstrate the 
importance of the hydrogen bond donor function at this position, and are in agreement with the 
previous hypothesis that an H-bond interaction is established with Asn152 of 17β-HSD1.30, 32 
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Table 1. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 
A, B and 1-6. 
 
SO SO
O
A, 1-5 B, 6
R R
 
cmpd R % inhibition @ 1 µM
a
 
h17β-HSD1b h17β-HSD2c 
A OH 80 94 
1 H n.i. n.i. 
2 CH3 14 n.i. 
3 Cl n.i. n.i. 
4 COOCH3 14 11 
5 COOH 18 n.i. 
B OH 88 69 
6 NH2 24 n.i. 
a
 Mean value of three determinations, standard deviation less than 15%. 
b
 Human 
placenta, cytosolic fraction, substrate [
3
H]-E1, 500 nM, cofactor NADH, 500 
µM. 
c
 Human placenta, microsomal fraction, substrate [
3
H]-E2, 500 nM, 
cofactor NAD
+
, 1500 µM. n.i. = no inhibition (inhibition <10%). 
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Attempts were made to enhance the inhibitory activity of compound 6 by modulating the 
hydrogen bond donating properties of the NH2-group. For this purpose, several electron-
withdrawing or –donating substituents were introduced. These modifications, however, led to a 
complete loss of activity (compounds 7-16, chart 1), probably due to the bulkiness of the 
introduced groups. 
Modification b 
Modifications of the keto-linker function (modification b; fig. 4) had a strong impact on 
biological activity, depending on the nature of the linker group: The thioketo-analog 18 of the 
reference compound A only showed a slightly reduced inhibitory potency (75 % vs. 80 % inhibn. 
at 1 µM, table 2). In contrast, replacement of the keto-group with an olefinic moiety (compound 
20) or saturated groups (compounds 17 and 19) led to a strong decrease of inhibitory activity. 
None of the four compounds 17-20 showed selectivity over 17β-HSD2. 
Modification c 
Another structural element under investigation in this study was the phenolic OH-group on ring 
C which was replaced by a hydroxymethyl-group and different ether functions (modification c; 
fig. 4). These structural variations led to highly active compounds: The formal insertion of CH2 
between the aromatic ring (3- or 4-position) and the OH-group afforded the benzylic alcohols 21 
and 22, showing complete inhibition of h17β-HSD1 at a concentration of 1 µM (table 2). Also 
the bulky ether derivatives 23 and 24 strongly inhibited the target enzyme. All four compounds 
displayed similarly low IC50-values in the range of 90 nM to 157 nM (table 3), but no selectivity 
over the type 2 enzyme with the exception of compound 24 (SF = 5.5). 
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Table 2. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds A, 
C and 17-28. 
 
SX
SO
Y
A, C, 17-24 25-28
HO
R
R
A
B C
A
B
C
HO
3
4
3
4
 
 
cmpd X R Y % inhibition @ 1 µM
a
 
h17β-HSD1b h17β-HSD2c 
A C=O H - 80 94 
17 CF2 H - 35 36 
18 C=S H - 75 85 
19 CH2 H - 16 29 
20 C=CH2 H - 33 49 
C C=O 3-OH - 89 89 
21 C=O 3-CH2OH - 100 100 
22 C=O 4-CH2OH - 100 81 
23 C=O 3-O-isopropyl - 82 73 
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24 C=O 3-O-isobutyl - 85 51 
25 - 3-OH S 84 70 
26 - 3-OH SO2 70 76 
27 - 4-OH S 66 79 
28 - 4-OH SO2 62 80 
a
 Mean value of three determinations, standard deviation less than 15%. 
b
 Human 
placenta, cytosolic fraction, substrate [
3
H]-E1, 500 nM, cofactor NADH, 500 µM. 
c
 
Human placenta, microsomal fraction, substrate [
3
H]-E2, 500 nM, cofactor NAD
+
, 1500 
µM. n.i. = no inhibition (inhibition <10%). 
 
Modification d 
Compounds bearing an additional linker group, namely between the thiophene ring and the 
hydroxyphenyl ring C (modification d; fig. 4), showed slightly reduced activity towards the 
target enzyme, compared to the reference C (IC50 = 22 nM) when the OH-group on the benzoyl 
moiety was in the 4-position (compounds 27 and 28, tables 2 and 3). Moving the OH-group to 
the 3-position, however, resulted in compounds 25 and 26 with higher activities (IC50 = 104 nM 
and 275 nM, respectively). Thus, concerning the hydroxybenzoyl moiety, the SAR of these novel 
compounds with two linker functions appears to be similar to that found previously for 
compounds bearing the keto-linker group only.
32
 The compounds 25-28 showed comparable 
IC50-values for the inhibition of h17β-HSD1 and 2 (table 3).  
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Table 3. IC50 values and selectivity factors for compounds C 
and 21-28.  
cmpd IC50 [nM]
a
 SF
d
 
h17β-HSD1b h17β-HSD2c 
C 22 109 5.0 
21 90 51 0.6 
22 157 202 1.3 
23 120 224 1.9 
24 152 836 5.5 
25 104 245 2.4  
26 275 283 1.0 
27 752 247 0.3 
28 630 389 0.6 
a
 Mean value of three determinations, standard deviation less than 15%. 
b
 
Human placenta, cytosolic fraction, substrate [
3
H]-E1, 500 nM, cofactor 
NADH, 500 µM. 
c
 Human placenta, microsomal fraction, substrate [
3
H]-
E2, 500 nM, cofactor NAD
+
, 1500 µM. n.i. = no inhibition (inhibition 
<10%). 
d
 Selectivity factor: IC50(17β-HSD2) / IC50(17β-HSD1). 
 
Inhibition of murine 17β-HSD1 
 
The murine 17β-HSD1 enzyme was expressed in HEK293 cells. The inhibitory potencies of 
compound 25 and the reference compound C were evaluated in an assay similar to those of the 
human enzyme. 
Compound 25 turned out to be an inhibitor of murine 17β-HSD1 (20 % inhibn. at 1 µM; C: 10 
%). This is notable since the human and the murine enzymes differ considerably in primary 
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structure
43
 and most of the compound classes described by us to show strong inhibition of human 
17β-HSD1 are inactive towards the murine enzyme (unpublished results). Thus, compound 25 is 
a valuable starting point for the design of more potent and selective inhibitors of the murine 
enzymes that allow for in vivo evaluation (proof of principle).  
 
Molecular modeling 
Computational methods were used in order to elucidate the binding modes of the novel inhibitors 
with two linker functions. Molecular docking results indicate that both thioether 25 and sulfone 
26 fit well into the steroid binding pocket of h17β-HSD1 (fig. 5). Interestingly, they dock 
inversely: The sulfone moiety of compound 26 and the keto-group of 25 are located in the same 
region of the binding pocket which is distant from Tyr218 and Ser222. An interaction of the 
sulfone group with these amino acids, which was aimed at, would thus be unlikely.  
 
 
 
Figure 5. Compounds 25 and 26, docked into human 17β-HSD1 (PDB: 1FDT). Upper left: 
Cofactor NADPH. 
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Ligand-protein interactions can be seen in more detail in figure 6: Both compounds form a 
hydrogen bond with the key amino acid residue, Ser142. Considering compound 25, this bond is 
formed via the keto-group of the inhibitor, whereas in case of compound 26 the sulfone moiety is 
the interaction partner for Ser142 while the keto-group does not appear to play a role in protein 
binding.  
The reversed docking poses of 25 and 26 seem to have an additional effect on ligand-protein 
interaction: Whereas both phenolic OH-groups of compound 25 are suggested to be involved in 
hydrogen bonding (with Tyr155 and His221), only one such interaction (with Glu282) can be 
found for 26. This is in agreement with the higher inhibitory potency of 25 (IC50 = 104 nM; table 
4) compared to 26 (IC50 = 275 nM). 
 
  
 
Figure 6. Suggested binding modes showing three H-bonds to Tyr155, Ser142 and His221 for 
compound 25 (left) and two H-bonds to Glu282 and Ser142 for 26 (right). 
 
Discussion and Conclusions 
 
The aim of our study was the elucidation of structure activity relationships in the class of bicyclic 
substituted methanones which have previously been identified as highly active inhibitors of the 
h17β-HSD1 enzyme.30, 32 Modifications have been made in several positions of the inhibitor. 
One of the structural features under investigation was the phenolic OH-group at the benzoyl 
moiety (ring A) of inhibitors A and B which bears the risk to lead to phase II metabolism issues. 
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Thus, a search for an appropriate replacement of this group was initiated. The functionalities 
under investigation covered a broad spectrum of lipophilic and electronic properties. In addition, 
they differed in their abilities to form hydrogen bond interactions with the target. The 
introduction of chlorine appeared interesting to us as it is known that this substituent, due to its 
σ-hole property, is able to replace classical donors like OH in H-bonding interactions.44 On the 
other hand, also hydrogen bond acceptors (such as ester or carboxylate function) seemed 
promising, as it was hypothesized earlier that the OH-group of the inhibitor – as a donor - forms 
a hydrogen bond with the carbonyl function of the Asn152 side chain.
32
 This amino acid residue, 
however, is in principle also able to act as an H-bond donor via its NH2-group, allowing for an 
interaction with an appropriate acceptor function of the inhibitor. Regardless of the properties of 
the chosen residue, however, a complete loss or a strong reduction of inhibitory activity was 
observed (compounds 2-5). Even the NH2-group cannot replace the OH-group of compound B in 
a satisfactory manner (compound 6), in spite of comparable physico-chemical and H-bonding 
properties. Similarly sharp structure activity relationships have also been reported for other 
classes of 17β-HSD1 inhibitors.28, 45  
In contrast to the OH-group at the benzoyl moiety (ring A, cf. fig. 4) of compound C, the 
hydroxy-function attached to the phenyl-group (ring C) can be replaced or structurally modified 
to a considerable extent. It was shown earlier that even bulky aromatic residues are well tolerated 
by h17β-HSD1 and can be introduced to increase selectivity over the type 2 enzyme.30 A similar 
observation can be made when the OH group is transformed to an aliphatic ether: In spite of their 
voluminous ether groups, compounds 23 and 24 (IC50 = 120 and 152 nM, respectively; table 3) 
are only five- to seven-fold less active than the reference C (IC50 = 22 nM), and their activities 
are comparable to those shown by compounds 21 and 22 (IC50 = 90 and 157 nM, respectively), 
each bearing a rather small hydroxymethyl group. As expected for compounds 21-24, selectivity 
over 17β-HSD2 is enhanced with increasing bulkiness or lipophilicity of the substituent 
(selectivity factors 0.6 (compound 21) to 5.5 (compound 24)). 
Considerable attention was paid to the analysis of the role that is played by the keto-group of the 
lead compound A. Replacement of the keto- (compound A) by the thioketo-group led to a 
compound with slightly decreased activity (compound 18, table 2). This may be explained by the 
fact that the thioketone retains the geometry of the parent compound A, but is a poorer 
interaction partner for hydrogen bonding. Olefin 20 showed a significant decrease in activity 
compared to 18 (33 % vs. 75 % inhibn. at 1 µM), which is in agreement with the lacking 
hydrogen bonding function. Compounds 17 and 19 were weak inhibitors of 17β-HSD1. Both the 
difluoromethylene group (compound 17) and its methylene analog (19) show a different 
geometry compared to compound A, due to their sp
3
-hybridized carbon atoms. The finding that 
the fluorinated compound 17 is a stronger inhibitor than 19 (35 % vs. 16 % inhibn. at 1 µM) 
matches with the fact that fluorine atoms may show weak hydrogen bond accepting 
capabilities.
46
 Thus, the biological data obtained for compounds 17-20 is in agreement with 
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former molecular docking studies which suggests a bifurcated H-bond interaction between the 
carbonyl-group of the inhibitor and Tyr155 and Ser142.
32
 
The introduction of a second linker function was triggered by the concept to establish additional 
hydrogen bond interactions of the inhibitor with the OH groups of Tyr218 and Ser222 (sulfones 
26 and 28). As suggested by molecular docking results of 26 (fig. 6b), however, they showed a 
different binding mode compared to the bicyclic substituted hydroxyphenylmethanone class 
which precludes an establishment of these hydrogen bond interactions. 
The structure of the strong inhibitor 25 may be looked upon as the result of a sequential 
enlargement of the bis(hydroxyphenyl)thiophene compound class (fig. 7, D) and can be 
considered as a starting point for the investigation of a novel and potent class of h17β-HSD1 
inhibitors bearing two linker groups. 
SO
HO
S
OH
S
S
O
HO
OH OH
HO
D, (IC50 = 173 nM)               C, (IC50 = 22 nM)                            25, (IC50 = 104 nM)  
Figure 7. Comparison of potent h17β-HSD1 inhibitors: representatives of 
bis(hydroxyphenyl)thiophenes
31
 (D), bicyclic substituted hydroxyphenylmethanones
32
 (C) and 
compound 25. 
  
In conclusion, rational structure modifications have been carried out in order to investigate 
structure-activity relationships of bicyclic substituted hydroxyphenylmethanones (fig. 7, C) 
which have recently been described as promising non-steroidal inhibitors of h17β-HSD1. The 
results revealed that inhibitory activity is highly sensitive to changes in the hydroxybenzoyl part 
of the compounds, whereas in the phenyl moiety major changes in nature and size of the 
substituent are well tolerated. The biological data obtained support the conception that the keto 
linker group is involved in hydrogen-bonding interactions with the target. The introduction of a 
second linker function led to the discovery of the potent inhibitor (4-hydroxyphenyl)-[5-(3-
hydroxyphenylsulfanyl)-thiophen-2-yl]methanone (25) which is regarded as a member of a novel 
inhibitor class and a starting point for further optimization concerning selectivity towards h17β-
HSD2 and inhibition of m17β-HSD1. 
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Experimental Section 
 
Chemical Methods. Chemical names follow IUPAC nomenclature. Starting materials were 
purchased from Aldrich, Acros, Lancaster, Maybridge, Combi Blocks, Merck, or Fluka and were 
used without purification. 
Column chromatography (CC) was performed on silica gel (70 – 200µm), reaction progress was 
monitored by thin layer chromatography (TLC) on Alugram SIL G UV254 (Macherey-Nagel). 
1
H NMR and 
13
C NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 
300 K. Chemical shifts are reported in δ (parts per million: ppm), by reference to the 
hydrogenated residues of deuteriated solvent as internal standard (CDCl3: δ = 7.24 ppm (1H 
NMR) and δ = 77 ppm (13C NMR), CD3OD: δ = 3.35 ppm (
1
H NMR) and δ = 49.3 ppm (13C 
NMR), CD3COCD3: δ = 2.05 ppm (
1
H NMR) and δ = 29.9 ppm (13C NMR), CD3SOCD3 δ = 
2.50 ppm (
1
H NMR) and δ = 39.5 ppm (13C NMR)). Signals are described as s, d, t, dd, ddd, m, 
dt, q, sept for singlet, doublet, triplet, doublet of doublets, doublet of doublets of doublets, 
multiplet, doublet of triplets, quadruplet and septet, respectively. All coupling constants (J) are 
given in hertz (Hz). 
Melting points (mp) were measured in open capillaries on a Stuart Scientific SMP3 apparatus 
and are uncorrected. 
A mass spectra ESI was recorded on a TSQ Quantum (Thermo Finnigan) instrument. 
Tested compounds are >95% chemical purity as measured by HPLC. The methods for HPLC 
analysis and a table of data for all tested compounds are provided in the supporting information. 
The following compounds were prepared according to previously described procedures: 2-
phenylthiophene (1a),
34
 phenyl-(5-phenyl-thiophen-2-yl)-methanone (1),
35
 (5-bromo-thiophen-2-
yl)-(3-nitro-phenyl)-methanone (6b),
36
 (5-bromo-thiophen-2-yl)(3-methoxy-phenyl)methanone 
(21b)
32
 and (5-bromo-thiophen-2-yl)(3-hydroxyphenyl)methanone (23d)
32
.  
General Procedure for Suzuki coupling. Method A. A mixture of arylbromide (1 equiv), 
boronic acid derivative (1.2 equiv), cesium carbonate (4 equiv) and tetrakis(triphenylphosphine) 
palladium (0.01 equiv) was suspended in an oxygen-free DME/water (1:1) solution and refluxed 
under nitrogen for 4h. The reaction mixture was cooled to room temperature. The aqueous layer 
was extracted with ethyl acetate. The combined organic layers were washed with brine, dried 
over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC. 
General Procedure for Friedel-Crafts Acylation. Method B. A mixture of monosubstituted 
thiophene derivate (1 equiv), arylcarbonyl chloride (0.9 equiv), and aluminum trichloride (1 
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equiv) in anhydrous dichloromethane was warmed to room temperature and stirred for 3h. 1M 
HCl was used to quench the reaction. The aqueous layer was extracted with dichloromethane. 
The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, 
and concentrated to dryness. The product was purified by CC.  
General Procedure for Ether Cleavage. Method C. To a solution of ether derivative (1 equiv) 
in anhydrous dichloromethane at -78 
o
C (dry ice/acetone bath), boron tribromide in 
dichloromethane (1M, 3 equiv per methoxy function) -boron trichloride in dichloromethane (1M, 
2 equiv) in case of 23 and 24- was added dropwise. The reaction mixture was stirred overnight at 
room temperature under nitrogen atmosphere. Water was added to quench the reaction, and the 
aqueous layer was extracted with dichloromethane. The combined organic layers were washed 
with brine, dried over magnesium sulfate, filtered, and concentrated to dryness. The product was 
purified by CC. 
General procedure for sulfonamide/amide coupling. Method D. The amino phenyl derivative 
(1 equiv) was dissolved in absolute pyridine and was spiked with sulfonyl chloride/acid chloride 
(1.5 equiv). The reaction mixture was stirred overnight at rt (refluxed in case of amide coupling). 
The reaction was quenched by adding 10 mL of 2N HCl and extracted with ethyl acetate. The 
organic layers were washed with saturated NaHCO3 and brine, dried over magnesium sulfate, 
filtered and concentrated to dryness. The product was purified by CC. 
(5-Phenylthiophen-2-yl)(m-tolyl)methanone (2). The title compound was prepared by reaction 
of 2-phenylthiophene (150 mg, 0.94 mmol) (1a), 3-methylbenzoyl chloride (111 µl, 0.84 mmol) 
and aluminum chloride (125 mg, 0.94 mmol) according to method B. The product was purified 
by CC (hexane/ethyl acetate 98:2); yield: 57 % (149 mg). 
1
H NMR (CD3COCD3) δ 7.84-7.80 (m, 
2H), 7.72 (d, J=3.8 Hz, 1H), 7.71-7.67 (m, 2H), 7.61 (d, J=3.8 Hz, 1H), 7.52-7.40 (m, 5H), 2.45 
(s, 3H);
13
C NMR (CD3COCD3) δ 186.62, 151.84, 141.70, 137.84, 135.67, 132.62, 132.41, 
128.77, 128.63, 127.91, 125.64, 125.52, 124.04, 20.08; MS (ESI): 279.40 (M+H)
+
. 
(3-Chlorophenyl)(5-phenylthiophen-2-yl)methanone (3). The title compound was prepared by 
reaction of 2-phenylthiophene (150 mg, 0.94 mmol) (1a), 3-chlorobenzoyl chloride (180 µl, 0.84 
mmol) and aluminum chloride (125 mg, 0.94 mmol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 98:2); yield: 12 % (30 mg). 
1
H NMR (CD3COCD3) δ 7.89-
7.82 (m, 4H), 7.76 (d, J=4.1 Hz, 1H), 7.73-7.69 (m, 1H), 7.65-7.62 (m, 2H), 7.54-7.49 (m, 2H), 
7.48 -7.43 (m, 1H);
13
C NMR (CD3COCD3) δ 186.61, 154.12, 142.57, 140.85, 137.61, 135.04, 
134.03, 132.94, 131.31, 130.45, 129.41, 128.31, 127.24, 125.77; MS (ESI): 299.80 (M+H)
+
. 
Methyl 3-(5-phenylthiophene-2-yl-carbonyl)benzoate (4). The title compound was prepared 
by reaction of 2-phenylthiophene (300 mg, 1.87 mmol) (1a), methyl-3-(chloroformyl)benzoate 
(334 mg, 1.68 mmol) and aluminum chloride (250 mg, 1.87 mmol) according to method B. The 
product was purified by CC (dichloromethane/methanol 95:5); yield: 18 % (108 mg; yellow oil). 
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1
H NMR (CD3COCD3) δ 8.47 (dt, J= 2.0, 1.1 Hz, 1H), 8.30-8.26 (m, 1H), 8.17-8.13 (m, 1H), 
7.85-7.81 (m, 2H), 7.78-7.73 (m, 2H), 7.64 (d, J= 3.8 Hz, 1H), 7.53-7.49 (m, 2H), 7.48-7.42 (m, 
1H), 3.94 (s, 3H); 
13
C NMR (CD3COCD3) δ 187.12, 166.67, 154.02, 142.74, 139.32, 137.41, 
134.07, 133.62, 131.63, 130.44, 130.26, 130.01, 127.17, 125.62, 52.76; MS (ESI): 323.42 
(M+H)
+
.  
Methyl 3-(5-phenylthiophene-2-yl-carbonyl)benzoic acid (5). Methyl 3-(5-phenylthio-phene-
2-yl-carbonyl)benzoate (70 mg, 0.22 mmol, 1.00 equiv)  (4) was dissolved in 5ml methanol: 
water (70:30). Lithium hydroxide (15.6 mg, 0.66 mmol, 3.00 equiv) was added and the reaction 
mixture stirred at 50°C for 2h. The mixture was cooled to room temperature, quenched with 1N 
NaOH (pH 10-12) and washed two times with ethyl acetate. The aqueous layer was acidified 
with 1N HCl to pH 1 and extracted three times with ethyl acetate. The combined organic layers 
were dried over magnesium sulfate, filtered and evaporated under reduced pressure. No further 
purification was required; yield: 95 % (65 mg; white solid). 
1
H NMR (CD3COCD3) δ 11.46-
11.04 (m, 1H), 8.56-8.50 (m, 1H), 8.31 (dt, J= 7.9, 1.1Hz, 1H), 8.16 (dq, J= 7.6, 1.1Hz, 1H), 
7.86-7.81 (m, 2H), 7.78-7.74 (m, 2H), 7.65 (d, J= 3.8Hz, 1H), 7.53-7.49 (m, 2H), 7.48-7.43 (m, 
1H); 
13
C NMR (CD3COCD3) δ 187.54, 154.02, 142.71, 139.23, 137.47, 134.01, 133.85, 130.74, 
130.22, 139.91, 127.10, 125.55; MS (ESI): 309.56 (M+H)
+
.  
(3-Aminophenyl)(5-bromothiophen-2-yl)methanone (6a). A suspension of 6b (665 mg, 2 
mmol) and tin(II)-chloride dihydrate (2388 mg, 11 mmol) in methanol (10 mL) was refluxed for 
2 h. The solvent was removed under vacuum and the residue was diluted with saturated NaHCO3 
and water. The suspension was extracted with ethyl acetate. The combined extracts were washed 
with brine, dried over magnesium sulfate, filtered and evaporated under reduced pressure to give 
6a (450 mg, 75 %, brown solid, mp. 102-4 
o
C). The product was sufficiently pure for use in the 
subsequent reaction.  
(3-Amino-phenyl)(5-(3-ethoxy-phenyl)-thiophen-2-yl)methanone (6). The title compound was 
prepared by reaction of (3-amino-phenyl)-(5-bromo-thiophen-2-yl)-methanone (6a) (600 mg, 
2.13 mmol), 3-ethoxyphenylboronic acid (424 mg, 2.55 mmol), cesium carbonate (2772 mg, 
8.51 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 µmol) according to method A. 
The product was purified by CC (hexane/ethyl acetate 80:20); yield: 83 % (570 mg; yellow 
solid). 
1
H NMR (CDCl3) δ 7.54 (d, J = 4.0 Hz, 1H), 7.26 – 7.22 (m, 2H), 7.18 (dd, J = 1.6, 1.1 
Hz, 1H), 7.18 – 7.14 (m, 2H), 7.13 – 7.11 (m, 1H), 7.07 (dd, J = 2.1, 1.4 Hz, 1H), 6.83 (ddd, J = 
8.2, 2.5, 1.0 Hz, 1H), 6.80 (ddd, J = 7.5, 2.4, 1.6 Hz, 1H), 4.01 (q, J = 7.0 Hz, 2H), 3.78 (s, 2H), 
1.37 (t, J = 7.0 Hz, 3H); 
13
C NMR (CDCl3) δ 188.17, 159.37, 152.88, 146.62, 142.24, 139.09, 
135.78, 135.36, 134.55, 130.10, 129.17, 123.87, 119.37, 118.67, 118.65, 115.06, 112.41, 63.57, 
14.75; MS (ESI): 324.00 (M+H)
+
. 
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N-(3-(5-(3-Ethoxyphenyl)-thiophene-2-yl-carbonyl)-phenyl)-C,C,C-trifluoro-
methanesulfonamide (7). The title compound was prepared by reaction of (3-amino-phenyl)-(5-
(3-ethoxyphenyl)-thiophen-2-yl)methanone (6) (155 mg, 0.48 mmol) and trifluoro-
methanesulfonyl chloride (121 mg, 0.72 mmol) according to method D. The product was purified 
by CC (DCM); yield: 28 % (60 mg; yellow oil). 
1
H NMR (CDCl3) δ 7.76 – 7.72 (m, 1H), 7.67 
(d, J = 7.7 Hz, 1H), 7.56 – 7.49 (m, 2H), 7.41 (t, J = 7.9 Hz, 1H), 7.22 (dd, J = 15.2, 6.0 Hz, 2H), 
7.14 (t, J = 3.8 Hz, 1H), 7.11 – 7.05 (m, 1H), 6.85 – 6.77 (m, 1H), 3.98 (q, J = 7.0 Hz, 2H), 1.33 
(t, J = 7.0 Hz, 3H); 
13
C NMR (CDCl3) δ 187.28, 159.43, 154.79, 140.96, 139.04, 136.94, 135.09, 
134.16, 130.24, 129.80, 127.58, 126.43, 124.37, 123.62, 121.08, 119.79 (d, J = 323.1 Hz) 
118.78, 115.57, 112.50, 63.67, 14.75; MS (ESI): 455.84 (M+H)
+
. 
(5-(3-Ethoxyphenyl)-thiophen-2-yl)-(3-isopropylamino-phenyl)methanone (8). To a 
degassed mixture of 2-bromo-propane (123 mg, 1 mmol), cupper II oxide (72 mg, 0.5 mmol) and 
potassium hydroxide (56 mg, 1 mmol) in DMF (1 mL) was slowly added (3-aminophenyl)-(5-(3-
ethoxyphenyl)-thiophen-2-yl)-methanone (6) (323mg, 1 mmol). The resulting mixture was 
heated at 135
o
C for 4 days, allowed to cool to rt and poured into a 0
o
C 6N HCl solution. After 15 
min. the precipitate was filtered and washed with benzene. The filtrate was extracted with 
benzene, dried over magnesium sulfate, filtered, and concentrated to dryness. The product was 
purified by CC (hexane/ethyl acetate 95:5); yield: 46 % (168 mg; brownish oil). 
1
H NMR 
(CDCl3) δ 7.63 (d, J = 3.9 Hz, 1H), 7.32 – 7.28 (m, 2H), 7.26 – 7.22 (m, 2H), 7.20 – 7.17 (m, 
1H), 7.15 – 7.11 (m, 1H), 7.04 – 7.01 (m, 1H), 6.89 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 6.76 (ddd, J 
= 8.1, 2.5, 0.9 Hz, 1H), 4.07 (q, J = 7.0 Hz, 2H), 3.67 (sept, J = 12.4, 6.2 Hz, 2H), 1.43 (t, J = 7.0 
Hz, 3H), 1.22 (d, J = 6.3 Hz, 6H). 
13
C NMR (CDCl3) δ 188.75, 159.65, 153.00, 147.81, 142.72, 
139.36, 135.92, 134.90, 130.36, 129.34, 124.11, 118.93, 118.10, 117.17, 115.31, 113.20, 112.67, 
63.84, 44.43, 23.15, 15.03; MS (ESI): 366.62 (M+H)
+
. 
1-(3-(5-(3-Ethoxyphenyl)-thiophene-2-yl-carbonyl)-phenyl)-3-methyl-thiourea (9). A 
suspension of (3-amino-phenyl)-(5-(3-ethoxyphenyl)-thiophen-2-yl)-methanone (6) (205 mg, 0.6 
mmol) and CH3NCS (46 mg, 0.6 mmol) in THF was refluxed overnight. The solution was cooled 
and the product precipitated with heptane and purified by CC (hexane/ethyl acetate 3:1) to give 
9; yield: 56 % (140 mg; yellow solid; mp. 145-6 
o
C). 
1
H NMR (CD3COCD3) δ 9.14 (br., 1H, 
NH), 8.14 (d, J = 9.9 Hz, 1H), 7.87 (d, J = 3.9 Hz, 1H), 7.70 (dd, J = 6.2, 3.1 Hz, 1H), 7.64 – 
7.61 (m, 1H), 7.60 (d, J = 4.0 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.40 – 7.36 (m, 1H), 7.35 (dt, J = 
7.7, 1.5 Hz, 1H), 7.32 – 7.30 (m, 1H), 6.98 (ddd, J = 7.8, 2.5, 1.4 Hz, 1H), 4.14 (q, J = 7.0 Hz, 
2H), 3.08 (d, J = 4.6 Hz, 3H), 1.40 (t, J = 7.0 Hz, 3H). 
13
C NMR (CD3COCD3) δ 188.17, 175.10, 
159.37, 152.88, 146.62, 142.24, 139.09, 135.78, 135.36, 134.55, 130.10, 129.17, 123.87, 119.37, 
118.67, 118.65, 115.06, 112.41, 63.57, 35.17, 14.75; MS (ESI): 397.89 (M+H)
+
. 
(3-Benzylaminophenyl)-(5-(3-ethoxyphenyl)-thiophen-2-yl)-methanone (10). The title 
compound was prepared by reaction of (3-amino-phenyl)-(5-(3-ethoxyphenyl)-thiophen-2-yl)-
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methanone (6) (135mg, 0.42 mmol) and (bromomethyl)benzene (108mg, 0.63 mmol) in acetone 
(10 mL). The resulting mixture was stirred at rt for 10 h and poured into water. The precipitate 
was filtered and purified by CC (hexane/ethyl acetate 97:3); yield: 42 % (72 mg; yellow oil). 
1
H 
NMR (CDCl3) δ 7.35 (d, J = 4.0 Hz, 3H), 7.23 (tdd, J = 10.6, 9.0, 7.2 Hz, 14H), 7.18 – 7.14 (m, 
6H), 7.13 – 7.11 (m, 7H), 7.08 – 7.05 (m, 6H), 6.96 (dd, J = 2.2, 1.7 Hz, 3H), 6.78 (ddd, J = 8.2, 
2.5, 1.0 Hz, 3H), 6.71 (ddd, J = 8.1, 2.5, 1.0 Hz, 3H), 4.25 (s, 7H), 3.96 (q, J = 7.0 Hz, 6H), 1.32 
(t, J = 7.0 Hz, 9H); 
13
C NMR (CDCl3) δ 188.28, 159.34, 152.70, 147.94, 142.32, 138.91, 138.83, 
135.70, 134.56, 130.06, 129.12, 128.66, 127.35, 127.27, 123.86, 118.63, 118.31, 116.67, 114.97, 
112.76, 112.41, 63.54, 47.97, 14.74; MS (ESI): 414.81 (M+H)
+
. 
N-(3-(5-(3-Ethoxyphenyl)-thiophene-2-yl-carbonyl)-phenyl)-benzenesulfonamide (11). The 
title compound was prepared by reaction of (3-aminophenyl)-(5-(3-ethoxyphenyl)-thiophen-2-
yl)-methanone (6) (265 mg, 0.82 mmol) and benzenesulfonyl chloride (217 mg, 1.23 mmol) 
according to method D. The product was purified by CC (hexane/ethyl acetate 90:10); yield: 39 
% (150 mg; white solid; mp. 136 
o
C). 
1
H NMR (CDCl3) δ 7.60 – 7.56 (m, 2H), 7.41 – 7.37 (m, 
1H), 7.34 – 7.29 (m, 2H), 7.24 (d, J = 0.9 Hz, 1H), 7.23 – 7.20 (m, 2H), 7.18 – 7.15 (m, 2H), 
7.10 (t, J = 8.0 Hz, 1H), 7.07 (d, J = 4.0 Hz, 1H), 7.01 (ddd, J = 7.7, 1.7, 1.0 Hz, 1H), 6.96 – 6.94 
(m, 1H), 6.69 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 3.86 (q, J = 7.0 Hz, 2H), 1.22 (t, J = 7.0 Hz, 3H); 
13
C NMR (CDCl3) δ 186.93, 159.43, 153.77, 141.55, 139.04, 138.89, 136.75, 136.13, 134.35, 
133.25, 130.19, 129.63, 129.21, 127.21, 125.94, 125.03, 124.11, 121.92, 118.74, 115.25, 112.57, 
63.64, 14.78; MS (ESI): 463.92 (M+H)
+
. 
N-(3-(5-(3-Ethoxyphenyl)-thiophene-2-yl-carbonyl)-phenyl)-benzamide (12). The title 
compound was prepared by reaction of (3-aminophenyl)-(5-(3-ethoxyphenyl)-thiophen-2-yl)-
methanone (6) (170 mg, 0.53 mmol) and benzoyl chloride (74 mg, 0.53 mmol) according to 
method D. The product was purified by CC (hexane/ethyl acetate 85:15); yield: 80 % (180 mg; 
white solid; mp. 145-6 
o
C). 
1
H NMR (CDCl3) δ 8.15 (br. s, 1H, NH), 8.05 (t, J = 1.8 Hz, 1H), 
8.00 (ddd, J = 8.1, 2.2, 1.0 Hz, 1H), 7.91 – 7.85 (m, 2H), 7.66 (d, J = 4.0 Hz, 1H), 7.64 – 7.61 
(m, 1H), 7.56 – 7.52 (m, 1H), 7.48 (ddd, J = 9.5, 5.2, 3.1 Hz, 3H), 7.31 (dd, J = 10.7, 6.0 Hz, 
2H), 7.24 – 7.21 (m, 1H), 7.18 – 7.15 (m, 1H), 6.89 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 4.07 (q, J = 
7.0 Hz, 2H), 1.43 (t, J = 7.0 Hz, 3H); 
13
C NMR (CDCl3) δ 187.73, 166.22, 159.67, 153.72, 
142.17, 138.98, 138.45, 136.49, 134.81, 134.74, 132.34, 130.41, 129.53, 129.11, 127.36, 125.36, 
124.45, 124.20, 121.07, 119.00, 115.48, 112.74, 63.87, 15.04; MS (ESI): 428.84 (M+H)
+
. 
N-(3-(5-(3-Ethoxyphenyl)-thiophene-2-yl-carbonyl)-phenyl)-4-methoxy-
benzenesulfonamide (13). The title compound was prepared by reaction of (3-amino-phenyl)-
(5-(3-ethoxyphenyl)-thiophen-2-yl)-methanone (6) (155 mg, 0.48 mmol) and 4-methoxy-
benzenesulfonyl chloride (149 mg, 0.72 mmol) according to method D. The product was purified 
by CC (hexane/ethyl acetate 85:15); yield: 75 % (179 mg; white solid; mp. 162-3 
o
C). 
1
H NMR 
(CD3COCD3) δ 7.81 – 7.76 (m, 2H), 7.72 (ddd, J = 2.2, 1.7, 0.5 Hz, 1H), 7.60 – 7.57 (m, 2H), 
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7.54 (d, J = 4.0 Hz, 1H), 7.52 (ddd, J = 8.1, 2.2, 1.4 Hz, 1H), 7.50 – 7.46 (m, 1H), 7.42 – 7.37 
(m, 1H), 7.37 – 7.33 (m, 1H), 7.32 – 7.28 (m, 1H), 7.08 – 7.03 (m, 2H), 7.00 (ddd, J = 8.0, 2.5, 
1.2 Hz, 1H), 4.15 (q, J = 7.0 Hz, 2H), 3.85 (s, 3H), 1.40 (t, J = 7.0 Hz, 3H); 
13
C NMR 
(CD3COCD3) δ 187.16, 164.15, 160.65, 153.66, 142.81, 139.69, 139.31, 136.96, 135.31, 132.29, 
131.30, 130.51, 130.21, 125.57, 125.55, 125.10, 121.71, 119.35, 116.29, 115.19, 112.98, 64.30, 
56.13, 15.08; MS (ESI): 493.92 (M+H)
+
. 
3-Cyano-N-(3-(5-(3-ethoxyphenyl)-thiophene-2-yl-carbonyl)phenyl)-benzenesulfonamide 
(14). The title compound was prepared by reaction of (3-amino-phenyl)-(5-(3-ethoxy-phenyl)-
thiophen-2-yl)-methanone (6) (255 mg, 0.79 mmol) and 3-cyano-benzenesulfonyl chloride (239 
mg, 1.18 mmol) according to method D. The product was purified by CC (hexane/ethyl acetate 
85:15); yield: 46 % (180 mg; white solid; mp. 130-1 
o
C). 
1
H NMR (CDCl3) δ 8.04 – 7.99 (m, 
1H), 7.92 (ddd, J = 8.0, 1.9, 1.1 Hz, 1H), 7.74 – 7.69 (m, 1H), 7.59 (dd, J = 7.2, 1.6 Hz, 1H), 
7.52 – 7.48 (m, 1H), 7.47 – 7.45 (m, 2H), 7.40 (ddd, J = 8.1, 2.1, 1.5 Hz, 1H), 7.39 – 7.34 (m, 
1H), 7.26 – 7.22 (m, 2H), 7.15 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H), 7.10 – 7.07 (m, 1H), 6.84 (ddd, J 
= 8.0, 2.5, 0.9 Hz, 1H), 4.00 (q, J = 7.0 Hz, 2H), 1.36 (t, J = 7.0 Hz, 3H); 
13
C NMR (CDCl3) δ 
187.01, 159.44, 154.27, 141.21, 140.74, 139.20, 136.42, 136.34, 136.23, 134.20, 131.16, 130.79, 
130.27, 130.23, 129.82, 126.56, 125.24, 124.26, 122.17, 118.77, 116.98, 115.39, 113.75, 112.58, 
63.66, 14.78; MS (ESI): 488.84 (M+H)
+
. 
N-(3-(5-(3-Ethoxyphenyl)-thiophene-2-yl-carbonyl)phenyl)-isophthalamic acid methyl ester 
(15). The title compound was prepared by reaction of (3-aminophenyl)-(5-(3-ethoxy-phenyl)-
thiophen-2-yl)-methanone (6) (315 mg, 0.98 mmol) and 3-chlorocarbonyl-benzoic acid methyl 
ester (194 mg, 0.98 mmol) according to method D. The product was purified by CC 
(hexane/ethyl acetate 85:15); yield: 78 % (370 mg; white solid; mp. 138-9 
o
C). 
1
H NMR (CDCl3) 
δ 8.45 (dd, J = 6.3, 4.7 Hz, 2H), 8.12 (d, J = 7.8 Hz, 1H), 8.08 (dd, J = 7.8, 1.5 Hz, 1H), 8.04 (t, J 
= 1.7 Hz, 1H), 7.98 (dd, J = 8.1, 1.2 Hz, 1H), 7.58 (dd, J = 9.3, 5.9 Hz, 2H), 7.49 (t, J = 7.8 Hz, 
1H), 7.43 (t, J = 7.8 Hz, 1H), 7.27 – 7.21 (m, 2H), 7.15 (d, J = 7.7 Hz, 1H), 7.12 – 7.07 (m, 1H), 
6.83 (dd, J = 8.2, 1.8 Hz, 1H), 4.01 (q, J = 7.0 Hz, 2H), 3.84 (s, 3H), 1.37 (t, J = 7.0 Hz, 3H). 
13
C 
NMR (CDCl3) δ 187.47, 166.17, 165.02, 159.40, 153.52, 141.82, 138.67, 138.08, 136.28, 
134.91, 134.42, 132.88, 132.03, 130.65, 130.14, 129.27, 129.13, 127.78, 125.26, 124.18, 124.09, 
120.98, 118.72, 115.23, 112.45, 63.60, 52.42, 14.78; MS (ESI): 485.93 (M)
+
. 
N-(3-(5-(3-Ethoxy-phenyl)-thiophene-2-yl-carbonyl)-phenyl)-isophthalamic acid (16). A 
reaction of compound 15 (320 mg, 0.66 mmol) in ethanol (5 mL) and 10% sodium hydroxide (15 
mL) was refluxed in for 2 h on a water bath. The reaction mixture was cooled, diluted with water 
and neutralized with acetic acid. The crude product precipitated and was purified by CC 
(hexane/ethyl acetate 1:3); yield: 80 % (250 mg; greenish-yellow solid; mp. > 280 
o
C). 
1
H NMR 
(CD3COCD3) δ 10.06 (s, 1H, COOH), 8.69 (br. s, 1H, NH), 8.46 (s, 1H), 8.21 (dd, J = 37.3, 7.8 
Hz, 3H), 7.81 (d, J = 4.0 Hz, 1H), 7.69 – 7.53 (m, 4H), 7.42 – 7.30 (m, 3H), 7.02 – 6.94 (m, 1H), 
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4.15 (q, J = 7.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H); 
13
C NMR (CD3COCD3) δ 187.63, 165.96, 
160.63, 153.48, 143.10, 140.31, 139.25, 137.15, 135.39, 133.71, 133.69, 133.67, 133.66, 132.79, 
132.76, 132.72, 131.27, 129.97, 129.65, 125.69, 125.18, 121.73, 119.35, 116.28, 112.89, 64.28, 
15.07; MS (ESI): 472.92 (M+H)
+
. 
(3-Methoxyphenyl)(5-phenylthiophen-2-yl)methanone (17c). The title compound was 
prepared by reaction of 2-phenylthiophene (1000mg, 6.24 mmol) (1a), 3-methoxybenzoyl 
chloride (958mg, 5.62 mmol) and aluminum chloride (832 mg, 6.24 mmol) according to method 
B. The product was purified by CC (hexane/dichloromethane 6:4 to dichloromethane pure); 
yield: 66 % (1021 mg; yellow oil). 
1
H NMR (CD3COCD3) δ 7.84-7.79 (m, 2H), 7.75 (d, J= 
3.9Hz, 1H), 7.61 (d, J= 3.9Hz, 1H), 7.52-7.41 (m, 5H), 7.40-7.38 (m, 1H), 7.24-7.22 (m, 1H), 
3.90 (s, 3H). 
(3-Methoxyphenyl)-(5-phenylthiophen-2-yl)-methanethione (17b). (3-methoxyphenyl)(5-
phenylthiophen-2-yl)methanone (17c) (300 mg, 1.02 mmol, 1.00 equiv) was dissolved under 
nitrogen in 20 ml abs. toluene and Lawesson’s reagent was added. The mixture was stirred for 2h 
under reflux and concentrated under reduced pressure. Purification by column chromatography 
(hexane: ethyl acetate 9:1); yield: 96 % (300 mg; dark green oil); Used in the next step without 
any characterisation.  
2-(Difluoro(3-methoxyphenyl)methyl)-5-phenylthiophene (17a). Under N2 (3-
methoxyphenyl)(5-phenylthiophen-2-yl)methanethione) (17b) (100 mg, 0.34 mmol, 1 equiv) was 
placed in a 100 ml teflon flask and dissolved under nitrogen in 3 ml abs. dichloromethane. 
Diethylaminosulfur trifluoride (DAST, 167µl, 1.36 mmol, 3 equiv) to the solution was added 
slowly at room temperature and the mixture was stirred for 3 h. The reaction was carefully 
quenched with cold sat. Sodium hydrogen carbonate and extracted three times with diethyl ether. 
The combined organic layers were washed two times with sat. Sodium hydrogen carbonate, one 
time with water, one time with brine, dried over magnesium sulfate, filtered and concentrated 
under reduced pressure. The crude product was purified by CC (hexane/ethyl acetate 85:15); 
yield: 63 % (68 mg, red viscous oil). 
1
H NMR (CD3COCD3) δ 7.71-7.67 (m, 2H), 7.49-7.42 (m, 
3H), 7.41-7.35 (m, 2H), 7.23-7.19 (m, 1H), 7.18-7.13 (m, 2H), 7.13-7.10 (m, 1H), 3.87 (s, 3H); 
13
C NMR (CD3COCD3) δ 187.70, 160.70, 153.45, 143.15, 140.35, 137.05, 134.10, 130.55, 
130.10, 127.15, 125.50, 122.10, 119.15, 114.50, 55.80; MS (ESI): 317.40 (M+H)
+
.  
3-(Difluoro(5-phenylthiophen-2-yl)methyl)phenol (17). The title compound was prepared by 
reaction of 2-(difluoro(3-methoxyphenyl)methyl)-5-phenylthiophene (17a) (60 mg, 0.18 mmol) 
and boron tribromide (0.56 mmol) according to method C. The product was purified by CC 
(hexane : ethyl acetate 8:2) followed by preparative TLC (hexane : ethyl acetate 7:3); yield 14 % 
(13 mg; dark green oil). 
1
H NMR (CD3COCD3) δ 7.87-7.85 (m, 1H), 7.52-7.48 (m, 4H), 7.37-
7.34 (m, 2H), 7.21-7.17 (m, 1H), 7.15-7.13 (m, 1H), 7.09-7.00 (m, 2H); 
13
C NMR (CD3COCD3) 
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δ 189.55, 168.80, 155.35, 140.30, 135.85, 134.75, 132.40, 128.20, 127.05, 126.40, 121.05, 
118.15, 111.00; MS (ESI): 303.35 (M+H)
+
.  
(3-Hydroxyphenyl)(5-phenylthiophen-2-yl)methanethione (18). The title compound was 
prepared by reaction of (3-methoxyphenyl)(5-phenylthiophen-2-yl)methanethione) (17b) (100 
mg, 0.32 mmol) and boron tribromide (0.96 mmol) according to method C. The product was 
purified by CC (hexane/ethyl acetate 8:2) followed by preparative TLC (hexane : ethyl acetate 
8:2); yield 14 % (68 mg). 
1
H NMR (CD3COCD3) δ 9.82 (s, 1H), 7.87-7.84 (m, 2H), 7.76 (d, 
J=4.1 Hz, 1H), 7.52-7.46 (m, 4H), 7.29 (t, 
 
J=7.9 Hz, 1H), 7.12-7.09 (m, 1H), 7.08 (t, J= 1.9 Hz, 
1H), 7.01 (ddd, J=1.1, 2.4, 8.1 Hz, 1H); 
13
C NMR (CD3COCD3) δ 157.45, 157.00, 152.95, 
147.30, 133.85, 132.50, 129.90, 129.55, 129.50, 129.30, 126.40, 126.15, 126.00, 119.35, 118.65, 
115.30; MS (ESI): 297.15 (M+H)
+
.  
2-(3-Methoxybenzyl)-5-phenylthiophene (19a). (3-Methoxyphenyl)(5-phenylthiophen-2-
yl)methanone (17c) (300 mg, 1.01mmol, 1 equiv) was dissolved in 20ml acetic acid, tin (II) 
chloride dihydrate (1.16 mg, 5.20 mmol, 5.20equiv) was added in 3.33 ml hydrogen chloride and 
the mixture was refluxed over night. The mixture was cooled to room temperature, quenched 
with water, extracted two times with dichloromethane, dried and evaporated under reduced 
pressure. The crude product was purified by CC (hexane/ethyl acetate 9:1); yield: 50 % (147 mg, 
white oil). 
1
H NMR (CD3COCD3) δ 7.54-7.61 (m, 2H), 7.32-7.40 (m, 2H), 7.19-7.28 (m, 3H), 
6.87-6.92 (m, 3H), 6.75-6.83 (m, 1H), 4.15 (s, 2H), 3.78 (s, 3H).  
3-((5-Phenylthiophen-2-yl)methyl)phenol (19). The title compound was prepared by reaction 
of 2-(3-methoxybenzyl)-5-phenylthiophene (19a) (140 mg, 0.49 mmol) and boron tribromide 
(1.50 mmol) according to method C. No further purification was required; yield 49 % (65 mg). 
1
H NMR (CD3COCD3) δ 8.24 (s, 1H), 7.65-7.52 (m, 2H), 7.41-7.30 (m, 2H), 7.28-7.20 (m, 2H), 
7.17-7.08 (m, 1H), 6.92-6.83 (m, 1H), 6.82-6.75 (m, 2H), 6.72-6.70 (m, 1H), 4.11 (s, 2H); 
13
C 
NMR (CD3COCD3) δ 158.50, 145.05, 143.40, 142.95, 135.50, 130.45, 129.85, 128.10, 127.30, 
126.10, 123.80, 120.65, 116.45, 116.35, 114.35, 36.70; MS (ESI): 278.56 (M+H)
+
.  
2-(1-(3-Methoxyphenyl)vinyl)-5-phenylthiophene (20a).  Methyltriphenylphosphonium 
bromide (364 mg, 1.01 mmol, 1 equiv) was suspended in 5ml dry tetrahydrofurane, n-
butyllithium (400 µl, 2.5 M in hexane) was added dropwise, stirred at room temperature for 90 
min, (3-methoxyphenyl)(5-phenylthiophen-2-yl)methanone  (17c) (300 mg, 1.01mmol, 
1.00equiv), previously solubilised in 2ml dry tetrahydrofurane, was added dropwise and stirred 
at room temperature for 1h, then at 65°C over night. The mixture was cooled to room 
temperature, quenched with water and extracted two times with ethyl acetate. The combined 
organic layers were washed one time with water, dried and evaporated under reduced pressure. 
The crude product was purified by CC (hexane/ethyl acetate 9:1); yield: 35 % (105 mg, yellow 
oil). 
1
H NMR (CD3COCD3) δ 7.68 (d, J= 8.2 Hz, 2H), 7.40-7.45 (m, 2H), 7.38 (d, J= 3.8 Hz, 
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1H), 7.29-7.36 (m, 2H), 7.01-7.06 (m, 2H), 6.94-7.00 (m, 2H), 5.64 (d, J= 1.5 Hz, 1H), 5.29 (d, 
J= 1.5 Hz, 1H), 3.83 (s, 3H).  
2-(1-(3-Methoxyphenyl)vinyl)-5-phenylthiophene (20). The title compound was prepared by 
reaction of 2-(1-(3-methoxyphenyl)vinyl)-5-phenylthiophene (20a) (100 mg, 0.34 mmol) and 
boron tribromide (1.30 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 8:2); yield 5 % (4.3 mg; yellow oil). 
1
H NMR (CD3COCD3) δ 8.42 (s, 
1H), 7.70-7.63 (m, 2H), 7.42 (d, J= 7.8 Hz, 2H), 7.38 (d, J= 3.8 Hz, 1H), 7.31 (d, J= 7.8 Hz, 1H), 
7.25 (d,
 
J= 8.2 Hz, 1H), 6.97 (d, J= 3.8 Hz, 1H), 6.96-6.94 (m, 2H), 6.89-6.82 (m, 1H), 5.60 (d, 
J= 0.7 Hz, 1H), 5.25 (d, J= 0.7 Hz, 1H); MS (ESI): 266.66 (M+H)
+
. 
(5-((3-Hydroxymethyl)phenyl)thiophen-2-yl)-(3-methoxyphenyl)methanone (21a). The title 
compound was prepared by reaction of (5-bromothiophene-2-yl)(3-methoxyphenyl)methanone 
(21b) (150 mg, 0.50 mmol), 3-(hydroxymethyl)phenylboronic acid (92 mg, 0.60 mmol), cesium 
carbonate (658 mg, 2.02 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 µmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 73 % 
(120 mg; brown oil). 
1
H NMR (CDCl3) δ 7.70 (s, 1H), 7.64 (d, J = 4.0 Hz, 1H), 7.62 – 7.59 (m, 
1H), 7.46 (dt, J = 7.5, 1.3 Hz, 1H), 7.44 – 7.37 (m, 4H), 7.36 (d, J = 4.0 Hz, 1H), 7.14 (ddd, J = 
8.1, 2.7, 1.1 Hz, 1H), 4.76 (d, J = 4.3 Hz, 2H), 3.87 (s, 3H). 
13
C NMR (CDCl3) δ 187.77, 159.63, 
153.06, 142.20, 141.93, 139.32, 135.95, 133.57, 129.40, 129.35, 127.54, 125.55, 124.72, 124.00, 
121.64, 118.54, 113.73, 64.90, 55.47;  MS (ESI): 325.26 (M+H)
+
. 
(5-((3-Hydroxymethyl)phenyl)thiophen-2-yl)-(3-hydroxyphenyl)methanone (21). The title 
compound was prepared by reaction of (5-((3-hydroxymethyl)phenyl)thiophen-2-yl)-(3-
methoxyphenyl)methanone (21a) (100 mg, 0.31 mmol) and boron tribromide (0.92 mmol) 
according to method C. The product was purified by CC (dichloromethane/methanol 99.75:0.25); 
yield 63 % (60 mg; yellow oil).  
1
H NMR (CD3COCD3) δ 8.74 (s, 1H, OH), 7.92 (t, J = 1.6 Hz, 
1H), 7.77 – 7.74 (m, 1H), 7.73 (d, J = 4.0 Hz, 1H), 7.63 (t, J = 4.4 Hz, 1H), 7.53 (dt, J = 7.6, 1.4 
Hz, 1H), 7.49 (dd, J = 9.5, 5.8 Hz, 1H), 7.41 (dd, J = 9.5, 5.8 Hz, 1H), 7.38 (dt, J = 7.6, 1.4 Hz, 
1H), 7.36 – 7.33 (m, 1H), 7.14 (ddd, J = 7.7, 2.5, 1.4 Hz, 1H), 4.73 (s, 2H); 13C NMR 
(CD3COCD3) δ 192.02, 162.73, 156.77, 147.76, 144.87, 144.55, 141.09, 138.92, 135.08, 134.96, 
134.90, 131.99, 131.22, 129.96, 125.40, 124.59, 120.60, 37.95; MS (ESI): 311.56 (M+H)
+
. 
(5-(4-(Hydroxymethyl)phenyl)thiophen-2-yl)-(3-methoxyphenyl)methanone (22a). The title 
compound was prepared by reaction of (5-bromo-thiophen-2-yl)(3-methoxyphenyl)methanone 
(21b) (150 mg, 0.50 mmol), 4-(hydroxymethyl)phenylboronic acid (92 mg, 0.60 mmol), cesium 
carbonate (657 mg, 2.02 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 µmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 70 % 
(118 mg, brown oil). 
1
H NMR (CDCl3) δ 7.57 (d, J = 1.8 Hz, 1H), 7.57 – 7.55 (m, 1H), 7.53 (d, J 
= 4.0 Hz, 1H), 7.35 (dt, J = 7.6, 1.2 Hz, 1H), 7.33 – 7.27 (m, 4H), 7.24 (d, J = 4.0 Hz, 1H), 7.03 
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(ddd, J = 8.1, 2.7, 1.1 Hz, 1H), 4.63 (s, 2H), 3.77 (s, 3H); 
13
C NMR (CDCl3) δ 187.74, 159.63, 
152.97, 142.11, 141.97, 139.34, 135.98, 132.59, 129.40, 127.59, 126.47, 123.83, 121.63, 118.52, 
113.72, 64.79, 55.47;  MS (ESI): 325.25 (M+H)
+
. 
(5-(4-(Hydroxymethyl)phenyl)thiophen-2-yl)(3-hydroxyphenyl)-methanone (22). The title 
compound was prepared by reaction of (5-(4-(hydroxymethyl)phenyl)thiophen-2-yl)-(3-
methoxyphenyl)methanone (22a) (100 mg, 0.31 mmol) and boron tribromide (0.92 mmol) 
according to method C. The product was purified by CC (dichloromethane/methanol 99.75:0.25); 
yield 58 % (55 mg, yellow oil). 
1
H NMR (CDCl3) δ 7.57 – 7.51 (m, 3H), 7.36 – 7.34 (m, 1H), 
7.34 – 7.32 (m, 1H), 7.32 – 7.29 (m, 1H), 7.28 – 7.22 (m, 3H), 7.00 (ddd, J = 8.0, 2.6, 1.1 Hz, 
1H), 4.42 (d, J = 5.3 Hz, 2H); 
13
C NMR (CDCl3) δ 188.05, 156.28, 152.60, 142.26, 139.16, 
138.74, 136.30, 133.29, 129.83, 129.68, 126.68, 124.25, 121.40, 119.73, 115.72, 32.72; MS 
(ESI): 311.24 (M+H)
+
. 
(3-(Benzyloxy)phenyl)(5-bromothiophen-2-yl)methanone (23c). (5-bromothiophen-2-yl)(3-
hydroxyphenyl)methanone (23d) (10.44 g, 36.9 mmol, 1.00 equiv) was dissolved under nitrogen 
in 40 ml  acetone. cesium carbonate (25.2 g, 77.43 mmol, 2.10 equiv) and isopropyliodide (265 
mg, 1.56 mmol, 1.5 equiv) were added and the mixture stirred at room temperature overnight.  
The reaction was quenched with water. The combined organic layers were washed one time with 
water, one time with sat. Sodium hydrogen carbonate, one time with brine, dried over sodium 
sulfate, filtered and concentrated under vacuum.  The crude product was recrystallized in 
hexane/acetone (99:1); yield: 50 % (6.9 g, white solid). 
1
H NMR (CD3COCD3) δ 7.46 (t, J= 8.2 
Hz, 3H), 7.41-7.36 (m, 5H), 7.33-7.27 (m, 3H), 5.21 (s, 2H); 
13
C NMR (CD3COCD3) δ 186.80, 
159.75, 146.15, 139.45, 128.05, 136.50, 132.95, 130.80, 129.45, 128.85, 128.45, 123.00, 122.30, 
120.65, 115.55, 70.40; MS (ESI): 373.0 (M+H)
+
. 
(3-(Benzyloxy)phenyl)(5-(3-hydroxyphenyl)thiophen-2-yl)methanone (23b). The title 
compound was prepared by reaction of (3-(benzyloxy)phenyl)(5-bromothiophen-2-yl)methanone 
(23c) (3.2 g, 8.57 mmol), 3-hydroxyphenylboronic acid (1.42 g, 10.30 mmol), cesium carbonate 
(6.98 g, 21.40 mmol) and tetrakis(triphenylphosphine) palladium (2 mg) according to method A. 
The residue was purified by column chromatography (hexane/ethyl acetate 7:3); yield: 81 % (2.7 
g; yellow solid, mp. 142.0 
o
C). 
1
H NMR (CD3COCD3) δ 8.63 (s, 1H), 7.60 (t, J= 4.0 Hz, 1H), 
7.52-7.46 (m, 6H), 7.41 (t, J= 7.8 Hz, 2H), 7.33-7.31 (m, 3H), 7.25-7.24 (m, 2H), 6.91(d, J= 8.2 
Hz, 1H), 5.25 (s, 2H); 
13
C NMR (CD3COCD3) δ 187.61, 159.70, 159.07, 153.52, 142.91, 140.37, 
138.11, 137.04, 135.42, 131.38, 130.61, 129.40, 128.84, 128.53, 125.30, 122.37, 120.20, 118.45, 
117.27, 115.62, 113.84, 70.73;  MS (ESI): 386.76 (M+H)
+
. 
(3-(Benzyloxy)phenyl)(5-(3-isopropoxyphenyl)thiophen-2-yl)methanone (23a). (3-
(Benzyloxy)phenyl)(5-(3-hydroxyphenyl)thiophen-2-yl)methanone (23b) (400 mg, 1.04 mmol, 
1.0 equiv) was dissolved in 25 ml  acetone under N2. Caesium carbonate (678 mg, 2.08 mmol, 
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2.0 equiv) and isopropyl iodide (265 mg, 1.56 mmol, 1.5 equiv) were added and the mixture was 
stirred at room temperature overnight.  The reaction was quenched with water and extracted with 
ethyl acetate. The combined organic layers were washed one time with sat. Sodium hydrogen 
carbonate, one time with brine, dried over sodium sulfate, filtered and concentrated under 
reduced pressure.  The crude product was recrystallized from hexane/acetone (9:1); yield: 90 % 
(400 mg, white solid, mp. 98 
o
C). 
1
H NMR (CD3COCD3) δ 7.61 (d, J= 4.0 Hz, 1H), 7.57(d, J= 
4.0 Hz, 1H), 7.52-7.46 (m, 5H), 7.43-7.30 (m, 7H), 7.00 (ddd, J= 1.0, 2.5, 8.5 Hz, 1H), 5.25 (s, 
2H), 4.75 (sept, J= 6.0 Hz, 1H), 1.34 (d, J= 6.0 Hz, 6H); 
13
C NMR (CD3COCD3) δ 186.71, 
158.80, 158.75, 152.51, 142.12, 139.34, 137.27, 136.15, 134.52, 130.49, 129.81, 121.44, 119.32, 
118.40, 116.54, 114.61, 113.52, 69.83, 69.74, 21.42;  MS (ESI): 428.70 (M+H)
+
. 
(3-Hydroxyphenyl)(5-(3-isopropoxyphenyl)thiophen-2-yl)methanone (23). The title 
compound was prepared by reaction of (3-(benzyloxy)phenyl)(5-(3-isopropoxyphenyl)thiophen-
2-yl)methanone (23a) (400 mg, 0.93 mmol) and boron trichloride (1.86 mmol) according to 
method C. The product was purified by CC (hexane/ethyl acetate 8:2); yield 44 % (150 mg; 
yellow solid, mp. 100 
o
C). 
1
H NMR (CD3COCD3) δ 8.83 (s, 1H), 7.71 (d, J= 4.0 Hz, 1H), 7.59 
(d, J= 4.0 Hz, 1H), 7.42-7.33 (m, 5H), 7.30 (t, J= 2.3 Hz, 1H), 7.14 (ddd, J=1.2, 2.3, 7.7 Hz, 1H), 
6.99 (ddd, J= 1.2, 2.3, 7.7 Hz, 1H), 4.74 (sept, J= 6.0 Hz, 1H), 1.34 (d, J= 6.0 Hz, 6H); MS 
(ESI): 339.15 (M+H)
+
. 
(3-(Benzyloxy)phenyl)(5-(3-isobutoxyphenyl)thiophen-2-yl)methanone (24a). (3-
(benzyloxy)phenyl)(5-(3-hydroxyphenyl)thiophen-2-yl)methanone (23b) (300 mg, 0.78 mmol, 1 
equiv) was dissolved in 20 ml  acetone. Caesium carbonate (508 mg, 1.56 mmol, 2.0 equiv) and 
isobutyl iodide (215 mg, 1.17 mmol, 1.5 equiv) were added and the mixture was stirred at room 
temperature overnight.  The reaction was quenched with water. The combined organic layers 
were washed one time with water, one time with sat. Sodium hydrogen carbonate, one time with 
brine, dried over sodium sulfate, filtered and concentrated under reduced pressure.  The crude 
product was recrystallized in hexane/acetone (9:1); yield: 44 % (152 mg, white solid, mp. 94 
o
C). 
1
H NMR (CD3COCD3) δ 7.62 (d, J= 4.0 Hz, 1H), 7.58 (d, J= 4.0 Hz, 1H), 7.52-7.46 (m, 5H), 
7.43-7.30 (m, 7H), 7.01 (ddd, J= 1.2, 2.4, 7.9 Hz, 1H), 5.25 (s, 2H), 3.87 (d, J= 6.5 Hz, 2H), 2.10 
(m, 1H), 1.05 (d, J= 6.8 Hz, 6H); 
13
C NMR (CD3COCD3) δ 187.61, 160.94, 159.70, 153.42, 
143.01, 140.34, 138.11, 136.92, 135.43, 131.37, 130.62, 129.45, 128.81, 128.50, 125.64, 122.33, 
120.22, 119.47, 116.38, 115.55, 113.04, 75.14, 70.72, 29.13, 19.57;  MS (ESI): 442.70 (M+H)
+
. 
 (3-Hydroxyphenyl)(5-(3-isobutoxyphenyl)thiophen-2-yl)methanone (24). The title 
compound was prepared by reaction of (3-(benzyloxy)phenyl)(5-(3-isobutoxyphenyl)thiophen-2-
yl)methanone (24a) (200 mg, 0.45 mmol) and boron trichloride (0.90 mmol) according to 
method C. The product was purified by CC (hexane/ethyl acetate 8:2); yield 51 % (81 mg; white 
solid, mp. 90 
o
C). 
1
H NMR (CD3COCD3) δ 8.86 (s, 1H), 7.71 (d, J= 3.9 Hz, 1H), 7.59 (d, J= 3.9 
Hz, 1H), 7.42-7.33 (m, 6H), 7.13 (d, J=7.0 Hz, 1H),  7.00 (d, J= 7.3 Hz, 1H), 3.87 (d, J= 6.4 Hz, 
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2H), 2.09 (sept, J= 6.6 Hz, 1H), 1.05 (d, J= 6.7 Hz, 6H); 
13
C NMR (CD3COCD3) δ 187.81, 
160.94, 158.51, 153.32, 143.22, 140.35, 136.87, 135.42, 131.34, 130.68, 125.53, 121.18, 120.35, 
119.34, 116.32, 113.01, 75.10, 29.14, 19.52;  MS (ESI): 352.90 (M+H)
+
. 
3-(Methoxyphenyl)-(5-(3-methoxyphenyl)sulfanyl-thiophen-2-yl)-methanone (25a). 3-
Methoxybenzenethiol (111 mg, 1.0 mmol) was slowly added to a degassed mixture of (5-bromo-
thiophen-2-yl)(3-methoxyphenyl)methanone (21b) (300mg, 1.0 mmol), cupper II oxide (72 mg, 
0.5 mmol) and potassium hydroxide (56 mg, 1.0 mmol) in dimethylformamide (1 mL). The 
resulting mixture was heated at 135
o
C for 3 h, allowed to cool to rt and poured into a 0
o
C 6N 
HCl solution. After 15 min. the precipitate was filtered and washed with benzene. The filtrate 
was extracted with benzene, dried over magnesium sulfate, filtered, and concentrated under 
reduced pressure. The product was purified by CC (hexane/ethyl acetate 97:3); yield 75 % (270 
mg; yellow oil). 
1
H NMR (CDCl3) δ 7.65 (d, J = 3.9 Hz, 1H), 7.54 – 7.47 (m, 2H), 7.46 (dd, J = 
2.4, 1.4 Hz, 1H), 7.39 – 7.36 (m, 1H), 7.26 – 7.21 (m, 2H), 7.13 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H), 
7.10 – 7.07 (m, 1H), 6.95 (ddd, J = 8.3, 2.5, 0.8 Hz, 1H), 3.97 (s, 3H), 3.90 (s, 3H); 13C NMR 
(CDCl3) δ 186.88, 160.17, 159.61, 145.61, 145.27, 138.98, 136.07, 135.10, 131.94, 130.24, 
129.40, 122.77, 121.55, 118.61, 116.00, 113.77, 113.66, 55.42, 55.33; MS (ESI): 357.25 
(M+H)
+
.  
(3-Hydroxyphenyl)-(5-(3-hydroxyphenyl)sulfanylthiophen-2-yl)methanone (25). The title 
compound was prepared by reaction of (3-methoxyphenyl)-(5-(3-methoxy-phenylsulfanyl)-
thiophen-2-yl)methanone (25a) (300 mg, 0.84 mmol) and boron tribromide (5.04 mmol) 
according to method C. The product was purified by CC (Dichloromethane/methanol 99.5:0.5); 
yield 51 % (140 mg; yellow oil). 
1
H NMR (CD3OD) δ 7.60 (d, J = 4.0 Hz, 1H), 7.34 (t, J = 7.9 
Hz, 1H), 7.29 – 7.25 (m, 1H), 7.22 – 7.17 (m, 3H), 7.05 (ddd, J = 8.1, 2.5, 1.1 Hz, 1H), 6.91 
(ddd, J = 7.7, 1.7, 0.9 Hz, 1H), 6.88 – 6.85 (m, 1H), 6.77 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H); 13C 
NMR (CD3OD) δ 188.97, 159.59, 158.92, 147.64, 146.28, 140.15, 137.06, 137.00, 133.34, 
131.50, 130.78, 122.64, 121.32, 120.80, 118.28, 116.50, 116.49; MS (ESI): 328.92 (M)
+
.  
(5-(3-Hydroxybenzenesulfonyl)-thiophen-2-yl)-(3-hydroxyphenyl)methanone (26). The title 
compound was prepared by reaction of (3-hydroxy-phenyl)-(5-(3-hydroxy-
phenylsulfanyl)thiophen-2-yl)-methanone (25) (100 mg, 0.30 mmol) and H2O2 (30%, 0.1 mL) in 
acetic acid (2 mL). The solution was allowed to stand at rt for 4 days and was then poured into 
water. The solid was filtered off, washed with water and dried. The product was purified by CC 
(Dichloromethane/methanol 99:1); yield 64 % (70 mg, yellow solid, mp. 102 
o
C). 
1
H NMR 
(CD3OD) δ 7.72 (d, J = 4.0 Hz, 1H), 7.61 (d, J = 4.0 Hz, 1H), 7.49 – 7.44 (m, 1H), 7.44 – 7.38 
(m, 2H), 7.33 (t, J = 7.8 Hz, 1H), 7.27 (d, J = 7.7 Hz, 1H), 7.24 – 7.20 (m, 1H), 7.07 (dddd, J = 
5.0, 3.7, 2.5, 0.9 Hz, 2H); 
13
C NMR (CD3OD) δ 188.96, 159.83, 159.03, 151.00, 150.83, 143.33, 
139.20, 135.32, 134.36, 132.05, 130.97, 122.40, 121.66, 121.56, 119.45, 116.63, 114.92. MS 
(ESI): 362.23 (M+H)
+
. 
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(5-Bromothiophen-2-yl)(4-methoxyphenyl)methanone (27b). The title compound was 
prepared by reaction of 2-bromothiophene (1000 mg, 6.13 mmol), 4-methoxybenzoyl chloride 
(1046 mg, 6.13 mmol) and aluminum chloride (818 mg, 6.13 mmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 98:2); yield: 82 % (1.5 g; yellow powder; mp. 
103-104 
o
C). 
1
H NMR (CDCl3) δ 8.13 – 8.09 (m, 2H), 7.75 (d, J = 3.9 Hz, 1H), 7.45 (d, J = 3.9 
Hz, 1H), 7.22 – 7.20 (m, 2H), 4.14 (s, 3H); 13C NMR (CDCl3) δ 185.80, 162.10, 144.02, 137.59, 
133.23, 130.55, 125.10, 113.75, 55.40. 
(4-Methoxyphenyl)-(5-(3-methoxyphenyl)sulfanylthiophen-2-yl)methanone (27a). 3-
Methoxybenzenethiol (111 mg, 1.0 mmol) was slowly added to a degassed mixture of (5-Bromo-
thiophen-2-yl)(4-methoxyphenyl)methanone (27b) (300mg, 1.0 mmol), CuO (72 mg, 0.5 mmol) 
and potassium hydroxide (56 mg, 1.0 mmol) in dimethylformamide (1 mL). The resulting 
mixture was heated at 135
o
C for 3 h, allowed to cool to rt and poured into a 0
o
C 6N HCl 
solution. After 15 min. the precipitate was filtered and washed with benzene. The filtrate was 
extracted with benzene, dried over magnesium sulfate, filtered, and concentrated under reduced 
pressure. The product was purified by CC (hexane/ethyl acetate 99:1); yield 90 % (322 mg; 
brown oil). 
1
H NMR (CDCl3) δ 8.15 – 8.10 (m, 2H), 7.78 (d, J = 3.9 Hz, 1H), 7.53 – 7.49 (m, 
1H), 7.41 (d, J = 3.9 Hz, 1H), 7.27 – 7.23 (m, 2H), 7.21 (dt, J = 7.6, 1.9 Hz, 2H), 7.08 (ddd, J = 
8.3, 2.5, 0.8 Hz, 1H), 4.14 (s, 3H), 4.04 (s, 3H); 
13
C NMR (CDCl3) δ 185.84, 163.18, 160.16, 
146.00, 143.97, 136.55, 134.24, 132.43, 131.50, 130.28, 130.19, 122.40, 115.62, 113.75, 113.55, 
55.48, 55.35. 
(4-Hydroxyphenyl)-(5-(3-hydroxyphenyl)sulfanylthiophen-2-yl)methanone (27). The title 
compounds was prepared by reaction of (4-methoxyphenyl)-(5-(3-methoxyphenyl)sulfanyl-
thiophen-2-yl)methanone (27a) (300 mg, 0.84 mmol) and boron tribromide (5.04 mmol) 
according to method C. The product was purified by CC (dichloromethane/methanol 99:1); yield 
69 % (190 mg; yellow oil). 
1
H NMR (CD3OD) δ 7.78 – 7.76 (m, 1H), 7.75 – 7.74 (m, 1H), 7.53 
(d, J = 3.9 Hz, 1H), 7.17 – 7.12 (m, 2H), 6.91 – 6.89 (m, 1H), 6.89 – 6.87 (m, 1H), 6.86 (ddd, J = 
8.2, 2.4, 0.9 Hz, 1H), 6.85 – 6.83 (m, 1H), 6.73 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H); 13C NMR 
(CD3OD) δ 187.86, 163.59, 159.47, 146.94, 145.93, 137.47, 136.20, 133.80, 133.03, 131.47, 
129.96, 122.34, 117.94, 116.44, 116.28;  MS (ESI): 329.78 (M+H)
+
. 
(5-(3-Hydroxybenzenesulfonyl)-thiophen-2-yl)(4-hydroxyphenyl)methanone (28). The title 
compound was prepared by reaction of (4-hydroxy-phenyl)-(5-(3-hydroxy-
phenyl)sulfanylthiophen-2-yl)-methanone (27) (100 mg, 0.30 mmol) and hydrogen peroxide 
(30%, 0.1 mL) in acetic acid (2 mL). The solution was allowed to stand at rt for 4 days and 
poured into water, the solid was filtered off, washed with water, dried. The product was purified 
by CC (dichloromethane/methanol 99:1); yield 53 % (58 mg; yellow solid; mp. 88-9
o
C).  
1
H 
NMR (CD3OD) δ 7.82 – 7.80 (m, 1H), 7.80 – 7.78 (m, 1H), 7.73 (d, J = 4.0 Hz, 1H), 7.61 (d, J = 
4.0 Hz, 1H), 7.47 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.40 (t, J = 2.0 Hz, 
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1H), 7.08 (ddd, J = 8.0, 2.5, 1.1 Hz, 1H), 6.92 – 6.90 (m, 1H), 6.90 – 6.88 (m, 1H); 13C NMR 
(CD3OD) δ 187.49, 164.27, 159.84, 151.51, 150.11, 143.49, 134.41, 134.28, 133.36, 132.01, 
129.13, 122.31, 119.37, 116.57, 114.87; MS (ESI): 362.38 (M+H)
+
. 
 
Biological methods. [2,4,6,7-3H]-E1 and [2,4,6,7-3H]-E2 were bought from Perkin-Elmer, 
Boston. Quickszint Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
Preparation of human 17β-HSD1 and 17β-HSD2. Human 17β-HSD1 and 17β-HSD2 were 
obtained from human placenta according to previously described procedures.
39
 Fresh human 
placenta was homogenized, and cytosolic fraction and microsomes were separated by fractional 
centrifugation. For the partial purification of 17β-HSD1, the cytosolic fraction was precipitated 
with ammonium sulfate. 17β-HSD2 was obtained from the microsomal fraction. 
Inhibition of human 17β-HSD1. Inhibitory activities were evaluated by an established method 
with minor modifications.
39
 Briefly, the enzyme preparation was incubated with NADH (500 
µM) in the presence of potential inhibitors at 37
o
C in a phosphate buffer (50 mM) supplemented 
with 20% of glycerol and EDTA (1 mM). Inhibitor stock solutions were prepared in DMSO. The 
final concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was 
started by addition of a mixture of unlabelled- and [2, 4, 6, 7-
3
H]-E1 (final concentration: 500 
nM, 0.15 µCi). After 10 min, the incubation was stopped with HgCl2 and the mixture was 
extracted with diethylether. After evaporation, the steroids were dissolved in acetonitrile. E1 and 
E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 reverse phase 
chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to 
a HPLC-system (Agilent 1200 Series, Agilent Technologies, Waldbronn). Detection and 
quantification of the steroids were performed using a radioflow detector (Berthold Technologies, 
Bad Wildbad). The conversion rate was calculated after analysis of the resulting chromatograms 
according to the following equation: 
%conversion = [%E2/(%E2 + %E1)]x100 
Each value was calculated from at least three independent experiments. 
Inhibition of human 17β-HSD2. The h17β-HSD2 inhibition assay was performed similarly to 
the h17β-HSD1 procedure. The microsomal fraction was incubated with NAD+ [1500 µM], test 
compound and a mixture of unlabelled- and [2,4,6,7-
3
H]-E2 (final concentration: 500 nM, 0.11 
µCi) for 20 min at 37 
o
C. Further treatment of the samples and HPLC separation was carried out 
as mentioned above.  
The conversion rate was calculated after analysis of the resulting chromatograms according to 
the following equation: 
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%conversion = [%E1/(%E1 + %E2)]x100 
Preparation of murine 17β-HSD1. Recombinant mouse 17β-HSD1 enzyme was produced by 
transfection of HEK 293 cells with a mouse 17β-HSD1 expression plasmid (coding sequence of 
NM_010475 in pCMV6Entry vector, OriGene Technologies, Inc.). 48 hours after transfection 
cells were homogenized by sonication (3 x 10 s) in a buffer containing saccharose (40 mM Tris, 
250 mM saccharose, 5 mM EDTA, 7 mM DTT, 1 mM PMSF, pH 7.5). Cell lysate was 
centrifuged (1000 g, 15 min, 4°C) and 20% glycerol was added to the supernatant before aliquots 
were frozen and stored at -70°C.
47
 
Inhibition of murine 17β-HSD1. Inhibitory activities of the compounds towards mouse 17β-
HSD1 were evaluated by an established method with minor modifications.
48
 The enzyme 
preparation was incubated with inhibitors, NADPH (0.5 mM) and a mixture of unlabeled- and 
[3H]-E1 (final concentration: 10 nM, 0.15 μCi) for 10 min at 37 oC. Further treatment of the 
samples and HPLC separation was carried out as mentioned above.  
The conversion rate was calculated after analysis of the resulting chromatograms according to 
the following equation: 
%conversion = [%E2/(%E2 + %E1)]x100 
Molecular Modeling 
Local docking experiments followed by an energy minimization step were performed with 
YASARA structure using the AMBER03 force field.
49, 50
 Protein coordinates were prepared 
starting from a crystal structure of human 17β-HSD1 in complex with estradiol and NADP+ 
(PDB ID: 1FDT).
51
 After removal of ligand atoms, a grid box of approximately 7.5 nm³ was set 
up around the active site of the enzyme.  The flexible local docking experiment using the built-in 
AutoDock 4 algorithm and 999 docking runs was performed with energy-minimized manual 
models of inhibitors 25 and 26.
52
 Highest-ranked enzyme-inhibitor complexes were subjected to 
an energy minimization step with fixed protein backbone atoms. Ligand-protein interactions of 
the yielded structures were analyzed with MOE 2010. 
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Spplemantary table S1: HPLC Purity Control of Final Compounds 
The purity of the compounds was evaluated by LC/MS. The Surveyor®-LC-system consisted of 
a pump, an auto sampler, and a PDA detector. Mass spectrometry was performed on a TSQ® 
Quantum (ThermoFisher, Dreieich, Germany). The triple quadrupole mass spectrometer was 
equipped with an electrospray interface (ESI). The system was operated by the standard software 
Xcalibur®. A RP C18 NUCLEODUR® 100-5 (3 mm) column (Macherey-Nagel GmbH, 
Dühren, Germany) was used as stationary phase. All solvents were HPLC grade. In a gradient 
run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) was increased from an 
initial concentration of 0% at 0 min to 100 % at 15 min and kept at 100 % for 5 min. The 
injection volume was 15 µL and flow rate was set to 800 µL/min. MS analysis was carried out at 
a needle voltage of 3000 V and a capillary temperature of 350 °C. Mass spectra were acquired in 
positive mode from 100 to 1000 m/z and UV spectra were recorded at the wave length of 254 
nm. 
 
Spplemantary table S1: HPLC Purity Control of Final Compounds 
Comd Rt 
(min) 
HPLC 
purity 
(≥ %) 
Comd Rt 
(min) 
HPLC 
purity 
(≥ %) 
Comd Rt 
(min) 
HPLC 
purity 
(≥ %) 
1 14.49 99 11 15.90 98 21 14.62 98 
2 15.25 97 12 15.66 98 22 13.75 99 
3 15.65 95 13 15.95 99 23 11.93 95 
4 14.49 98 14 16.48 98 24 14.13 95 
5 12.18 95 15 16.74 98 25 13.46 99 
6 11.68 99 16 14.91 96 26 10.95 97 
7 16.27 98 17 12.11 95 27 12.20 99 
8 14.76 98 18 14.49 95 28 10.74 99 
9 14.30 98 19 14.58 95    
10 17.23 96 20 13.43 99    
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3.II Halogenated 17β-HSD1 Inhibitors: Discovery of Highly Potent 
and Metabolically Stable Compounds Enabling a Proof of Principle 
Study in Rodents 
 
 This chapter will be submitted for publication in the Journal of Medicinal Chemistry 
 The structures of the compounds described therein and their biological properties are 
subject of patent applications.  
 
Abstract 
 
The most potent naturally occurring member of estrogens is 17β-estradiol (E2), which known to 
be involved in development and proliferation of estrogen-dependent diseases (EDD) like breast 
cancer and endometriosis. 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the 
last step of E2 biosynthesis from its weakly estrogenic precursor estrone (E1). Consequently, 
17β-HSD1 came into the focus of interest as a novel therapeutic target for the treatment of EDD. 
Bicyclic substituted hydroxyphenyl methanones (BSHs), an inhibitor class described by us 
previously, not only display high inhibitory potency towards human 17β-HSD1, but also activity 
towards mouse 17β-HSD1 and fair metabolic stability in human liver microsomes. The aim of 
this study were structural optimizations in the BSHs class to obtain a suitable candidate for a 
proof of principle (PoP) study in an animal disease model for endometriose. In this work, we 
describe the most potent nonsteroidal h17β-HSD1 inhibitors up to date with IC50s in the 
picomolar range. In addition, they showed good selectivities towards the type 2 enzyme, which 
catalyzes the reverse reaction, and the estrogen receptors α and β. Compound 43, one of the most 
interesting h17β-HSD1 inhibitors discovered in this study, showed high stability towards both 
phase I and II metabolism in human liver microsomes (S9 fraction; 72 % remaining after 60 
min). Moreover, activity towards rodent 17β-HSD1 could be significantly improved. Compound 
47 showed strong inhibition of the rat enzyme (63 % inhibition @ 250 nM) and could thus be 
considered a possible candidate for a PoP study. 
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Introduction 
 
In humans, 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyses the NAD(P)H 
dependent transformation of estrone (E1) to estradiol (E2) which represents the most potent 
estrogen (fig. 1).
1
 E2 is known to play a crucial role in the development and progression of 
several estrogen dependent diseases (EDD).
2-5
 Increased E2/E1 ratios as well as elevated 17β-
HSD1 m-RNA levels are indicators of the essential importance of 17β-HSD1 in breast cancer6, 7, 
ovarian tumor
8
, endometriosis
9
, endometrial hyperplasia
10
 and other EDD
11
. Consequently, the 
selective inhibition of this enzyme is considered as a valuable treatment option. Due to the 
tissue-selective expression and the intracrine mode of action of 17β-HSD112, its inhibition should 
be associated with less side effects compared to established treatments using GnRH-analogs, 
aromatase inhibitors, anti-estrogens or selective estrogen receptor modulators (SERMs).
13-15
 For 
the prospect of less side effects, however, inhibition of 17β-HSD1 should be selective. For 
instance, 17β-HSD2, which may have opposing action, and the estrogen receptors (ER) α and β 
should not be influenced. 
 
17-HSD2, NAD+HO
O
HO
OH
17-HSD1, NAD(P)H
E1                                                                                            E2  
Figure 1. Interconversion of Estrone (E1) and Estradiol (E2). 
 
Therapeutics interfering with intracrine pathways of hormone biosynthesis are already in clinical 
use, eg. 5α-reductase inhibitors.16-19 Although a number of steroidal and non-steroidal inhibitors 
of 17β-HSD120-22 are described and there is experimental evidence for the effectiveness of 17β-
HSD1 inhibition against human tumor cell lines in vitro and in animal models, there is no 
inhibitor under clinical evaluation. Moreover, no proof of principle study has been conducted for 
the indication endometriosis, although this is a widespread disease for which no adequate 
medical treatment is available. 
One important reason for this may be interspecies differences between human 17β-HSD1 and 
animal orthologs which impede corresponding in vivo experiments, eg. in rodents.
23
 Thus, human 
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and rodent 17β-HSD1 are 83 % similar and show significant differences concerning the topology 
of the substrate binding site.
24, 25
 As a consequence, compounds highly active towards the human 
enzyme are often weakly active or inactive towards mouse or rat 17β-HSD1.  
The aim of this study was the design of compounds inhibiting both human and rodent 17β-
HSD1, displaying favorable in vitro ADME properties. Starting point was the class of bicyclic 
substituted hydroxyphenylmethanones (BSHs).
26, 27
 In contrast to most other classes of 17β-
HSD1 inhibitors described by us
28-35
, it contains members which not only are strong inhibitors of 
the human enzyme but also show inhibition of the murine ortholog (unpublished results). 
Examples are compounds I and II (fig. 2).
26, 27
 Drug design included modification of the 
sulfonamide moiety as well as optimization of the core structure (ABC-system) with the aim of 
enhancing inhibitory activity towards rodent 17β-HSD1 (mouse, rat) while maintaining activity 
towards the human enzyme and selectivity over the type 2 enzyme. Rational strategies were 
applied to elucidate drug metabolism and to obtain metabolically stable compounds. In addition, 
the implementation of favorable lipophilicities was taken into account.  
 
CB
A
SO
HO
OHCB
A
SO
HO
NH
SO O
D
Compound I Compound II
Human 17b-HSD1: (IC50 = 12 nM)
Human 17b-HSD2: (IC50 = 168 nM)
Mouse 17b-HSD1: (% inhibition @ 1 µM =  28)
Metabolic stability: t1/2 (phase I) = 13 min
Human 17b-HSD1: (IC50 = 8 nM)
Human 17b-HSD2: (IC50 = 384 nM)
Mouse 17b-HSD1: (% inhibition @ 1 µM =  20)
Metabolic stability: t1/2 (phase I) = 100 min, t1/2 (s9) = 4 min
 
Figure 2. Examples of bicyclic substituted hydroxyphenylmethanones (BSHs). 
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Design 
From previous studies it was known that in the class of bicyclic substituted 
hydroxyphenylmethanones, inhibition of the target enzyme is strongly dependent on the 
substitution pattern of the benzoyl ring (fig. 2, ring A). Here, already minor variations were 
found to induce dramatic changes in activity. In contrast, it is rather selectivity (towards 17β-
HSD2) than inhibitory potency which is influenced by the introduction of substituents at the 
phenyl ring (ring C). For instance, the presence of an aromatic sulfonamide moiety proved to be 
beneficial.
27
 
The fact that only one inhibitor bearing an aromatic sulfonamide moiety was described in the 
past prompted us to explore this group in more detail (chart 1, design step I). Its optimal position 
on the phenyl ring C (compounds 1-10) was determined, and the analogous (methylated) 
carbonic acid amides were investigated as possible bioisosteres (compounds 11 and 12). 
Moreover, compounds 13-29 with diverse substituents on ring D were prepared in a parallel 
synthesis approach in order to explore the chemical space more thoroughly. 
At this point, there was evidence that, in terms of biological activities towards human 17β-HSD1 
and 2, the synthesized sulfonamides do not have advantages over compounds devoid of the 
sulfonamide group. In addition, the core structure of the inhibitors, consisting of the ABC-ring 
system, displayed liability towards phase II metabolism reactions due to the presence of phenolic 
OH-groups. For these reasons, further optimiziation steps were performed which focused on the 
core structure, considering the following structure activity relationships obtained in a previous 
study: 
26, 27
 
Ring A 
 the OH-group on the benzoylic moiety (ring A) is very important for activity 
 only minor structural variations in this part are tolerated by the target enzyme 
 
Ring C 
 the OH-group on the phenyl ring (ring C) is not essential for inhibitory activity, 
though generally it proved to be beneficial for selectivity towards the type 2 
enzyme 
 major structural variations can be carried out without loss of activity 
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Two strategies were applied to enhance metabolic stability (design step II, compounds 31-50): 
 Small substituents (methyl or fluorine) were introduced in ring A in order to 
protect its hydroxy group from phase II metabolism (first strategy). 
 The OH-group of ring C was replaced by other functionalities or shielded by 
bulky and/or electron withdrawing groups (second strategy).  
In addition, ring C was modified by replacement with heterocycles or by substitution with 
heterocyclic moieties in order to decrease the lipophilicity of the compounds (compounds 51-53 
and 56-60). 
Biological data suggested that the presence of the sulfonamide moiety is beneficial concerning 
inhibition of mouse 17β-HSD1, thus possibly allowing for an in vivo proof of principle study. 
Therefore, a final design step was envisaged based upon the results of the design steps I and II, 
leading to fluorinated sulfonamide-type inhibitors (design step III; compounds 62-69).  
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Chart 1. Design of Synthesized Compounds 1 – 69. 
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30-55
1
2
3
4
5
6
SO
R3
HO R1
R2
1, 3-5
SO
HO
56-60
SO
HO
R2
R1
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Comd R1 R2 R3 Comd R1 R2 R3 
1 - - NH2 2 - H NH2 
3 - - S
O
NH
O  
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O
NH
O
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O
CF3
 
5 - - 
S
O
NH
O
CN
 
6 - H S
O
NH
O  
7 - H 
S
O
NH
O
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O
CF3
 
8 - H 
S
O
NH
O
CN
 
9 - H S
O
NH
O S  
10 - H 
S
O
NH
O
OH
 
11 - H 
O
NH
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O
N
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O
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O
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S
O
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O
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Comd R1 R2 R3 Comd R1 R2 R3 
15 - H 
S
O
NH
O
NO2
 
16 - H S
O
NH
O
NO2
 
17 - H 
S
O
NH
O
O2N NO2
 
18 - H 
S
O
NH
O
F
 
19 - H 
S
O
NH
O
F
 
20 - H S
O
NH
O
F
 
21 - H S
O
NH
O
Br
 
22 - H S
O
NH
O
Br
F
F  
23 - H S
O
NH
O
OH
Cl
Cl
 
24 - H 
S
O
NH
O
OCH3
 
25 - H 
S
O
NH
O
NH
O
 
26 - H S
O
NH
O  
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Comd R1 R2 R3 Comd R1 R2 R3 
27 - H S
O
NH
O  
28 - H 
S
O
NH
O
F
OCH3
 
29 - H 
S
O
NH
O
F
OH
 
30 H H 
F
F
 
31 2-CH3 H 
F
F
 
32 2-CH3 CH3 
F
F
 
33 2-F H 
F
F
 
34 2,6-di-F H 
F
F
 
35 2-CH3 H 
OH
Cl
 
36 2,6-di-F H 
OCH3
Cl
 
37 2,6-di-F H 
OH
Cl
 
38 2,6-di-F CH3 
OCH3
Cl
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OH
Cl
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Cl
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F
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S
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Comd R1 R2 R3 Comd R1 R2 R3 
67 2,6-di-F H S
O
NH
O  
68 2,6-di-F CH3 S
O
NH
O  
69 2,6-di-F CH3 S
O
N
O  
    
 
Chart 2. Overview on synthesized compounds 1-69. 
 
Chemistry 
 
The key intermediates I-VI were synthesized in good yield from the appropriate benzoyl 
chlorides and thiophenes using Friedel-Crafts conditions (scheme 1, method A). Followed by 
ether cleavage
36
 of intermediates I, V and VI yielded VII, VIII and IX (method B) in 
quantitative yield, respectively. 
VII Was reacted with 4-aminophenylboronic acid pinacol ester in a Suzuki cross coupling 
reaction
37
 to afford the final compound 1. Compounds 2 and 61 were prepared from I and V, 
respectively, using the same methods as for 1 but in reversed order because the intermediates 2a 
and 61a were needed as starting materials in the syntheses according to scheme 2, vide infra. 
The sulfonic acid amides 3-28 and 65-67 were synthesized by reaction of 1, 2 and 61, 
respectively, with the corresponding sulfonic acid chlorides at room temperature. Cleavage of the 
ether function of 28 gave the dihydroxylated compound 29. (Scheme 1) 
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Comd R5 Comd R5 Comd R5 
3 H 16 4-NO2 25 3-NHCOMe 
4 4-Br-2-OCF3 17 2,3-di-NO2 26 2-Me 
5 3-CN 18 2-F 27 3-Me 
6 H 19 3-F 28 2-F-4-OMe 
7 4-Br-2-OCF3 20 4-F 29 2-F-4-OH 
8 3-CN 21 4-Br 65 
N
 
13 4-CN 22 4-Br- 2,5-di-F 66 
N
N
 
14 2-NO2 23 3,5-di-Cl-4-OH 67 
 
15 3-NO2 24 3-OMe   
Scheme 1: synthesis of compounds 1-29 and 65-67.  a) method A, AlCl3, anhydrous CH2Cl2, 0 
o
C, 
0.5h and then rt, 3h. b) method B, BBr3, CH2Cl2, -78
o
C to rt, overnight. c) method C1, 3-
aminophenylboronic acid or 4-aminophenylboronic acid pinacol ester, Cs2CO3, Pd(PPh3)4, DME/water 
(1:1), reflux, 4h. d) method D, pyridine, corresponding sulfonyl chloride, rt, overnight. 
 
Reaction of 2a with 3-methoxybenzenesulfonyl- or 3-methoxybenzoyl chloride yielded the 
corresponding intermediates 10a and 11a, which were submitted to ether cleavage to give the 
final compounds 10 and 11, respectively. (Scheme 2) 
N-Methylation of compound 11a with methyl iodide afforded 12a which was reacted with BBr3 
in dichloromethane (method B) to give 12. 
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Interestingly, the synthesis of the fluorinated sulfonamides 62-64 starting from the phenol 61 
(analogously to the preparation of the fluorinated sulfonamides 65-67) proved to be difficult due 
to purification issues. This problem could be solved by employing the ether intermediate 61a 
instead of the phenol 60 as starting material and conducting O-demethylation of the 
intermediates 62a-64a as the final step. 
 
2a(R1 = OCH3, R2 = H)
61a(R1 = OCH2CH3, R2 = 2,6-di-F)
10a(X = SO2)
11a(X = CO)
62a(R3 = 2-OCF3-4-Br)
63a(R3 = 2-OCF3)
64a(R3 = 2-CF3)
1
2
3
4
5
6
a
O
OH
S
N
X
R3
c
b
b
OH
12a
a
b
10(R3 = H, X = SO2)
11(R3 = H, X = CO)
12(R3 = CH3, X = CO)
62(R3 = 2-OCF3-4-Br)
63(R3 = 2-OCF3)
64(R3 = 2-CF3)
SO
NH2
R1 R2
SO
NH
O
X
O
SO
N
O
X
O
SO
NH
O
SO O
F
F
R3
SO
NH
HO
SO O
F
F
R3
 
Scheme 2: synthesis of compounds 10-12 and 62-64. a) method D, pyridine, ArXCl, rt (reflux in case of X = CO), 
overnight. b) method B, BBr3, CH2Cl2, -78
o
C to rt, overnight. c) NaH, DMF, MeI, 0
o
C to rt, 0.5h.  
 
For the preparation of compounds 30-35 the key intermediates I-V were submitted to a Suzuki 
reaction (method C1 or C2) with the appropriate boronic acid to give the corresponding 
intermediates 30a-34a, 35b, 52a and 53a. Which were treated in different ways: The esters 31a, 
32a, and 35b were saponificated with 2M NaOH to give the phenols 31, 32, and 35a in good 
yield. The other intermediates were submitted to ether cleavage with BBr3 in dichloromethane to 
afford the final compounds 30, 33-35, 52, and 53. (Scheme 3) 
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III(R2 = H)
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Scheme 3: synthesis of compounds 30-35, 52, and 53. a) method C1, corresponding boronic acid, Cs2CO3, 
Pd(PPh3)4, DME/water (1:1), reflux, 4h; method C2, 4- pyridinylboronic acid pinacol ester or 3-pyridinylboronic 
acid for 52a and 53a, respectively, Na2CO3, Pd(PPh3)4, toluene/ethanol (1:1), reflux, overnight.  b) method B, BBr3, 
CH2Cl2, -78
o
C to rt, overnight. c) 10% NaOH, ethanol, reflux, 2h. 
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As depicted in scheme 4, the compounds 36-43, 41a, 46-51, 54 and 55 were obtained from the 
intermediates VII-IX by standard methods (either Suzuki reaction (method C1) alone or 
followed by ether cleavage (method B)). 
The synthesis of compound 45 was accomplished as shown in scheme 5: Bromination of 2-
chloro-6-methylphenol with NBS in acetic acid selectively gave the ring-brominated compound 
44c, which underwent methylation upon treatment with methyl iodide. The resulting compound 
44b was transformed to the boronic acid ester 44a. Finally, Suzuki cross coupling reaction of the 
latter with VIII yielded compound 44, which was sub mitted to ether cleavage with BBr3, 
resulting in 45. 
2 6
4
5
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VIII(R1 = 2,6-di-F, R2 = H)
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Comd R1 R2 R3 Comd R1 R2 R3 
36 H H OCH3 43 Cl - Cl 
37 H H OH 46 CH3 OCH3 CH3 
38 CH3 H OCH3 47 CH3 - CH3 
39 CH3 H OH 48 F OCHF2 F 
40 H H H 49 CN OCH(CH3)2 H 
41a H OCH3 H 50 CN - H 
41 H OH H 51 
SO2-4-
morpholine 
OCH3 H 
42 Cl OCH3 Cl     
Scheme 4: synthesis of compounds 36-43, 46-51, 54 and 55. a) method C1, boronic acid derivative, 
Cs2CO3, Pd(PPh3)4, DME/water (1:1), reflux, 4h. b) method B, BBr3, CH2Cl2, -78
o
C to rt, overnight. 
 
The boronic acid ester 44a was also used as starting material for the syntheses leading to 
compounds 56-58 (scheme 5). By using NBS and DBPO in CCl4, 44a was converted to the 
brominated intermediate 56b. Nucleophilic substitution of the the bromine atom with 1-
piperazine-1-ylethanone yielded 56a. The latter was reacted with VIII in a Suzuki reaction 
(method C1) to afford compound 56, which gave access to 57 (via ether cleavage) and 58 (via 
amide hydrolysis under acidic conditions). O-demethylation of 58 failed. 
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Scheme 5: synthesis of compounds 44, 45, and 56-58. a) NBS, AcOH, rt, overnight. b) CH3I, K2CO3, DMF, rt, 
overnight. c) bispinocolato diborane, PddppCl2, KOAc/DMSO, 2h. d) method C1, III, Cs2CO3, Pd(PPh3)4, 
DME/water (1:1), reflux, overnight. e) method B, BBr3, CH2Cl2, -78
o
C to rt, overnight. f) NBS, DBPO, CCl4, reflux, 
2h. g) NEt3, 1-Piperazin-1-yl-ethanone. h) HCl 6M, reflux, 2h. 
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The azide intermediate 59c was prepared by reaction of 56b with NaN3 in DMF. The subsequent 
Suzuki cross-coupling reaction with VIII yielded 59b, which was submitted to a cycloaddition 
reaction with acetic acid vinyl ester
38
 to give the 1,2,3-triazole substituted compound. 
Interestingly, the latter was isolated as acetic acid ester 59a exclusively. Saponification with 2M-
NaOH gave the phenol 59, which was transformed to the diol 60 by reaction with BBr3 (method 
B). (Scheme 6) 
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Scheme 6: synthesis of compounds 59 and 60. a) DMF, rt, overnight. b) method C1, VIII, Cs2CO3, Pd(PPh3)4, 
DME/water (1:1), reflux, overnight. c) CH3COOCH=CH2, microwave, 120 
o
C, 10h. d) 2M NaOH, THF, rt, 2h. e) 
method B, BBr3, CH2Cl2, -78
o
C to rt, overnight. 
 
The synthesis of compounds 68 and 69 started with the reaction of 3-methyl-5-bromoaniline and 
cyclopropanesulfonyl chloride to afford 68b. Subsequent methylation yielded the N-methyl 
sulfonamide 69b. Intermediates 68b and 69b were converted to the corresponding boronic acid 
esters 68a and 69a, respectively, by a Pd-catalyzed reaction with bispinacolato diborane in the 
presence of potassium acetate in DMSO. Suzuki cross coupling reaction with VIII afforded the 
final compounds 68 and 69. (Scheme 7) 
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Scheme 7: synthesis of compounds 68 and 69. a) method D, pyridine, cyclopropanesulfonyl chloride, rt, overnight. 
b) bispinacolato diborane, PddppCl2, KOAc/DMSO, 2h. c) NaH, DMF, MeI, 0
o
C to rt, 0.5h. d) method C1, VIII, 
Cs2CO3, Pd(PPh3)4, DME/water (1:1), reflux, 3 days. 
 
Biological results 
 
Inhibition of human 17β-HSD1 and selectivity towards 17β-HSD2, ERα, and ERβ 
Human placental enzymes were used for both 17β-HSD assays and were obtained according to 
described methods.
39-41
 In the 17β-HSD1 assay, incubations were run with cytosolic fractions, 
tritiated E1, cofactor and inhibitor. The separation of substrate and product was accomplished by 
HPLC. The 17β-HSD2 assay was performed similarly using tritiated E2 as substrate and the 
microsomal fraction. Activities are given as percent inhibition at 1 µM (tables 1-6).  
The 17β-HSD1 inhibition of the sulfonamide-type compounds 3-8 is strongly dependent on the 
position of the sulfonamide nitrogen at phenyl ring C (cf. chart 1): Compounds bearing the 
sulfonamide moiety in m-position to the thiophene ring (compounds 6-8, table 1) show 
significantly higher inhibitory potency compared to their corresponding p-substituted isomers 3-
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5. Interestingly, the parent anilines 1 and 2 show a reversed correlation between position of the 
nitrogen atom and inhibitory potency. Bioisosteric replacement of the benzenesulfonic moiety of 
compound 6 with a thiophenesulfonic group leads to compound 9 with similar activity and 
selectivity towards the type 2 enzyme. In general, the compounds displayed in table 1 show 
rather low selectivities with respect to 17β-HSD2 inhibition with the exception of compound 7 
(SF = 25) which at the same time shows the strongest inhibition of the target enzyme (IC50 = 8 
nM).  
The m-sulfonamide function may be bioisosterically replaced by the carbonic acid amide 
function as can be seen by comparison of the inhibitory potencies of compounds 10 and the only 
slightly less active 11 (table 1). Methylation of the amide group further decreases activity 
(compound 12). 
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Table 1. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 1-12. 
1, 2 3 - 8, 10 9
1
2 3
4
56
A
11-12
SO
HO
SO
HO
SO
HO
NH
S
S
O
O
SO
HO
N
O
R
HO
NH
S
O
O
R
R
B C
D
1
2 3
4
56
 
Comd Ring C R IC50 [nM]
a
 SF
d
 LogP
e
 LogD@p
H 7.4
e
 
h17β-HSD1b 
h17β-
HSD2
c
 
1 - 4-NH2 145  120  0.8  3.02 3.0 
2 - 3-NH2 77 %
f
 68 %
f
 - 2.67 2.7 
3 4 H 195 459  2.3  4.90 4.8 
4 4 4-Br-2-OCF3 169 716 4.2 7.00 6.5 
5 4 3-CN 151  763  5.0  4.83 4.5 
6 3 H 21 112  5.2  4.59 4.5 
7 3 4-Br-2-OCF3 8 199  25.0  5.97 5.2 
8 3 3-CN 23  171  7.5  4.53 4.0 
9 - - 39 114 3.0 4.50 4.0 
10 3 3-OH 16  88  5.4  3.62 3.5 
11 - H 33 159  4.8  4.28 4.3 
12 - CH3 71  218  3.0  4.02 4.0 
a
 Mean value of three determinations, standard deviation less than 15%. 
b
 Human placenta, cytosolic fraction, 
substrate [
3
H]-E1, 500 nM, cofactor NADH, 500 µM. 
c
 Human placenta, microsomal fraction, substrate [
3
H]-E2, 
500 nM, cofactor NAD
+
, 1500 µM. 
d
 Selectivity factor: IC50(17β-HSD2) / IC50(17β-HSD1). 
e
 Calculated LogP and 
LogD@ pH 7.4 data. 
f
 Inhibition @ 1µM (inhibitor concentration). 
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The favorable biological data of compound 7 prompted us to further investigate the effect of 
different substituents R on the benzenesulfonyl moiety on inhibitory poteny (compounds 13-29, 
table 2). All these compounds basically show comparable inhibition of 17β-HSD1, 
independently of the nature of the substituent (electron-donating or –withdrawing). It seems, 
however, that bulky and/or hydrophilic substituents somewhat decrease potency (e.g. compounds 
17 and 25). None of the compounds 13-29 exceeds compound 7 concerning activity and 
selectivity. Compound 7, however, shows drawbacks like high lipophilicity and molecular 
weight, moderate metabolic stability, and insufficient activity towards the murine 17β-HSD1 
enzyme (see table 9). In order to tackle these problems, we turned our attention to the 
optimization of the the main parts of this class of inhibitors, namely the ABC-ring system (cf. 
chart 1). 
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Table 2. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 13-29. 
13-29
SO
HO
NH
SO
O
R
 
Comd R IC50 [nM]
a
 SF
d
 LogP
e
 LogD@ 
pH 7.4
e
 
h17β-HSD1b h17β-HSD2c 
13 4-CN 56  392  7.0  4.50 3.9 
14 2-NO2 32  148  4.6  4.61 4.2 
15 3-NO2 47  130  2.7  4.82 4.6 
16 4-NO2 42 320  7.7  4.79 4.1 
17 2,3-di-NO2 182  322  1.8  4.99 4.2 
18 2-F 50  116  2.3  4.40 4.1 
19 3-F 38  185  4.9  5.01 4.8 
20 4-F 30  83  2.7  4.91 4.5 
21 4-Br 50  162  3.2  5.63 5.3 
22 4-Br- 2,5-di-F 109  144  1.3  5.27 4.2 
23 3,5-di-Cl-4-OH 135  126  0.9  6.19 3.5 
24 3-OMe 35 130 3.7 4.95 4.8 
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25 3-NHCOMe 311 282 0.9 3.22 3.1 
26 2-Me 17  104  6.1  5.05 4.9 
27 3-Me 18  99  5.5  5.05 5.0 
28 2-F-4-OMe 51  112  2.2  4.97 4.6 
29 2-F-4-OH 112  215 1.9  4.53 3.6 
a-e
 See table 1. 
 
Starting from the moderately active compound 30, introduction of substituents to the benzoyl 
moiety results in very different effects on activity and selectivity, depending on the type of the 
substituent: Methylation leads to a strong decrease in 17β-HSD1 inhibition (compound 31). In 
addition, this compound shows stronger inhibition of the type 2 than of the type 1 enzyme, as 
does the parent compound 30. Compound 32, bearing a second methyl group at the thiophene 
ring, shows a similar behavior. In contrast, introduction of one or two fluorine atoms on the 
benzoyl part results in a strong increase of 17β-HSD1 inhibition (compound 33: IC50 = 11 nM; 
compound 34: 3.5 nM), which, unfortunately comes along with poor selectivity. In order to 
increase selectivity, we made use of the fact that an OH-group in 4-position of the phenyl ring 
(ring C) is beneficial for selectivity (compound C).
27
 Also in this case, introduction of a CH3-
group is detrimental to inhibitory potency and to selectivity (compound 35: IC50 = 90 nM; SF = 
0.3), whereas the introduction of fluorine increases activity toward 17β-HSD1 by a factor of 10 
and maintains selectivity (compound 37: IC50 = 0.5 nM, SF = 40). The additional introduction of 
a methyl group at the thiophene moiety reduces selectivity (compound 39). Maintaining the 2,6-
difluoro substitution pattern of the benzoyl moiety, which proved to be beneficial for activity 
towards 17β-HSD1, while removing the OH-group at the phenyl ring or changing its position 
from para to ortho leads to a decrease (compound 40) or a complete loss of selectivitity 
(compound 41). 
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Table 3. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 30-41. 
30-34
SO
HO
R1
R2
R3
F
F
C, 35-37
SO
HO
R1
R2
R3
Cl
38-41
SO
HO
F
F
R3
Cl
R1
R2
 
Comd R1 R2 R3 IC50 [nM]
a
 SF
d
 LogP
e
 LogD@ 
pH7.4
e
 
17β-
HSD1
b
 
17β-
HSD2
c
 
30 H H H 213
g
 177
g
 0.8 4.71 4.7 
31 CH3 H H 3427 299 0.09 4.6 4.6 
32 CH3 H CH3 20 %
 f
 66 %
 f
 - 5.63 5.6 
33 F H H 11
g
 8
g
 0.7 4.51 4.3 
34 F F H 3.5 9 2.5 4.44 4.3 
C H H OH 5.0 246 48.0 3.98 3.8 
35 CH3 H OH 355 90 0.3 4.44 4.3 
36 F F OCH3 1.3 11 9.0 4.52 4.4 
37 F F OH 0.5 20 40.0 4.16 3.8 
38 CH3 H OCH3 5.5 52 9.5 4.92 4.8 
39 CH3 H OH 0.8 11 13.0 4.63 4.3 
40 H H H 1.2 10 8.3 4.51 4.4 
41 H OH H 27 29 1.1 3.43 2.9 
a-f
 See table 1. 
g
 Calculated IC50(IC50(Logit)) = test concentration ((100-%inh.)/%inh.). 
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The SAR obtained so far indicate a beneficial effect of a p-OR group (R = H, CH3) at the phenyl 
ring (ring C) for selectivity over 17β-HSD2. Therefore, this group was retained in the further 
drug design concept. In order to protect it from possible metabolic alteration, bulky and/or 
electron withdrawing groups were introduced in the o-positions (table 4, compounds 42-51). 
Interestingly, compounds bearing chloro- and methyl-substituents (compounds 42-47) show 
similarly strong inhibition of the target enzyme but only in case of two identical substituents 
(either chloro or methyl) good selectivities can be achieved. This is especially true for the 
dichloro-substituted compound 42 which is not only one of the most active but also the most 
selective compound of its class (IC50 = 0.5 nM; SF = 82). Comparison with the inhibition data of 
the analog non-fluorinated compound 54 highlights again the beneficial impact of the fluorine 
atoms at the benzoyl moiety. The same dependence of activity on benzoyl fluorination can be 
seen when comparing compounds 43 and 55. The introduction of other strongly electron 
withdrawing functions as fluorine, nitrile or a sulfonamide group (compounds 48-51) leads to 
less favorable biological properties. The pyridine ring is not an adequate replacement for the 
hydroxyphenyl moiety (compounds 52 and 53). 
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Table 4. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 42-55. 
42-51
SO
HO
F
F
R2
52, 53
SO R1
R2
HO
F
F
54, 55
SO
HO
R1
Cl
R1
R3
Cl
 
 
Comd R1 R2 R3 IC50 [nM]
a
 SF
d
 LogP
e
 LogD@ 
pH7.4
e
 
17β-
HSD1
b
 
17β-
HSD2
c
 
42 Cl OCH3 Cl 0.5 41 82 5.21 4.9 
43 Cl OH Cl 2.4 39 16 4.71 2.4 
44 Cl OCH3 CH3 0.3 7.2 21 4.73 4.6 
45 Cl OH CH3 0.2 6.5 30 4.15 3.9 
46 CH3 OCH3 CH3 0.9 18 20 4.72 4.6 
47 CH3 OH CH3 0.4 7 20 4.43 3.8 
48 F OCHF2 F 7.0 36 5 3.92 3.8 
49 CN OCH(CH3)2 H 8.0 19 2 5.01 4.9 
50 CN OH H 3.3 29 9 3.91 2.7 
51 SO2-4-
morpholine 
OCH3 H 79 %
 f
 85 %
 f
 - 2.60 2.4 
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52 CH N - 270
f
 156
f
 0.6 3.04 2.9 
53 N CH - 75
g
 56
g
 0.8 3.07 2.9 
54 OCH3 - - 6.0 247 40 5.09 5.1 
55 OH - - 31
g
 255
g
 8 4.52 3.4 
a-f
 See table 1. 
g
 Calculated IC50(IC50(Logit)) = test concentration ((100-%inh.)/%inh.). 
 
The dichlorinated inhibitor 42 shows favorable properties concerning activity, selectivity, and 
metabolic stability, but it displays high lipophilicity and a solubility too low to be measured 
experimentally. In order to render the compound more hydrophilic and soluble, one of the 
chlorine atoms was replaced by heterocyclic substituents (table 5, compounds 56-60 and 59a).  
The synthesized compounds show greatly reduced lipophilicities and enhanced solubilities. 
Besides the ester 59a and dihydroxy compound 60, all compounds show IC50-values in the one-
digit nanomolar range. 
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Table 5. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 56-60 and 
59a. 
56-58
SO
HO
F
F
R1
Cl
N
N
R2
59a, 59, 60
SO
O
F
F
R1
Cl
N
N
N
R2
 
 
Comd R1 R2 IC50 [nM]
a
 SF
d
 LogP
f
 LogD@ 
pH7.4
f
 
17β-HSD1b 17β-HSD2c 
56 OCH3 COCH3 1.4 21 15.0 3.21 3.1 
57 OH COCH3 2.1 11 5.2 2.63 2.2 
58 OCH3 H 4.7 26 5.5 3.41 1.7 
59a OCH3 COCH3 26
g
 21
g
 0.8 3.34 3.3 
59 OCH3 H 2.1 8.8 4.2 3.44 3.3 
60 OH H 17
g
 26
g
 1.5 2.86 2.3 
a-f
 See table 1. 
g
 Calculated IC50(IC50(Logit)) = test concentration ((100-
%inh.)/%inh.). 
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Considering the strong inhibitory potency of sulfonamide-type compounds (e.g. compounds 7, 
26, and 27; tables 1 and 2) and the beneficial effect of 2,6-difluorination on h17β-HSD1 
inhibition observed  for non-sulfonamide compounds (tables 3-5) triggered the synthesis of 
compounds combining both structural elements. This strategy is supported by the fact that the 
fluorinated amine 61 (IC50 = 10 nM; table 4) is a much more potent inhibitor than its non-
fluorinated analog 2 (77 % inhibn. at 1 µM; table 1) and thus even exceeds the inhibitory 
potency of hit compound A (fig. 1). Indeed, compound 62 (table 4) shows an about five times 
stronger activity than its non-fluorinated analog 7, at the expense, however, of a slightly 
decreased selectivity towards the type 2 enzyme. As the bromine atom obviously does not 
contribute significantly to target affinity or may even reduce it (compare inhibitory data of 
compounds 6 (table 1) and compound 21 (table 2)), compounds 63 and 64 lacking this atom were 
synthesized. They show activities comparable to that of 62 but decreased selectivity. Exchange 
of the phenyl group of the sulfonamide moiety with heterocycles and the cyclopropyl substituent 
was carried out to decrease the high lipohilicities of compounds 62-64. These modifications 
(compounds 65-69) were well tolerated by the target enzyme but did not enhance selectivity.  
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Table 6. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 61-69. 
61
SO
HO
NH2
62-64
SO
HO
NH
SO
O
R1
F
F
F
F
65-69
SO
HO
N
SO
O
R1
F
F
R2
R3
 
Comd R1 R2 R3 IC50 [nM]
a
 SF
d
 LogP
e
 LogD@ 
pH 7.4
e
 
h17β-HSD1b h17β-HSD2c 
61 - - - 10 25 2.5 2.38 2.2 
62 4-Br-2-OCF3 - - 1.7  17 10.0 6.01 5.1 
63 2-OCF3 - - 3.1 13 4.1 5.25 4.8 
64 2-CF3 - - 2.3 6 2.5 5.27 4.9 
65 
N  
H H 4.0 3.7 0.9 3.21 2.3 
66 
N
N
 
H H 5.5 2.7 0.5 1.87 0.7 
67 
 
H H 1.8 6.5 3.7 3.04 2.9 
68 
 
CH3 H 87 %
 f
 54 %
 f
 - 3.50 3.3 
69 
 
CH3 CH3 67 %
 f
 37 %
 f
 - 3.57 3.4 
a-e
 See table 1.  
f
 Inhibition @ 10nM (inhibitor concentration). 
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The affinities of selected compounds to the recombinant human estrogen receptors α and β were 
determined by incubation of tritium labeled E2 with the respective receptor and subsequent 
addition of the compound in 1000-fold excess, based upon E2 concentration. Receptor affinities 
are expressed as the percentage of E2 replaced by a compound. ER-binding of 50% equals a 
binding affinity of 0.1 % of that of E2. 
The estrogen receptor affinities of the selected compounds cover a broad spectrum (table 7). The 
data suggest that fluorination of the benzoyl moiety increases ER-affinity (cf. compound 7 vs. 62 
and 131 vs. 197). A similar observation could be made upon methylation of the thiophene ring 
(compound 37 vs. 39). Increasing the number or size of substituents adjacent to the oxygen-
function of the phenyl ring (ring C) decreases ER-affinity (cf. compound 37 vs. 42, 43, 46, 47, 
50, and 51). 
Compounds 42, 43, 47, 54, which are highly active towards the target enzyme and selective over 
17β-HSD2 displayed very low affinities towards ER α and β. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
102 
 
Table 7. Binding Affinities for the Estrogen Receptors α and β for 
Selected Compounds 
Compd % Binding
a
 
ER-α binding 
(1000 folds E2 concn.) 
ER-β binding 
(1000 folds E2 concn.) 
7 63 53 
37 73 55 
39 98 82 
42 27 8 
43 37 11 
46 51 69 
47 17 22 
50 44 6 
51 0 4 
54 8 0 
62 71 74 
63 65 68 
64 20 20 
a
 Mean value of three determinations, standard deviation less than 15 %. 
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Further Biological Evaluations. 
Metabolic stability 
Metabolic stability of the most interesting compounds was evaluated using human liver 
microsomes (s9 fraction) and is expressed as the percentage of compound remaining after the 
indicated incubation time (table 8). Depending on the results, we can discern three 3 types of 
compounds: 
a) Metabolically unstable compounds (less than 25 % remaining after 15 min), compounds 
30, 33, 36, 39, 45, 47, 50, 51, 64, 68, and 69. 
b) Metabolically moderately stable compounds (between 25 % and 50 % remaining after 15 
min), compounds 7, 40, 46, and 62. 
c) Metabolically stable compounds (more than 50 % remaining after 15 min), compounds 
42, 43, and 44. 
Thus, compounds 42 and 43 display good metabolic stabilities (40 % and 72 % remaining after 
60 min, respectively), and this shows the great impact of the chlorine atoms at the phenyl moiety, 
compared to the analoguous methylated compounds 46, and 47, respectively (table 8). For 
compound 47, stabilities towards phase I and phase II metabolism were measured independently 
by conducting the assay selective exclusion using the cofactors for phase I and phase II reactions, 
respectively. The compound proved to be stable towards phase I metabolism (61 % remaining 
after 60 min) but instable towards conjugation reactions (data not shown). 
Within the group of compounds bearing a sulfonamide moieties, inhibitors 7 and 62 displayed 
favorable metabolic stabilities (compound 7: 36 % remaining after 45 min; compound 62: 21 % 
after 60 min).  
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Table 8. Metabolic stability of selected compounds in human hepatic S9-fraction. 
Comd % remaining (S9
a
) after Comd % remaining (S9
a
) after 
 15 min 60 min  15 min 60 min 
7* 47 36 (after 45 min) 47 6 n.d 
30 6 n.d 50 21 n.d 
33 3 n.d 51 2 n.d 
36 11 n.d 55 21 n.d 
39 5 n.d 56 18 n.d 
40 26 n.d 58 20 n.d 
42 56 40 62* 31 21 
43 91 72 63 20 n.d 
44 50 13 64 4 n.d 
45 7 n.d 68 19 n.d 
46 29 n.d 69 6 n.d 
* Test concentration 3 µM. 
a
 human hepatic S9 fraction: (1 mg/mL mixture of microsomes 
and cytosol of hepatocytes) supplemented with NADPH, UDPGA and PAPS. 
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Inhibition of murine and rat 17β-HSD1 and 17β-HSD2 
The murine and rat 17β-HSD1 enzymes were expressed in HEK293 cells, whereas the 17β-
HSD2 enyzmes were prepared from mouse or rat liver (microsomal fraction). 
Not surprisingly, inhibition of m17β-HSD1 is in general considerably weaker than inhibition of 
the human enzyme (tables 9 and 10). For instance, the non-fluorinated compound 7 which is a 
strong inhibitor of h17β-HSD1 (IC50 = 8 nM) is hardly active towards the murine enzyme (21 % 
inhibn. at 1 µM). In addition, selectivity towards the type 2 enzyme is much less pronounced 
than in case of the human protein. One of the compounds that retains some selectivity over the 
m17β-HSD2 enzyme is compound 26, which is also the most potent non-fluorinated inhibitor in 
this series (inhibition @ 1 µM:  m17β-HSD1 = 51 %; m17β-HSD2 = 48 %). 
A similarly dramatic difference in inhibition of the target enzymes of the two species is observed 
for the fluorinated compounds 42 and 43. A more pronounced m17β-HSD1 inhibitory activity is 
measured in case of compound 47, which at the same time – together with 42 - is the most active 
compound ever described for the human enzyme (47: IC50(h17β-HSD1) = 0.4 nM; 77 % 
inhibition of m17β-HSD1 at 1 µM). 
Interestingly, the combination of 2,6-difluorination of the benzoyl moiety with the presence of a 
sulfonamide function yielded the most active compounds not only towards the human, but also 
towards the murine 17β-HSD1 enzyme, cf. compound 7 (21% inhibition @ 1µM; non-
fluorinated sulfonamide) and compound 61 (30 % inhibition, fluorinated but without 
sulfonamide moiety) versus compound 62 (71 % inhibition, fluorinated, with sulfonamide 
moiety). Compound 64 is the most active inhibitor toward m17β-HSD1 in this study (IC50 = 250 
nM, table 10). Due to its even stronger inhibition of the murine type 2 enzyme, however, it is no 
candidate for in vivo evaluation in a mouse endometriosis model. 
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Table 9. Inhibition of murine 17β-HSD1 and 17β-HSD2 of selected compounds 
Comd % Inhibition @ 1µM
a
 Comd % Inhibition @ 1µM
a
 
m17β-
HSD1
b
 
m17β-
HSD2
c
 
m17β-HSD1b m17β-HSD2c 
1 4 n.d 45 43 n.d 
7 21 n.d 46 59 78 
10 26 n.d 47 77 96 
11 26 n.d 48 45 n.d 
12 17 n.d 50 23 n.d 
13 8 n.d 51 58 66 
20 25 n.d 53 14 n.d 
23 16 n.d 56 37 n.d 
25 13 n.d 57 16 n.d 
26 51 48 58 25 n.d 
31 5 n.d 59a 20 n.d 
34 41 n.d 59 32 n.d 
35 14 n.d 60 33 n.d 
36 40 n.d 61 30 n.d 
37 50 95 62 71 100 
38 25 n.d 63 91 100 
39 38 n.d 64 97 100 
40 60 94 65 47                                                                                                                                                                           n.d 
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41 42 n.d 66 10 n.d 
42 43 n.d 67 76 100 
43 23 n.d 68 33 % @ 250 nM 100 
44 32 n.d 69 32 % @ 250 nM 90 
a
 Mean value of three determinations, standard deviation less than 15%. 
b
 Mouse recombinant enzyme, 
expressed in HEK 293, substrate [
3
H]-E1, 10 nM, cofactor NADH, 500 µM. 
c
 Mouse liver, microsomal 
fraction, substrate [
3
H]-E2, 10 nM, cofactor NAD
+
, 1500 µM. 
 
Table 10. IC50 values for selected compounds.  
cmpd IC50 [nM]
a
 
m17β-HSD1b m17β-HSD2c 
47 400 120 
63 570 33 
64 250 20 
68 680 130 
69 600 55 
a
 Mean value of three determinations, standard deviation less than 15%. 
b
 Mouse recombinant enzyme, expressed in HEK 293, substrate [
3
H]-
E1, 10 nM, cofactor NADH, 500 µM. 
c
 Mouse liver, microsomal 
fraction, substrate [
3
H]-E2, 10 nM, cofactor NAD
+
, 1500 µM. 
 
Selected compounds were tested for inhibition of rat 17β-HSD1 (table 11). Most compounds 
turned out to be stronger inhibitors of the rat enzyme than of the murine analog (tables 9 and 10). 
The most potent - though unselective - compound was 64, showing an inhibition of 59 % at a 
concentration of 100 nM. Compound 47, however, combined good inhibitory potency (63 % 
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inhibn. at 250 nM) with acceptable selectivity towards rat 17β-HSD2. Thus, this compound 
could be a candidate for in vivo evaluation in a rat endometriosis model. 
 
Table 11. Inhibition of rat 17β-HSD1 and 17β-HSD2 of selected compounds. 
 
Comd Comd concentration % Inhibition
a
 
r17β-HSD1b r17β-HSD2c 
43 5000 nM 59 n.d 
46 250 nM 39 27 
47 250 nM 63 35 
51 250 nM 26 n.i 
57 250 nM n.i n.i 
58 500 nM 51 55 
59 250 nM 39 64 
60 250 nM 21 54 
62 250 nM 56 86 
63 250 nM 70 74 
64 100 nM 59 70 
65 250 nM 32 28 
66 250 nM 29 31 
67 250 nM 51 49 
a
 Mean value of three determinations, standard deviation less than 15%. 
b
 Rat recombinant 
enzyme, expressed in HEK 293, substrate [
3
H]-E1, 10 nM, cofactor NADH, 500 µM. 
c
 Rat liver, 
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microsomal fraction, substrate [
3
H]-E2, 10 nM, cofactor NAD
+
, 1500 µM. 
Cytotoxicity 
Hek293 cell viability was measured in the MTT assay. Incubation was carried out at the 
indicated inhibitor concentrations for 66 hours at 37
o
C. 100%-values were determined without 
inhibitor. Only compounds displaying substantial inhibition of mouse or rat 17β-HSD1 were 
subjected to this assay. 
Compounds 47, 63, and 64, which are the most potent inhibitors of rat 17β-HSD1, exhibited 
cytotoxic effects only at concentrations of 12.5µM and above (compound 47: 25 µM and above). 
In all cases, this is clearly more than ten times higher than the corresponding IC50-values, as 
roughly estimated from the percentages of inhibition (table 12). 
 
Table 12. Cytotoxicity of selected compounds. 
Conc.  Compound 
(µM) 46 47 57 58 59 60 62 63 64 65 66 67 
0 100 100 100 100 100 100 100 100 100 100 100 100 
6.25 61 100 75 16 56 93 100 87 100 89 98 100 
12.50 10 91 60 8 28 84 45 56 60 73 100 100 
25 7 41 29 7 12 50 14 19 17 47 69 55 
50 7 21 6 8 7 11 14 18 11 11 33 23 
100 7 20 4 7 6 9 15 18 10 4 9 16 
Hek 293 cell viability as measured in the MTT assay (incubation with compound 66 hours at 37
o
C), 100% 
= vehicle only = 1% DMSO, no compound. 
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Figure 3. Cytotoxicity of selected compounds. 
 
 
Discussion and Conclusions 
 
The aim of the present study was the design of potent and selective inhibitors of human 17β-
HSD1, which can be used to conduct a proof of principle study in an animal (rodent) disease 
model for EDD. The class of BSHs was chosen as a starting point because this compound class, 
unlike many others, is characterized not only by high inhibitory potency towards human 17β-
HSD1, but also by activity towards the murine enzyme.  
In a first approach, variations in the sulfonamide moiety of the lead compound I (rings C and D) 
were carried out (design step I). It was found that the introduction of the sulfonamide in m-
position to the thiophene ring is clearly favored over the p-position in terms of h17β-HSD1 
inhibition. Major issues that were encountered with the synthesized compounds were low 
metabolic stability (S9) and insufficient activity towards m17β-HSD1. These problems were 
addressed in the further design process (design steps II and III). 
It is striking that the introduction of fluorine atoms in the benzoyl moiety (ring A) which was 
carried out to improve metabolic stability, resulted in a strong increase of activity towards both 
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the human and the rodent enzymes. This may be explained by the electron-withdrawing effect of 
the fluorine atoms which strongly influence the hydrogen bonding properties of the OH-group.
42
 
On the other hand, it is known that fluorine itself is able to contribute to ligand binding, eg. by 
interacting with carbon atoms of carbonyl groups of the target.
43
 
Low stability towards metabolism (phase II) was due to the presence of the phenolic OH-groups. 
In previous SAR studies no adequate replacement could be found for the OH-group on the 
benzoyl moiety. Moreover, it was known that the target enzyme does not tolerate substituents 
much bigger than hydrogen on this ring. It is therefore an important progress that the approach to 
enhance metabolic stability by introducing fluorine was successful, as can be seen when 
comparing the metabolic stability of compound 55 (21 % remaining after 15 min, table 7) with 
that of its fluorinated analog 43 (72 % remaining after 60 min). For the OH-group on the phenyl 
ring (ring C), the situation was different: On the one hand, the OH-group was found not to be 
essential for activity (though beneficial for selectivity over 17β-HSD2). On the other hand, the 
phenyl ring offered more freedom in the choice of substituents which could be introduced to 
optimize metabolic stability as even the presence of bulky groups was known to be tolerated by 
17β-HSD1. The best results were obtained by the introduction of two chlorine atoms adjacent to 
the OH-group (compound 43). Interestingly, the replacement of one or both chlorine atoms with 
the methyl group, which is similar in size but different concerning electronic properties, led to 
the metabolically instable compounds 45 and 47. Two explanations of the lacking metabolic 
stability of the latter compounds were likely: Either the methyl groups are not able to protect the 
adjacent phenolic OH-group from being conjugated (phase II reaction) or the methyl groups 
themselves are metabolically altered (phase I reaction). This motivated us to independently 
evaluate phase I and II metabolic stability for compound 47. The results clearly showed 
instability towards phase II metabolism, indicating that methyl groups were not able to protect 
the OH-group from being conjugated. Thus, the electron withdrawing effect of the chlorine 
atoms rather than steric “shielding” of the phenolic OH-group seem to be the reason for the 
outstanding metabolic stability of compound 43. 
The most interesting inhibitors which were identified in this study were BSHs 42, 43, 47, 63, and 
64. The chlorinated compounds 42 and 43 belong to the most active inhibitors of h17β-HSD1 
ever described (IC50 = 0.5 nM and 2.4 nM, respectively) and are characterized by good 
selectivities towards the human type 2 enzyme and the estrogen receptors α and β. In addition, 
they are the metabolically most stable members of this compound class (40 % and 72 % 
remaining (S9) after 60 min, respectively). Due to their more pronounced activities towards the 
rodent 17β-HSD1 enzymes, compounds 47, 63, and 64 may be possible candidates for an in vivo 
PoP-study. This is especially true for compound 47 as it showed the best selectivity over 17β-
HSD2 of the rat and displayed the most favourable cytotoxicity profile of the three inhibitors. At 
physiological pH, both compound 43 and 47 have clogD-values below 5 (43: 2.36; 47: 3.81).  
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17-HSD1
activity
17-HSD2
selectivity
Compound II
A
B C
minor
variations
human 17-HSD1: IC50 = 8 nM
human 17-HSD2: IC50 = 384 nM
mouse 17-HSD1: (% inhibition @ 1µM = 20)
rat 17-HSD1: IC50 = 5.49µM
met. stabitlity (phase I): t1/2  = 100 min
met. stabitlity (S9): % remaining (after 15 min) = 4
SO
OH
HO
SO
HO
F
F
Compound 43 (R = Cl)
Compound 47 (R = CH3)
R
OH
                                                               Comd 43               Comd 47
h17-HSD1:                             IC50   =  2.4 nM                   0.4 nM
h17-HSD2:                             IC50   =  39 nM                    7 nM
m17-HSD1: (% inhibition @ 1µM) =  23                           77
r17-HSD1:                              IC50  =  3.75µM                 63 % @ 250 nM
met. stab. (phase I): % remaining      =  not determined        61 (after 60 min)
met. stab. (S9): % remaining             =  72 (after 60 min)     6 (after 15 min)
R
 
Chart 4. Comparison of biological activities and metabolic stabilities of the reference compound 
II and compounds 43 and 47. 
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Experimental Section 
 
Chemical Methods. Chemical names follow IUPAC nomenclature. Starting materials were 
purchased from Aldrich, Acros, Lancaster, Maybridge, Combi Blocks, Merk, or Fluka and were 
used without purification. 
Column chromatography (CC) was performed on silica gel (70 – 200µm), reaction progress was 
monitored by thin layer chromatography (TLC) on Alugram SIL G UV254 (Macherey-Nagel). 
All microwave irradiation experiments were carried out in a CEM-Discover monomode 
microwave apparatus. 
1
H NMR and 
13
C NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 
300 K. Chemical shifts are reported in δ (parts per million: ppm), by reference to the 
hydrogenated residues of deuteriated solvent as internal standard (CDCl3: δ = 7.24 ppm (
1
H 
NMR) and δ = 77 ppm (13C NMR), CD3OD: δ = 3.35 ppm (
1
H NMR) and δ = 49.3 ppm (13C 
NMR), CD3COCD3: δ = 2.05 ppm (
1
H NMR) and δ = 29.9 ppm (13C NMR), CD3SOCD3 δ = 
2.50 ppm (
1
H NMR) and δ = 39.5 ppm (13C NMR)). Signals are described as s, d, t, dd, ddd, m, 
dt, q, sep, br. for singlet, doublet, triplet, doublet of doublets, doublet of doublets of doublets, 
multiplet, doublet of triplets, quadruplet, septet, and broad, respectively. All coupling constants 
(J) are given in hertz (Hz). 
A mass spectrum (ESI) was recorded on a TSQ Quantum (Thermo Finnigan) instrument. 
Tested compounds are >95% chemical purity as measured by HPLC. The methods for HPLC 
analysis and a table of data for all tested compounds are provided in the supporting information. 
The following compounds were prepared according to previously described procedures: (5-
bromo-thiophen-2-yl)(3-methoxyphenyl)methanone (I),
26
 (5-bromo-thiophen-2-yl)(3-hydroxy-
phenyl)methanone (VII),
26
 (5-(3-aminophenyl)thiophen-2-yl)(3-methoxyphenyl)methanone 
(2a),
44
 (5-(3-aminophenyl)thiophen-2-yl)(3-hydroxyphenyl)methanone (2),
44
 4-bromo-N-(3-(5-
(3-hydroxybenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethoxybenzenesulfonamide (7),
44
 4-
bromo-2-chloro-6-methyl-phenol (44c),
45
 5-bromo-1-chloro-2-methoxy-3-methyl-benzene 
(44b)
46
. 
General procedure for Friedel-Crafts acylation. Method A. An ice-cooled mixture of 
monosubstituted thiophene derivate (1 or 1.5 equiv), arylcarbonyl chloride (1 equiv), and 
aluminumtrichloride (1 equiv) in anhydrous dichloromethane was warmed to room temperature 
and stirred for 2-4 h. 1M HCl was used to quench the reaction. The aqueous layer was extracted 
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with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium 
sulfate, filtered, and concentrated to dryness. The product was purified by CC.  
General procedure for ether cleavage. Method B. To a solution of methoxybenzene derivative 
(1 equiv) in anhydrous dichloromethane at -78 
o
C (dry ice/acetone-d6 bath), boron tribromide in 
dichloromethane (1M, 3 equiv per methoxy function) was added dropwise. The reaction mixture 
was stirred overnight at room temperature under nitrogen atmosphere. Water was added to 
quench the reaction, and the aqueous layer was extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated 
to dryness. The product was purified by CC. 
General procedure for Suzuki coupling. Method C1. A mixture of arylbromide (1 equiv), 
boronic acid derivative (1.2 equiv), cesium carbonate (4 equiv) and tetrakis(triphenylphosphine) 
palladium (0.01 equiv) was suspended in an oxygen-free DME/water (1:1) solution and refluxed 
under nitrogen atmosphere. The reaction mixture was cooled to room temperature. The aqueous 
layer was extracted with ethyl acetate. The combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by 
CC. 
Method C2. A mixture of arylbromide (1 equiv), boronic acid derivative (1.2 equiv), Na2CO3 (2 
equiv) and tetrakis(triphenylphosphine) palladium (0.01 equiv) was suspended in an oxygen-free 
toluene/ethanol (1:1) solution was refluxed overnight under nitrogen atmosphere. The aqueous 
layer was extracted with ethyl acetate. The combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by 
CC. 
General procedure for sulfonamide/amide coupling. Method D. The amino phenyl derivative 
(1 equiv) was dissolved in pyridine absolute and was spiked with sulfonyl chloride/acid chloride 
(1.5 equiv). The reaction mixture was stirred overnight at rt (refluxed in case of amide coupling). 
The reaction was quenched by adding 10 mL of 2N HCl and extracted with ethyl acetate. The 
organic layers were washed with saturated NaHCO3 and brine, dried over magnesium sulfate, 
filtered and concentrated to dryness. The product was purified by CC. 
5-Bromo-thiophen-2-yl)-(2-fluoro-3-methoxy-phenyl)-methanone (II). The title compound 
was prepared by reaction of 2-bromothiophene (1297 mg, 7.95 mmol), 2-fluoro-4-
methoxybenzoyl chloride (1000 mg, 5.30 mmol) and aluminum chloride (707 mg, 5.30 mmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 96:4); yield: 57% 
(1000 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 7.32 (d, J = 7.4 Hz, 1H), 7.33 (ddd, J = 7.3, 4.9, 
1.4 Hz, 1H), 7.12 (d, J = 7.4 Hz, 1H), 7.09 (t, J = 7.4 Hz, 1H), 6.92 – 6.87 (m, 1H), 3.82 (s, 3H); 
13
C NMR (125 MHz, acetone-d
6) δ 184.05, 151.12 (d, J = 246.0 Hz), 149.54, 143.29,136.87, 
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128.24 (dd, J = 9.9, 4.4 Hz), 126.67 (d, J = 13.0 Hz),122.18 (d, J = 4.3 Hz), 117.46 (d, J = 3.0 
Hz), 116.52 (d, J = 1.3 Hz), 115.94 (dd, J = 12.8, 4.1 Hz), 54.21; MS (ESI): 316.41 (M+H)
+
. 
Acetic acid 3-(5-bromo-thiophene-2-carbonyl)-2-methyl-phenyl ester (III). The title 
compound was prepared by reaction of 2-bromothiophene (1150 mg, 7.05 mmol), 3-acetyloxy-2-
methylbenzoyl chloride (1000 mg, 4.70 mmol) and aluminum chloride (627 mg, 4.70 mmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 93:7); yield: 38% 
(600 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 8.49 (d, J = 7.4 Hz, 1H), 8.37 (d, J = 7.4 Hz, 1H), 
8.24 – 8.02 (m, 3H), 3.11 (s, 3H), 2.84 (s, 3H); 13C NMR (125 MHz, acetone-d6) δ 187.12, 
160.08, 155.10, 149.79, 140.43, 137.8, 129.61, 124.04, 124.51, 123.41, 120.35, 115.51, 114.60, 
101.89, 21.63, 10.91; MS (ESI): 340.12 (M+H)
+
. 
Acetic acid 3-(5-bromo-4-methyl-thiophene-2-carbonyl)-2-methyl-phenylester (IV). The title 
compound was prepared by reaction of 2-bromo-3-methyl-thiophene (2490 mg, 14.06 mmol), 3-
acetyloxy-2-methylbenzoyl chloride (1993 mg, 9.37 mmol) and aluminum chloride (1250 mg, 
9.37 mmol) according to method A. The product was purified by CC (hexane/ethyl acetate 96:4); 
yield: 32% (1570 mg). MS (ESI): 354.02 (M+H)
+
. 
5-Bromo-thiophen-2-yl)-(3-ethoxy-2,6-difluoro-phenyl)-methanone (V). The title compound 
was prepared by reaction of 2-bromothiophene (2217 mg, 13.60 mmol), 2,6-difluoro-4-
ethoxybenzoyl chloride (3000 mg, 13.60 mmol) and aluminum chloride (1813 mg, 13.60 mmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 97:3); yield: 79% 
(3740 mg). 
1
H NMR (300 MHz, acetone-d
6) δ 7.34 (dd, J = 4.1, 0.9 Hz, 1H), 7.22 (dd, J = 6.7, 
4.7 Hz, 2H), 6.98 (td, J = 9.0, 2.0 Hz, 1H), 4.05 (q, J = 7.0 Hz, 2H), 1.27 (t, J = 7.0 Hz, 3H); 13C 
NMR (75 MHz, acetone-d
6) δ 179.03, 153.83, 153.76, 150.63, 145.09, 136.88, 132.66, 128.96, 
124.50, 117.19, 117.06, 65.44, 14.08; 
13
C NMR (75 MHz, acetone-d
6) δ 179.03, 152.19 (dd, J = 
242.2, 5.8 Hz), 148.69 (dd, J = 250.5, 7.4 Hz), 145.09, 143.94 (dd, J = 10.6, 3.3 Hz), 136.88, 
132.66, 128.96, 124.50, 117.11 (dd, J = 9.3, 3.2 Hz), 111.26 (dd, J = 22.6, 4.1 Hz), 65.44, 14.08; 
MS (ESI): 448.64 (M+H)
+
. 
(5-Bromo-4-methyl-thiophen-2-yl)-(3-ethoxy-2,6-difluoro-phenyl)-methanone (VI). The title 
compound was prepared by reaction of 2-bromo-3-methoxy-thiophene (1204 mg, 6.80 mmol), 
2,6-difluoro-4-ethoxybenzoyl chloride (1000 mg, 4.53 mmol) and aluminum chloride (604 mg, 
4.53 mmol) according to method A. The product was purified by CC (hexane/ethyl acetate 97:3); 
yield: 49% (800 mg). MS (ESI): 362.09 (M+H)
+
. 
 (5-Bromo-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (VIII). The title 
compound was prepared by reaction of 5-bromo-thiophen-2-yl)-(3-ethoxy-2,6-difluoro-phenyl)-
methanone (V) (3000 mg, 8.64 mmol) and boron tribromide (43.20 mmol, 5 equiv) according to 
method B. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 84% (2310 mg). 
MS (ESI): 320.12 (M+H)
+
. 
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(5-Bromo-4-methyl-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (IX). The 
title compound was prepared by reaction of (5-bromo-4-methyl-thiophen-2-yl)-(3-ethoxy-2,6-
difluoro-phenyl)-methanone (VI) (850 mg, 2.35 mmol) and boron tribromide (11.76 mmol, 5 
equiv) according to method B. The product was used in the next step without further purification 
and without any characterization; yield: 77% (600 mg). 
(5-(4-Aminophenyl)thiophen-2-yl)(3-hydroxyphenyl)methanone (1). The title compound was 
prepared by reaction of (5-bromothiophen-2-yl)(3-hydroxyphenyl)methanone (VII) (140 mg, 
0.50 mmol), 4-aminophenylboronic acid pinacol ester (155 mg, 0.71 mmol), cesium carbonate 
(658 mg, 2.02 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 µmol) according to 
method C1. The product was purified by CC (dichloromethan/methanol 99:1); yield: 82% (120 
mg). 
1
H NMR (500 MHz, CDCl3) δ 8.75 (br., s, 1H), 7.65 (d, J = 4.0 Hz, 1H), 7.44 (d, J = 4.0 
Hz, 1H), 7.37 (t, J = 7.7 Hz, 1H), 7.33 (dt, J = 7.6, 1.3 Hz, 1H), 7.31 – 7.29 (m, 1H), 7.13 (t, J = 
7.8 Hz, 1H), 7.10 (ddd, J = 7.9, 2.5, 1.2 Hz, 1H), 7.07 (t, J = 1.9 Hz, 1H), 6.99 (ddd, J = 7.6, 1.7, 
0.9 Hz, 1H), 6.71 (ddd, J = 8.0, 2.2, 0.8 Hz, 1H), 4.85 (br., 2H,NH2); 
13
C NMR (125 MHz, 
CDCl3) δ 186.80, 157.50, 153.62, 149.30, 141.63, 139.55, 135.88, 129.86, 129.65, 129.65, 
123.79, 120.14, 119.23, 115.36, 115.29, 114.53, 111.59; MS (ESI): 296.23 (M+H)
+
.  
N-(4-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (3). The title 
compound was prepared by reaction of (5-(4-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (1) (100 mg, 0.34 mmol) and benzenesulfonyl chloride (90 mg, 0.51 
mmol) according to method D. The product was purified by CC (dichloromethan/methanol 
99.5:0.5); yield: 77% (114 mg). 
1
H NMR (500 MHz, CD3OD) δ 9.18 (br. s, 1H), 8.76 (br., s, 
1H), 7.74 – 7.70 (m, 2H), 7.52 (d, J = 4.0 Hz, 1H), 7.51 – 7.48 (m, 2H), 7.46 (dt, J = 2.3, 1.6 Hz, 
1H), 7.39 (dd, J = 10.5, 4.7 Hz, 2H), 7.28 (d, J = 4.0 Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H), 7.19 – 
7.16 (m, 1H), 7.13 – 7.10 (m, 1H), 7.10 – 7.06 (m, 2H), 6.95 (ddd, J = 8.1, 2.5, 1.0 Hz, 1H); 13C 
NMR (125 MHz, MeOD) δ 189.73, 158.89, 154.09, 142.82, 141.08, 140.52, 140.13, 137.95, 
134.08, 130.75, 130.67, 130.18, 128.20, 128.16, 125.13, 122.05, 121.26, 120.62, 116.48; MS 
(ESI): 436.24 (M+H)
+
. 
4-Bromo-N-(4-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethoxybenzene-
sulfonamide (4). The title compound was prepared by reaction of (5-(4-aminophenyl)thiophen-
2-yl)(3-hydroxyphenyl)methanone (1) (100 mg, 0.34 mmol) and 4-bromo-2-
trifluoromethoxybenzenesulfonyl chloride (172 mg, 0.51 mmol) according to method D. The 
product was purified by CC (DCM); yield: 36% (72 mg). 
1
H NMR (500 MHz, CD3OD) δ 9.30 
(br. s, 1H), 8.42 (br., s, 1H), 7.82 (d, J = 8.9 Hz, 1H), 7.54 – 7.51 (m, 2H), 7.50 – 7.48 (m, 2H), 
7.48 – 7.46 (m, 1H), 7.27 – 7.21 (m, 2H), 7.18 – 7.15 (m, 1H), 7.11 (dd, J = 2.2, 1.7 Hz, 1H), 
7.10 – 7.06 (m, 2H), 6.94 (ddd, J = 8.1, 2.5, 1.0 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 
188.11, 156.45, 152.18, 148.75, 145.99, 141.99, 139.02, 137.05, 136.42, 136.31, 132.55, 130.56, 
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129.97, 129.71, 129.66, 128.99, 127.38, 124.28, 123.88, 123.41, 123.40, 121.26, 121.22, 121.16, 
119.86, 119.07, 115.88; MS (ESI): 600.16 (M+H)
+
. 
3-Cyano-N-(4-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (5). The title 
compound was prepared by reaction of (5-(4-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (1) (100 mg, 0.34 mmol) and 3-cyanobenzenesulfonyl chloride (103 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 48% (74 mg). 
1
H NMR (500 MHz, CD3OD) δ 9.15 
(br. s, 1H), 8.43 (br., s, 1H), 8.06 (t, J = 1.5 Hz, 1H), 7.95 (ddd, J = 8.0, 1.8, 1.1 Hz, 1H), 7.86 – 
7.81 (m, 1H), 7.61 – 7.57 (m, 1H), 7.57 – 7.56 (m, 1H), 7.55 (dd, J = 3.1, 0.9 Hz, 2H), 7.33 (t, J 
= 5.2 Hz, 1H), 7.25 (t, J = 7.8 Hz, 1H), 7.22 – 7.17 (m, 1H), 7.12 (dd, J = 4.5, 2.2 Hz, 2H), 7.11 
– 7.09 (m, 1H), 6.95 (ddd, J = 8.1, 2.5, 1.1 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 189.73, 
158.91, 153.81, 143.04, 142.67, 140.50, 139.47, 137.92, 137.39, 132.36, 131.73, 131.57, 131.25, 
130.75, 128.36, 125.33, 122.45, 121.25, 120.64, 119.54, 118.20, 116.48, 114.68, 112.05; MS 
(ESI): 461.24 (M+H)
+
. 
N-(3-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (6). The title 
compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and benzenesulfonyl chloride (90 mg, 0.51 
mmol) according to method D. The product was purified by CC (dichloromethan/methanol 
99.5:0.5); yield: 14% (20 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 9.21 (br. s, 1H), 8.78 (br., s, 
1H), 7.90 – 7.85 (m, 2H), 7.70 (d, J = 4.0 Hz, 1H), 7.62 (tt, J = 2.6, 1.8 Hz, 2H), 7.56 (tt, J = 8.3, 
1.3 Hz, 2H), 7.53 – 7.48 (m, 2H), 7.41 – 7.39 (m, 1H), 7.38 – 7.34 (m, 2H), 7.34 – 7.33 (m, 1H), 
7.28 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.14 (ddd, J = 7.9, 2.6, 1.2 Hz, 1H); 
13
C NMR (125 MHz, 
acetone-d
6) δ 187.71, 158.44, 152.34, 150.65, 143.51, 140.74, 140.21, 139.79, 136.78, 135.09, 
133.88, 131.11, 130.60, 130.05, 128.01, 125.61, 124.59, 123.01, 121.90, 121.09, 120.30, 118.76, 
116.29; MS (ESI): 436.13 (M+H)
+
. 
3-Cyano-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (8). The title 
compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 3-cyanobenzenesulfonyl chloride (103 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 50% (78 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 
9.39 (br. s, 1H), 8.76 (br., s, 1H), 8.24 – 8.19 (m, 1H), 8.14 (ddd, J = 8.0, 1.9, 1.1 Hz, 1H), 8.07 – 
8.02 (m, 1H), 7.84 – 7.78 (m, 1H), 7.71 (d, J = 4.0 Hz, 1H), 7.62 (t, J = 1.8 Hz, 1H), 7.57 (ddd, J 
= 7.8, 1.8, 1.0 Hz, 1H), 7.53 (d, J = 4.0 Hz, 1H), 7.41 (td, J = 7.9, 3.0 Hz, 2H), 7.37 (dt, J = 7.6, 
1.3 Hz, 1H), 7.33 (dd, J = 2.2, 1.6 Hz, 1H), 7.30 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.14 (ddd, J = 
7.9, 2.5, 1.2 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 187.69, 158.44, 152.03, 143.64, 
141.97, 140.18, 139.03, 137.33, 136.76, 135.31, 132.18, 131.56, 131.49, 131.33, 130.61, 125.78, 
123.72, 122.42, 121.10, 120.32, 119.44, 117.87, 116.29, 114.34; MS (ESI): 461.17 (M+H)
+
. 
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Thiophene-2-sulfonic acid (3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)amide (9). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and thiophene-2-sulfonyl chloride (93 mg, 
0.51 mmol) according to method D. The product was purified by CC (dichloromethan/methanol 
99.5:0.5); yield: 34% (50 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.06 (br. s, 1H), 8.59 (br., s, 
1H), 7.82 (dd, J = 5.0, 1.3 Hz, 1H), 7.74 – 7.67 (m, 2H), 7.65 – 7.60 (m, 1H), 7.55 (d, J = 7.7 Hz, 
1H), 7.52 (d, J = 4.0 Hz, 1H), 7.44 – 7.32 (m, 5H), 7.17 – 7.09 (m, 2H);13C NMR (125 MHz, 
acetone-d
6) δ 187.78, 158.45, 152.34, 143.55, 141.13, 140.19, 139.55, 136.84, 135.13, 133.84, 
133.62, 131.17, 130.62, 128.42, 125.68, 123.36, 122.17, 121.12, 120.35, 118.97, 116.32; MS 
(ESI): 442.02 (M+H)
+
. 
3-Methoxy-N-(3-(5-(3-methoxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (10a). 
The title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
methoxyphenyl)methanone (2a) (770 mg, 2.49 mmol) and 3-methoxybenzenesulfonyl chloride 
(772 mg, 3.73 mmol) according to method D. The product was purified by CC (hexane/ethyl 
acetate 3:2); yield: 92% (1100 mg). 
1
H NMR (500 MHz, DMSO-d
6
) δ 10.49 (br. s, 1H), 7.73 (d, 
J = 4.0 Hz, 1H), 7.54 (d, J = 4.0 Hz, 1H), 7.48 (ddd, J = 9.2, 8.0, 6.1 Hz, 4H), 7.44 – 7.40 (m, 
1H), 7.36 (dt, J = 14.8, 4.8 Hz, 2H), 7.33 (dd, J = 2.5, 1.5 Hz, 1H), 7.31 – 7.29 (m, 1H), 7.26 
(ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 7.18 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 7.15 (ddd, J = 8.1, 2.1, 0.9 
Hz, 1H), 3.84 (s, 3H), 3.77 (s, 3H); 
13
C NMR (125 MHz, DMSO-d
6) δ 186.71, 159.37, 159.23, 
151.22, 141.61, 140.50, 138.72, 138.59, 136.79, 133.30, 130.57, 130.35, 129.87, 125.36, 121.71, 
121.12, 120.59, 118.86, 118.76, 118.55, 117.02, 113.46, 111.66, 55.56, 55.36; MS (ESI): 479.06 
(M+H)
+
. 
3-Hydroxy-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (10). The 
title compound was prepared by reaction of 3-methoxy-N-(3-(5-(3-methoxybenzoyl)thiophen-2-
yl)phenyl)benzenesulfonamide (10a) (100 mg, 0.21 mmol) and boron tribromide (7.5 mmol) 
according to method B. The product was purified by CC (dichloromethan/methanol 97:3); yield: 
74% (70 mg). 
1
H NMR (500 MHz, CD3OD) δ 7.67 (d, J = 4.0 Hz, 1H), 7.48 (t, J = 1.8 Hz, 1H), 
7.45 (ddd, J = 7.7, 1.7, 1.0 Hz, 1H), 7.43 (d, J = 4.0 Hz, 1H), 7.38 (dd, J = 14.4, 6.6 Hz, 1H), 
7.34 – 7.29 (m, 3H), 7.29 – 7.24 (m, 2H), 7.23 – 7.19 (m, 1H), 7.14 (ddd, J = 8.1, 2.1, 0.9 Hz, 
1H), 7.07 (ddd, J = 8.0, 2.5, 1.1 Hz, 1H), 6.97 (ddd, J = 7.9, 2.5, 1.2 Hz, 1H); 
13
C NMR (125 
MHz, CD3OD) δ 189.76, 159.28, 158.93, 153.82, 143.47, 141.91, 140.43, 140.13, 137.75, 
135.46, 131.21, 131.13, 130.77, 125.74, 123.36, 122.58, 121.31, 121.08, 120.71, 119.41, 119.03, 
116.51, 114.87; MS (ESI): 452.18 (M+H)
+
. 
3-Methoxy-N-(3-(5-(3-methoxybenzoyl)thiophen-2-yl)phenyl-benzamide (11a). The title 
compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
methoxyphenyl)methanone (2a) (770 mg, 2.49 mmol) and 3-methoxybenzoyl chloride (425 mg, 
3.73 mmol) according to method D. The product was purified by CC (dichloromethan/methanol 
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99.75:0.25); yield: 61% (672 mg). 
1
H NMR (500 MHz, CDCl3) δ 8.04 (t, J = 1.8 Hz, 1H), 7.95 
(br. s, 1H), 7.65 – 7.61 (m, 2H), 7.47 – 7.43 (m, 3H), 7.42 – 7.39 (m, 3H), 7.37 (dd, J = 4.4, 2.1 
Hz, 3H), 7.12 (ddd, J = 8.1, 2.7, 1.1 Hz, 1H), 7.08 (ddd, J = 7.6, 2.6, 1.5 Hz, 1H), 3.86 (s, 3H), 
3.85 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 187.73, 165.65, 160.08, 159.65, 152.58, 142.40, 
139.34, 138.76, 136.15, 135.87, 134.25, 129.90, 129.86, 129.42, 124.30, 122.49, 121.65, 120.62, 
118.67, 118.59, 118.27, 117.80, 113.69, 112.53, 55.51, 55.48; MS (ESI): 444.21 (M+H)
+
. 
3-Hydroxy-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzamide (11). The title 
compound was prepared by reaction of 3-methoxy-N-(3-(5-(3-methoxybenzoyl)thiophen-2-yl)-
phenyl)benzamide (11a) (74 mg, 0.17 mmol) and boron tribromide (1.00 mmol) according to 
method B. The product was purified by CC (dichloromethan/methanol 99:1); yield: 69% (48 
mg). 
1
H NMR (500 MHz, CD3OD) δ 8.21 (t, J = 1.8 Hz, 1H), 7.74 (ddd, J = 8.1, 2.0, 0.9 Hz, 
1H), 7.72 (d, J = 4.0 Hz, 1H), 7.56 (ddd, J = 4.0, 2.0, 1.2 Hz, 2H), 7.46 (t, J = 7.9 Hz, 1H), 7.42 
(ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 7.40 – 7.36 (m, 2H), 7.36 – 7.32 (m, 2H), 7.27 (dd, J = 2.2, 1.7 
Hz, 1H), 7.08 (ddd, J = 8.0, 2.5, 1.2 Hz, 1H), 7.02 (ddd, J = 8.1, 2.5, 1.0 Hz, 1H); 
13
C NMR (125 
MHz, CD3OD) δ 189.80, 159.00, 158.93, 154.44, 143.31, 140.95, 140.51, 137.81, 137.54, 
135.15, 130.77, 130.73, 125.70, 123.23, 122.75, 121.30, 120.68, 119.99, 119.67, 119.49, 119.45, 
116.52, 115.59; MS (ESI): 416.15 (M+H)
+
. 
3-Methoxy-N-(3-(5-(3-methoxybenzoyl)thiophen-2-yl)phenyl)-N-methylbenzamide (12a). 
After a mixture of 3-methoxy-N-(3-(5-(3-methoxybenzoyl)-thiophen-2-yl)phenyl)benzamide 
(11a) (666 mg, 1.50 mmol, 1 equiv) and NaH (60% suspension in mineral oil, 3.00 mmol, 2 
equiv) in DMF was stirred for 30 min at room temperature, iodomethane (213 mg, 1.50 mmol, 2 
equiv) was added. The reaction mixture was poured into water; then NaCl was added. The 
resulting precipitate was collected, washed with water, dried, and purified by CC (hexane/ethyl 
acetate 3:2); yield: 42% (290 mg). 
1
H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 4.0 Hz, 1H), 7.52 – 
7.48 (m, 2H), 7.46 (t, J = 7.7 Hz, 1H), 7.43 (dd, J = 2.5, 1.4 Hz, 1H), 7.41 (t, J = 1.8 Hz, 1H), 
7.35 (t, J = 7.9 Hz, 1H), 7.24 (d, J = 4.0 Hz, 1H), 7.21 – 7.17 (m, 1H), 7.17 – 7.11 (m, 2H), 6.98 
(dd, J = 2.5, 1.5 Hz, 1H), 6.96 – 6.92 (m, 1H), 6.88 – 6.83 (m, 1H), 3.93 (s, 3H), 3.73 (s, 3H), 
3.59 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 187.55, 170.40, 159.64, 159.10, 151.55, 145.67, 
142.74, 139.13, 136.88, 135.69, 134.33, 129.91, 129.42, 128.97, 126.94, 124.54, 124.26, 121.58, 
121.03, 118.57, 116.22, 113.74, 113.63, 55.45, 55.23, 38.24; MS (ESI): 458.19 (M+H)
+
. 
3-Hydroxy-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)-N-methyl-benzamide (12). 
The title compound was prepared by reaction of 3-methoxy-N-(3-(5-(3-methoxybenzoyl)-
thiophen-2-yl)phenyl)-N-methylbenzamide (12a) (290 mg, 0.63 mmol) and boron tribromide 
(3.80 mmol) according to method B. The product was purified by CC (dichloromethan/methanol 
98:2); yield: 56% (151 mg). 
1
H NMR (500 MHz, CD3OD) δ 7.55 (d, J = 4.0 Hz, 1H), 7.46 (dd, J 
= 7.8, 0.9 Hz, 1H), 7.41 (s, 1H), 7.30 (d, J = 4.0 Hz, 1H), 7.29 – 7.26 (m, 1H), 7.26 – 7.24 (m, 
1H), 7.21 – 7.18 (m, 1H), 7.13 (dd, J = 2.2, 1.7 Hz, 1H), 7.12 – 7.08 (m, 1H), 6.98 – 6.92 (m, 
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2H), 6.70 – 6.68 (m, 1H), 6.67 (d, J = 7.6 Hz, 1H), 6.62 – 6.59 (m, 1H), 3.40 (s, 3H); 13C NMR 
(125 MHz, CD3OD) δ 189.67, 173.12, 158.93, 158.40, 153.13, 146.69, 143.69, 140.40, 138.40, 
137.65, 135.59, 131.22, 130.78, 130.26, 128.45, 126.07, 126.00, 125.65, 121.31, 120.74, 120.52, 
118.03, 116.52, 116.20, 32.86; MS (ESI): 430.19 (M+H)
+
. 
4-Cyano-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (13). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-hydroxy-
phenyl)methanone (2) (100 mg, 0.34 mmol) and 4-cyanobenzenesulfonyl chloride (103 mg, 0.51 
mmol) according to method D. The product was purified by CC (dichloromethan/methanol 
99.5:0.5); yield: 51% (80 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 9.65 (br. s, 1H), 8.91 (br., s, 
1H), 8.07 – 8.02 (m, 2H), 8.02 – 7.97 (m, 2H), 7.71 (d, J = 4.0 Hz, 1H), 7.64 (t, J = 1.8 Hz, 1H), 
7.57 (ddd, J = 7.8, 1.7, 1.0 Hz, 1H), 7.53 (d, J = 4.0 Hz, 1H), 7.41 (td, J = 7.7, 1.4 Hz, 2H), 7.37 
(dt, J = 7.6, 1.3 Hz, 1H), 7.35 – 7.32 (m, 1H), 7.28 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.14 (ddd, J = 
7.9, 2.6, 1.2 Hz, 1H);
13
C NMR (125 MHz, acetone-d
6) δ 187.70, 158.43, 152.05, 144.60, 143.65, 
140.18, 139.06, 136.77, 135.30, 134.12, 131.31, 130.61, 128.81, 125.77, 123.67, 122.34, 121.10, 
120.32, 119.32, 118.03, 117.32, 116.28; MS (ESI): 461.15 (M+H)
+
. 
N-(3-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenyl)-2-nitrobenzenesulfonamide (14). The title 
compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 2-nitrobenzenesulfonyl chloride (113 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 23% (37 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 
9.54 (br. s, 1H), 8.48 (br., s, 1H), 8.08 (dd, J = 7.9, 1.3 Hz, 1H), 7.98 (dd, J = 7.9, 1.2 Hz, 1H), 
7.90 (td, J = 7.7, 1.4 Hz, 1H), 7.85 – 7.79 (m, 1H), 7.73 (t, J = 1.8 Hz, 1H), 7.71 (d, J = 4.0 Hz, 
1H), 7.62 – 7.57 (m, 1H), 7.55 (d, J = 4.0 Hz, 1H), 7.46 – 7.39 (m, 2H), 7.39 – 7.32 (m, 3H), 
7.14 (ddd, J = 7.9, 2.5, 1.2 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 187.70, 158.43, 152.05, 
149.20, 143.66, 140.18, 138.56, 136.77, 135.67, 135.29, 133.37, 132.58, 132.09, 131.28, 130.61, 
125.96, 125.80, 123.96, 122.92, 121.10, 120.32, 119.88, 116.29; MS (ESI): 481.16 (M+H)
+
. 
N-(3-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenyl)-3-nitrobenzenesulfonamide (15). The title 
compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-hydroxy-
phenyl)methanone (2) (100 mg, 0.34 mmol) and 3-nitrobenzenesulfonyl chloride (113 mg, 0.51 
mmol) according to method D. The product was purified by CC (dichloromethan/methanol 
99:1); yield: 40% (65 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 9.65 (br. s, 1H), 8.28 (br. s, 1H), 
8.65 – 8.61 (m, 1H), 8.48 (ddd, J = 8.2, 2.2, 1.0 Hz, 1H), 8.24 (ddd, J = 7.9, 1.7, 1.0 Hz, 1H), 
7.89 (t, J = 8.1 Hz, 1H), 7.70 (d, J = 4.0 Hz, 1H), 7.64 (t, J = 1.9 Hz, 1H), 7.57 (ddd, J = 7.8, 1.7, 
0.9 Hz, 1H), 7.52 (d, J = 4.0 Hz, 1H), 7.41 (td, J = 7.9, 2.9 Hz, 2H), 7.38 – 7.34 (m, 1H), 7.34 – 
7.29 (m, 2H), 7.13 (ddd, J = 7.9, 2.5, 1.2 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 187.69, 
158.43, 151.99, 149.33, 143.66, 142.26, 140.16, 138.95, 136.77, 135.34, 133.73, 132.02, 131.37, 
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130.61, 128.45, 125.79, 123.85, 122.87, 122.58, 121.10, 120.33, 119.56, 116.29; MS (ESI): 
481.15 (M+H)
+
. 
N-(3-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenyl)-4-nitrobenzenesulfonamide (16). The title 
compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 4-nitrobenzenesulfonyl chloride (113 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 46% (74 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 
9.17 (br. s, 1H), 8.20 (br. s, 1H), 8.44 – 8.37 (m, 2H), 8.16 – 8.10 (m, 2H), 7.70 (d, J = 4.0 Hz, 
1H), 7.66 (t, J = 1.9 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 4.0 Hz, 1H), 7.41 (td, J = 7.9, 
1.7 Hz, 2H), 7.38 – 7.34 (m, 1H), 7.34 – 7.28 (m, 2H), 7.14 (ddd, J = 7.9, 2.5, 1.1 Hz, 1H);13C 
NMR (125 MHz, acetone-d
6) δ 187.70, 158.43, 152.03, 151.37, 146.07, 143.66, 140.17, 138.99, 
136.77, 135.34, 131.35, 130.61, 129.55, 125.79, 125.35, 123.74, 122.38, 121.09, 120.33, 119.37, 
116.28; MS (ESI): 481.18 (M+H)
+
. 
N-(3-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenyl)-2,3-dinitrobenzenesulfonamide (17). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 2,3-dinitrobenzenesulfonyl chloride 
(135 mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 23% (40 mg). 
1
H NMR (500 MHz, CD3OD) δ 8.06 
(t, J = 1.5 Hz, 1H), 7.95 (ddd, J = 8.0, 1.8, 1.1 Hz, 1H), 7.86 – 7.81 (m, 1H), 7.61 – 7.57 (m, 1H), 
7.57 – 7.56 (m, 1H), 7.55 (dd, J = 3.1, 0.9 Hz, 2H), 7.33 (t, J = 5.2 Hz, 1H), 7.25 (t, J = 7.8 Hz, 
1H), 7.22 – 7.17 (m, 1H), 7.12 (dd, J = 4.5, 2.2 Hz, 2H), 7.11 – 7.09 (m, 1H), 6.95 (ddd, J = 8.1, 
2.5, 1.1 Hz, 1H); 
13
C NMR (125 MHz, CD3OD) δ 189.73, 158.91, 153.81, 143.04, 142.67, 
140.50, 139.47, 137.92, 137.39, 132.36, 131.73, 131.57, 131.25, 130.75, 128.36, 125.33, 122.45, 
121.25, 120.64, 119.54, 118.20, 116.48, 114.68, 112.05; MS (ESI): 526.21 (M+H)
+
. 
2-Fluoro-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (18). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 2-fluorobenzenesulfonyl chloride (99 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 57% (88 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 
9.49 (br. s, 1H), 8.77 (br. s, 1H), 7.96 (td, J = 7.6, 1.8 Hz, 1H), 7.73 – 7.66 (m, 3H), 7.51 (qd, J = 
1.9, 1.1 Hz, 2H), 7.43 – 7.38 (m, 2H), 7.38 – 7.33 (m, 4H), 7.33 – 7.30 (m, 1H), 7.14 (ddd, J = 
7.9, 2.5, 1.2 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 187.70, 159.71 (d, J = 254.7 Hz), 
158.45, 152.24, 143.56, 140.20, 139.23, 136.83 (d, J = 8.8 Hz),  136.78, 135.14, 131.77, 131.17, 
130.60, 125.71 (d, J = 3.8 Hz), 125.69, 125.65, 123.11, 121.48, 121.08, 120.31, 118.33, 118.10, 
117.93, 116.30; MS (ESI): 454.23 (M+H)
+
. 
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3-Fluoro-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl-phenyl)benzenesulfonamide (19). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 3-fluorobenzenesulfonyl chloride (99 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 53% (82 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 
9.30 (br. s, 1H), 8.76 (br. s, 1H), 7.74 – 7.67 (m, 2H), 7.65 – 7.50 (m, 5H), 7.45 – 7.36 (m, 4H), 
7.34 – 7.25 (m, 2H), 7.14 (d, J = 5.4 Hz, 1H); 13C NMR (125 MHz, acetone-d6) δ 187.69, 158.44, 
152.16, 143.59, 140.19, 139.37, 136.78, 135.21, 132.41, 132.35, 131.23, 130.60, 125.70, 124.18 
(d, J = 3.1 Hz), 123.43, 122.20, 121.09, 120.90, 120.32, 119.13, 116.29, 115.10, 114.90; MS 
(ESI): 454.15 (M+H)
+
. 
4-Fluoro-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (20). The 
title compound was prepared by reaction of (5-(3-amin-phenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 4-fluorobenzenesulfonyl chloride (99 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 44% (67 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 
8.06 (t, J = 1.5 Hz, 1H), 7.95 (ddd, J = 8.0, 1.8, 1.1 Hz, 1H), 7.86 – 7.81 (m, 1H), 7.61 – 7.57 (m, 
1H), 7.57 – 7.56 (m, 1H), 7.55 (dd, J = 3.1, 0.9 Hz, 2H), 7.33 (t, J = 5.2 Hz, 1H), 7.25 (t, J = 7.8 
Hz, 1H), 7.22 – 7.17 (m, 1H), 7.12 (dd, J = 4.5, 2.2 Hz, 2H), 7.11 – 7.09 (m, 1H), 6.95 (ddd, J = 
8.1, 2.5, 1.1 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 187.70, 166.01 (d, J = 252.5 Hz), 
158.43, 152.24, 143.56, 140.20, 139.60, 136.98 (d, J = 3.0 Hz), 136.78, 135.17, 131.18, 131.10, 
131.03, 130.60, 125.67, 123.24, 122.08, 121.09, 120.30, 118.99, 117.24, 117.06, 116.28; MS 
(ESI): 454.18 (M+H)
+
. 
4-Bromo-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (21). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 4-bromobenzenesulfonyl chloride (130 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 49% (85 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 
7.81 – 7.78 (m, 2H), 7.77 – 7.74 (m, 2H), 7.71 (d, J = 4.0 Hz, 1H), 7.63 (t, J = 1.8 Hz, 1H), 7.54 
(ddd, J = 7.8, 1.8, 1.0 Hz, 1H), 7.52 (d, J = 4.0 Hz, 1H), 7.38 (tt, J = 4.5, 2.8 Hz, 3H), 7.35 – 7.33 
(m, 1H), 7.27 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.14 (ddd, J = 7.9, 2.5, 1.2 Hz, 1H);
13
C NMR (125 
MHz, acetone-d
6) δ 187.70, 158.42, 152.20, 143.58, 140.20, 139.94, 139.44, 136.77, 135.21, 
133.30, 131.22, 130.61, 129.92, 128.15, 125.70, 123.34, 122.10, 121.10, 120.31, 119.04, 116.28; 
MS (ESI): 515.02 (M+H)
+
. 
4-Bromo-2,5-difluoro-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfon-
amide (22). The title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-
yl)(3-hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 4-bromo-2,5-difluoro-
benzenesulfonyl chloride (148 mg, 0.51 mmol) according to method D. The product was purified 
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by CC (dichloromethan/methanol 99.5:0.5); yield: 44% (82 mg). 
1
H NMR (500 MHz, acetone-
d
6
) δ 7.83 – 7.78 (m, 2H), 7.71 (d, J = 4.0 Hz, 1H), 7.69 (t, J = 1.9 Hz, 1H), 7.57 (ddd, J = 7.7, 
1.8, 1.0 Hz, 1H), 7.54 (d, J = 4.0 Hz, 1H), 7.44 – 7.39 (m, 2H), 7.38 – 7.33 (m, 3H), 7.14 (ddd, J 
= 7.9, 2.5, 1.3 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 187.70, 158.44, 152.02, 150.65, 
143.68, 140.18, 138.56, 136.77, 135.32, 131.35, 130.61, 125.79, 124.58, 123.72, 123.64, 123.42, 
121.94, 121.10, 120.32, 118.97, 118.71, 118.48, 116.29; MS (ESI): 551.97 (M+H)
+
. 
3,5-Dichloro-4-hydroxy-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfon-
amide (23). The title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-
yl)(3-hydroxyphenyl)methanone (2) (150 mg, 0.51 mmol) and 3,5-dichloro-4-hydroxybenzene-
sulfonyl chloride (199 mg, 0.76 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.25:0.75); yield: 45% (120 mg). 
1
H NMR (500 MHz, CD3OD) δ 
7.69 (d, J = 3.6 Hz, 2H), 7.63 (d, J = 4.0 Hz, 1H), 7.46 (t, J = 1.8 Hz, 1H), 7.46 – 7.42 (m, 1H), 
7.39 (d, J = 4.0 Hz, 1H), 7.35 (t, J = 5.3 Hz, 1H), 7.34 – 7.31 (m, 1H), 7.31 – 7.28 (m, 1H), 7.24 
(dd, J = 2.2, 1.7 Hz, 1H), 7.13 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.06 (ddd, J = 8.0, 2.5, 1.1 Hz, 
1H);
13
C NMR (125 MHz, CD3OD) δ 189.74, 158.88, 154.96, 153.56, 143.55, 140.38, 139.66, 
137.76, 135.63, 132.39, 131.34, 130.77, 128.75, 125.84, 123.80, 123.77, 122.72, 121.39, 120.74, 
119.63, 116.54; MS (ESI): 520.13 (M+H)
+
. 
3-Methoxy-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide (24). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-hydroxy-
phenyl)methanone (2) (100 mg, 0.34 mmol) and 3-methoxybenzenesulfonyl chloride (105 mg, 
0.51 mmol) according to method D. The product was purified by CC (dichloromethan/methanol 
99.5:0.5); yield: 38% (60 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.19 (br. s, 1H), 8.80 (br. s, 
1H), 7.68 (d, J = 4.0 Hz, 1H), 7.64 (t, J = 1.8 Hz, 1H), 7.51 – 7.47 (m, 2H), 7.45 – 7.41 (m, 2H), 
7.40 – 7.38 (m, 1H), 7.38 – 7.33 (m, 4H), 7.29 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.16 – 7.14 (m, 
1H), 7.14 – 7.11 (m, 1H), 3.79 (s, 3H); 13C NMR (125 MHz, acetone-d6) δ 187.78, 160.88, 
158.43, 152.37, 143.50, 141.84, 140.19, 139.79, 136.85, 135.08, 131.21, 131.14, 130.63, 125.64, 
123.07, 121.97, 121.15, 120.36, 120.07, 119.75, 118.81, 116.33, 113.03, 56.07; MS (ESI): 
466.17 (M+H)
+
. 
N-(3-(3-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenylsulfamoyl)phenyl)acetamide (25). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (80 mg, 0.27 mmol) and 3-acetylaminobenzenesulfonyl chloride 
(95 mg, 0.41 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99:1); yield: 70% (93 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 9.46 
(br., 1H,NH), 9.10 (br. s, 1H), 8.75 (br. s, 1H), 7.78 (s, 4H), 7.70 (d, J = 4.0 Hz, 1H), 7.62 (t, J = 
1.8 Hz, 1H), 7.50 (t, J = 5.8 Hz, 2H), 7.41 (t, J = 7.7 Hz, 1H), 7.39 – 7.35 (m, 2H), 7.34 – 7.32 
(m, 1H), 7.27 (dd, J = 8.1, 1.2 Hz, 1H), 7.13 (ddd, J = 7.9, 2.5, 1.2 Hz, 1H), 2.08 (s, 3H); 
13
C 
NMR (125 MHz, acetone-d
6) δ 189.92, 187.72, 158.44, 152.44, 144.54, 143.47, 140.21, 139.99, 
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136.80, 135.03, 134.32, 131.07, 130.60, 129.23, 128.56, 125.60, 122.83, 121.79, 121.08, 120.31, 
119.48, 118.63, 116.30, 114.20, 22.10; MS (ESI): 493.41 (M+H)
+
. 
N-(3-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenyl)-2-methylbenzenesulfonamide (26). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-hydroxy-
phenyl)methanone (2) (100 mg, 0.34 mmol) and 2-methylbenzenesulfonyl chloride (97 mg, 0.51 
mmol) according to method D. The product was purified by CC (dichloromethan/methanol 
99.5:0.5); yield: 51% (80 mg). 
1
H NMR (500 MHz, CDCl3) δ 9.30 (br. s, 1H), 8.79 (br. s, 1H), 
8.07 – 8.01 (m, 1H), 7.67 (d, J = 4.0 Hz, 1H), 7.58 (t, J = 1.8 Hz, 1H), 7.48 (s, 1H), 7.46 (d, J = 
4.0 Hz, 1H), 7.43 (ddd, J = 7.7, 1.7, 1.0 Hz, 1H), 7.37 (t, J = 7.7 Hz, 3H), 7.32 (ddd, J = 11.8, 
2.5, 1.5 Hz, 3H), 7.22 (ddd, J = 8.1, 2.2, 0.9 Hz, 1H), 7.11 (ddd, J = 7.9, 2.5, 1.2 Hz, 1H), 2.66 
(s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 186.81, 157.54, 151.50, 142.58, 139.31, 138.99, 138.78, 
137.30, 135.88, 134.16, 133.17, 132.71, 130.22, 129.95, 129.70, 126.26, 124.68, 121.52, 120.18, 
119.79, 119.40, 116.57, 115.38, 19.42; MS (ESI): 450.08 (M+H)
+
. 
N-(3-(5-(3-Hydroxybenzoyl)thiophen-2-yl)phenyl)-3-methylbenzenesulfonamide (27). The 
title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (100 mg, 0.34 mmol) and 3-methylbenzenesulfonyl chloride (97 
mg, 0.51 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 64% (100 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 
9.15 (br. s, 1H), 8.75 (br. s, 1H), 7.70 (dd, J = 4.5, 2.3 Hz, 2H), 7.69 – 7.64 (m, 1H), 7.62 (t, J = 
1.8 Hz, 1H), 7.52 – 7.49 (m, 2H), 7.45 – 7.42 (m, 2H), 7.42 – 7.35 (m, 3H), 7.34 – 7.32 (m, 1H), 
7.27 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 7.14 (ddd, J = 7.9, 2.5, 1.2 Hz, 1H), 2.37 (s, 3H); 
13
C NMR 
(125 MHz, acetone-d
6) δ 187.69, 158.43, 152.39, 143.50, 140.70, 140.23, 139.87, 136.77, 
135.06, 134.55, 131.08, 130.60, 129.90, 128.33, 125.59, 125.18, 122.88, 121.76, 121.09, 120.30, 
118.60, 116.29, 21.24; MS (ESI): 450.11 (M+H)
+
. 
2-Fluoro-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)-4-methoxybenzenesulfonamide 
(28). The title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)(3-
hydroxyphenyl)methanone (2) (200 mg, 0.68 mmol) and 2-fluoro-4-methoxybenzenesulfonyl 
chloride (228 mg, 1.02 mmol) according to method D. The product was purified by CC 
(dichloromethan/methanol 99:1); yield: 58% (190 mg). 
1
H NMR (500 MHz, CD3OD) δ 7.61 (d, 
J = 4.0 Hz, 1H), 7.58 (ddd, J = 8.7, 2.2, 1.2 Hz, 1H), 7.52 (dd, J = 10.6, 2.2 Hz, 1H), 7.45 (t, J = 
1.8 Hz, 1H), 7.41 (ddd, J = 7.8, 1.7, 1.0 Hz, 1H), 7.38 (d, J = 4.0 Hz, 1H), 7.34 (t, J = 7.8 Hz, 
1H), 7.31 – 7.26 (m, 2H), 7.24 (dd, J = 2.2, 1.7 Hz, 1H), 7.14 (ddd, J = 8.2, 4.8, 3.8 Hz, 2H), 
7.06 (ddd, J = 8.1, 2.5, 1.1 Hz, 1H), 3.86 (s, 3H); 
13
C NMR (125 MHz, CD3OD) δ 189.71, 
158.89, 153.6, 153.50 (d, J = 95.3 Hz), 152.47 (d, J = 144.8 Hz), 143.50, 140.37, 139.92, 137.76, 
135.51, 132.56 (d, J = 5.6 Hz), 131.25, 130.78, 125.92 (d, J = 3.7 Hz), 125.80, 123.50, 122.55, 
121.37, 120.74, 119.39, 116.53, 116.03, 115.86, 114.31 (d, J = 1.6 Hz), 57.00; MS (ESI): 484.26 
(M+H)
+
. 
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2-Fluoro-4-hydroxy-N-(3-(5-(3-hydroxybenzoyl)thiophen-2-yl)phenyl)benzenesulfonamide 
(29). The title compound was prepared by reaction of 2-fluoro-N-(3-(5-(3-hydroxybenzoyl)-
thiophen-2-yl)phenyl)-4-methoxybenzenesulfonamide (22) (155 mg, 0.32 mmol) and boron 
tribromide (0.96 mmol) according to method B. The product was purified by CC 
(dichloromethan/methanol 98.5:1.5); yield: 46% (70 mg). 
1
H NMR (500 MHz, CD3OD) δ 7.60 
(d, J = 4.0 Hz, 1H), 7.51 (dd, J = 10.5, 2.2 Hz, 1H), 7.47 (ddd, J = 4.9, 3.1, 1.4 Hz, 2H), 7.39 
(ddd, J = 7.8, 1.7, 0.9 Hz, 1H), 7.36 (d, J = 4.0 Hz, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.30 – 7.26 (m, 
2H), 7.25 – 7.23 (m, 1H), 7.13 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 7.06 (ddd, J = 8.0, 2.5, 1.1 Hz, 
1H), 6.97 (t, J = 8.4 Hz, 1H); 
13
C NMR (125 MHz, CD3OD) δ 158.86, 153.72, 152.13 (d, J = 
240.4 Hz), 151.11 (d, J = 7.2 Hz), 143.45, 140.37, 139.99, 137.82, 135.48, 131.32 (d, J = 5.4 
Hz), 125.87, 125.84, 125.78, 123.48, 122.55, 121.42, 120.76, 119.43, 118.88, 118.85, 116.64, 
116.55, 116.47; MS (ESI): 470.43 (M+H)
+
. 
 (5-(2,4-Difluoro-phenyl)-thiophen-2-yl)-(3-methoxy-phenyl)-methanone (30a). The title 
compound was prepared by reaction of (5-Bromo-thiophen-2-yl)-(3-methoxy-phenyl)-methanone 
(I) (500 mg, 1.68 mmol), 2,4-difluorophenylboronic acid (298 mg, 1.88 mmol), cesium 
carbonate (2189 mg, 6.7 mmol) and tetrakis(triphenylphosphine) palladium (5 µmol) according 
to method C1. The product was purified by CC (petroleum ether /ethyl acetate 96:4); yield: 75% 
(417 mg). MS (ESI): 331.04 (M+H)
+
. 
(5-(2,4-Difluoro-phenyl)-thiophen-2-yl)-(3-hydroxy-phenyl)-methanone (30). The title 
compound was prepared by reaction of (5-(2,4-difluoro-phenyl)-thiophen-2-yl)-(3-methoxy-
phenyl)-methanone (30a) (417 mg, 1.26 mmol) and boron tribromide (3.8 mmol) according to 
method B. The product was purified by CC (dichloromethan/methanol 99.75:0.25); yield: 41% 
(330 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 8.77 (s, 1H), 7.94 (td, J = 8.8, 6.3 Hz, 1H), 7.75 
(dd, J = 4.0, 1.1 Hz, 1H), 7.63 (dd, J = 4.0, 1.0 Hz, 1H), 7.43 – 7.40 (m, 1H), 7.39 – 7.37 (m, 
1H), 7.35 (ddd, J = 2.5, 1.5, 0.5 Hz, 1H), 7.27 – 7.21 (m, 1H), 7.20 – 7.15 (m, 1H), 7.14 (ddd, J 
= 7.7, 2.6, 1.5 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 187.84, 163.90 (dd, J = 250.2, 12.1 
Hz), 160.35 (dd, J = 254.0, 13.3 Hz), 158.45, 144.41 (dd, J = 91.1, 3.7 Hz), 140.16, 136.06, 
131.44 (dd, J = 9.9, 4.4 Hz), 130.63, 128.25 – 127.77 (m), 121.15, 120.39, 118.70 (dd, J = 12.9, 
4.1 Hz), 116.32, 113.36 (dd, J = 21.8, 3.6 Hz), 105.70 (t, J = 26.4 Hz); MS (ESI): 317.63 
(M+H)
+
. 
Acetic acid 3-(5-(2,4-difluoro-phenyl)-thiophene-2-carbonyl)-2-methyl-phenyl ester (31a). 
The title compound was prepared by reaction of acetic acid 3-(5-bromo-thiophene-2-carbonyl)-2-
methyl-phenyl ester (III) (500 mg, 1.47 mmol), 2,4-difluorophenylboronic acid (279 mg, 1.77 
mmol), cesium carbonate (1921 mg, 5.90 mmol) and tetrakis(triphenylphosphine) palladium (5 
µmol) according to method C1. The product was sufficiently pure for use in the subsequent 
reaction. The product was used without any characterization; yield: 78% (430 mg). 
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(5-(2,4-Difluoro-phenyl)-thiophen-2-yl)-(3-hydroxy-2-methyl-phenyl)-methanone(31). 
Compound (31a) (430 mg, 1.16 mmol) in ethanol (5 mL) was refluxed in 10% NaOH (15 mL) 
for 2 h on a water bath. The reaction mixture was cooled, diluted with water and neutralized with 
acetic acid. The product was purified by CC (dichloromethan/methanol 99.5:0.5); yield: 58% 
(220 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.51 (s, 1H, OH), 8.83 (dd, J = 15.1, 8.5 Hz, 1H), 
8.49 (d, J = 3.4 Hz, 1H), 8.37 (d, J = 3.4 Hz, 1H), 8.24 – 8.02 (m, 3H), 7.95 (d, J = 7.9 Hz, 1H), 
7.89 (d, J = 7.3 Hz, 1H), 3.11 (s, 3H); 
13
C NMR (125 MHz, acetone-d
6) δ 189.56, 163.02 (dd, J = 
251.3, 12.8 Hz), 159.45 (dd, J = 253.4, 12.4 Hz), 155.85, 144.44 (dd, J = 10.1, 4.1 Hz), 140.21, 
135.70, 130.55 (dd, J = 9.9, 4.4 Hz), 127.34, 127.28, 126.11, 122.33, 118.97, 117.80 (dd, J = 
12.8, 4.0 Hz), 116.62, 112.45 (dd, J = 21.8, 3.6 Hz), 104.79 (t, J = 26.4 Hz), 11.99; MS (ESI): 
331.04 (M+H)
+
. 
Acetic acid 3-(5-(2,4-difluoro-phenyl)-4-methyl-thiophene-2-carbonyl)-2-methyl-phenyl 
ester (32a). The title compound was prepared by reaction of acetic acid 3-(5-bromo-4-methyl-
thiophene-2-carbonyl)-2-methyl-phenylester (IV) (500 mg, 1.42 mmol), 2,4-difluorophenyl-
boronic acid (268 mg, 1.70 mmol), cesium carbonate (1845 mg, 5.66 mmol) and 
tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 88% (480 mg). MS (ESI): 487.11 (M+H)
+
. 
(5-(2,4-Difluoro-phenyl)-4-methyl-thiophen-2-yl)-(3-hydroxy-2-methyl-phenyl)-methanone 
(32). Compound (32a) (480 mg, 1.24 mmol) in ethanol (5 mL) was refluxed in 10% NaOH (15 
mL) for 2 h on a water bath. The reaction mixture was cooled, diluted with water and neutralized 
with acetic acid. The product was purified by CC (dichloromethan/methanol 99.5:0.5); yield: 
35% (150 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.51 (s, 1H), 8.83 (dd, J = 15.1, 8.5 Hz, 1H), 
8.49 (d, J = 3.4 Hz, 1H), 8.37 (d, J = 3.4 Hz, 1H), 8.24 – 8.02 (m, 3H), 7.95 (d, J = 7.9 Hz, 1H), 
7.89 (d, J = 7.3 Hz, 1H), 3.11 (s, 3H); 
13
C NMR (125 MHz, acetone-d
6) δ 189.48, 163.39 (dd, J = 
247.8, 10.1 Hz), 159.78 (dd, J = 250.9, 12.9 Hz), 155.83, 143.47, 140.24, 139.05, 137.92, 
137.66, 133.27 (dd, J = 9.9, 3.9 Hz), 126.06, 122.27, 118.92 , 117.48 (dd, J = 15.7, 3.9 Hz), 
116.53, 111.96 (dd, J = 21.6, 3.8 Hz), 104.47 (t, J = 26.3 Hz), 13.82 (d, J = 3.5 Hz), 11.99; MS 
(ESI): 445.93 (M+H)
+
. 
(5-(2,4-Difluoro-phenyl)-thiophen-2-yl)-(2-fluoro-3-methoxy-phenyl)-methanone (33a). The 
title compound was prepared by reaction of 5-bromo-thiophen-2-yl)-(2-fluoro-3-methoxy-
phenyl)-methanone (II) (500 mg, 1.52 mmol), 2,4-difluorophenylboronic acid (288 mg, 1.82 
mmol), cesium carbonate (1981 mg, 6.08 mmol) and tetrakis(triphenylphosphine) palladium (5 
µmol) according to method C1. The product was used in the next step without further 
purification; yield: 78% (428 mg). 
(5-(2,4-Difluoro-phenyl)-thiophen-2-yl)-(2-fluoro-3-hydroxy-phenyl)-methanone (33). The 
title compound was prepared by reaction of [5-(2,4-difluoro-phenyl)-thiophen-2-yl)-(2-fluoro-3-
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methoxy-phenyl)-methanone (33a) (428 mg, 1.23 mmol) and boron tribromide (7.4 mmol, 6.0 
equiv) according to method B. The product was purified by CC (dichloromethan/methanol 
99.50:0.50); yield: 49% (200 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.06 (s, 1H), 7.95 (td, J = 
8.8, 6.3 Hz, 1H), 7.64 – 7.60 (m, 2H), 7.28 – 7.24 (m, 1H), 7.24 – 7.21 (m, 1H), 7.21 – 7.18 (m, 
1H), 7.18 – 7.15 (m, 1H), 7.08 (ddd, J = 7.4, 5.6, 1.8 Hz, 1H); 13C NMR (125 MHz, acetone-d6) 
δ 185.08, 164.02 (dd, J = 251.6, 13.2 Hz), 160.38 (dd, J = 253.3, 12.5 Hz), 149.38 (d, J = 246.0 
Hz), 146.40, 146.30, 145.07 (dd, J = 196.2, 4.2 Hz), 136.91, 131.50 (dd, J = 9.9, 4.4 Hz), 128.73 
(d, J = 13.0 Hz), 128.32 (dd, J = 5.0, 0.5 Hz), 125.48 (d, J = 4.3 Hz), 121.40 (d, J = 3.0 Hz), 
120.71 (d, J = 1.3 Hz), 118.57 (dd, J = 12.8, 4.1 Hz), 113.41 (dd, J = 21.9, 3.7 Hz), 105.74 (t, J = 
26.4 Hz); MS (ESI): 335.04 (M+H)
+
. 
(5-(2,4-Difluoro-phenyl)-thiophen-2-yl)-(3-ethoxy-2,6-difluoro-phenyl)-methanone (34a). 
The title compound was prepared by reaction of 5-bromo-thiophen-2-yl)-(3-ethoxy-2,6-difluoro-
phenyl)-methanone (V) (300 mg, 0.86 mmol), 2,4-difluorophenylboronic acid (164 mg, 1.04 
mmol), cesium carbonate (1126 mg, 3.5 mmol) and tetrakis(triphenylphosphine) palladium (5 
µmol) according to method C1. The product was used in the next step without further 
purification and without any characterization; yield: 91% (300 mg).  
(2,6-Difluoro-3-hydroxy-phenyl)-(5-(2,4-difluoro-phenyl)-thiophen-2-yl)-methanone (34). 
The title compound was prepared by reaction of (5-(2,4-difluoro-phenyl)-thiophen-2-yl)-(3-
ethoxy-2,6-difluoro-phenyl)-methanone (34a) (300 mg, 0.79 mmol) and boron tribromide (3.9 
mmol, 5.0 equiv) according to method B. The product was purified by CC 
(dichloromethan/methanol 99.75:0.25); yield: 72% (280 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 
8.99 (s, 1H), 7.96 (td, J = 8.8, 6.3 Hz, 1H), 7.68 (ddd, J = 4.0, 1.9, 0.9 Hz, 1H), 7.65 (dd, J = 4.1, 
0.9 Hz, 1H), 7.29 – 7.23 (m, 1H), 7.23 – 7.16 (m, 2H), 7.04 (ddd, J = 9.1, 8.6, 1.9 Hz, 1H); 13C 
NMR (125 MHz, acetone-d
6) δ 180.88, 164.18 (dd, J = 251.5, 12.7 Hz), 160.45 (dd, J = 253.6, 
12.6 Hz), 152.56 (dd, J = 240.6, 5.8 Hz), 148.43 (dd, J = 245.8, 7.7 Hz), 145.46 (dd, J = 361.6, 
3.6 Hz), 142.65 (dd, J = 12.9, 3.2 Hz), 137.39, 131.60 (dd, J = 9.8, 4.4 Hz), 128.62, 128.59, 
120.41 (dd, J = 9.1, 3.9 Hz), 118.40 (dd, J = 12.7, 4.1 Hz), 118.04 (dd, J = 24.0, 19.6 Hz), 
113.46 (dd, J = 21.1, 4.5 Hz), 112.46 (dd, J = 22.8, 3.9 Hz), 105.76 (t, J = 26.4 Hz); MS (ESI): 
353.88 (M+H)
+
. 
Acetic acid 3-(5-(3-chloro-4-methoxy-phenyl)-thiophene-2-carbonyl)-2-methyl-phenyl ester 
(35b). The title compound was prepared by reaction of acetic acid 3-(5-bromo-thiophene-2-
carbonyl)-2-methyl-phenyl ester (III) (600 mg, 1.77 mmol), 3-chloro-4-methoxy-phenylboronic 
acid (296 mg, 2.12 mmol), cesium carbonate (2305 mg, 7.08 mmol) and 
tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was 
purified by CC (dichloromethan/methanol 99.5:0.5); yield: 37% (260 mg). The product was used 
in the next step without any characterization. 
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(5-(3-Chloro-4-methoxy-phenyl)-thiophen-2-yl)-(3-hydroxy-2-methyl-phenyl)-methanone 
(35a). Compound (35b) (200 mg, 0.50 mmol) in ethanol (5 mL) was refluxed in 10% NaOH (15 
mL) for 2 h on a water bath. The reaction mixture was cooled, diluted with water and neutralized 
with acetic acid. The product was purified by CC (dichloromethan/methanol 99.75:0.25); yield: 
78% (140 mg). The product was used in the next step without any characterization. 
(5-(3-Chloro-4-hydroxy-phenyl)-thiophen-2-yl)-(3-hydroxy-2-methyl-phenyl)-methanone 
(35). The title compound was prepared by reaction of (5-(3-chloro-4-methoxy-phenyl)-thiophen-
2-yl)-(3-hydroxy-2-methyl-phenyl)-methanone (35a) (140 mg, 0.39 mmol) and boron tribromide 
(1.95 mmol, 5.0 equiv) according to method B. The product was purified by CC 
(dichloromethan/methanol 99.75:0.25); yield: 60% (80 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 
10.30 (s, 1H; OH), 9.26 (s, 1H, OH), 7.34 (d, J = 2.3 Hz, 2H), 7.12 (dd, J = 8.5, 2.3 Hz, 2H), 
7.06 (d, J = 4.0 Hz, 2H), 6.90 (d, J = 4.0 Hz, 2H), 6.71 – 6.65 (m, 2H), 6.59 (d, J = 8.5 Hz, 2H), 
6.53 (dd, J = 8.1, 0.9 Hz, 2H), 6.41 (dd, J = 7.5, 1.0 Hz, 2H), 1.61 (s, 6H); 
13
C NMR (125 MHz, 
acetone-d
6) δ 179.68, 146.17, 144.64, 142.15, 132.09, 130.03, 127.45, 117.74, 116.59, 116.46, 
115.23, 114.69, 111.95, 110.99, 108.52, 107.57, 106.84, 38.93); MS (ESI): 345.71 (M+H)
+
. 
(5-(3-Chloro-4-methoxy-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (36). The title compound was prepared by reaction of (5-bromo-thiophen-2-yl)-(2,6-
difluoro-3-hydroxy-phenyl)-methanone (VIII) (445 mg, 1.71 mmol), 3-chloro-4-methoxy-
phenylboronic acid (382 mg, 2.05 mmol), cesium carbonate (2226 mg, 6.83 mmol) and 
tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was 
purified by CC (petroleum ether/ethyl acetate 80:20); yield: 69% (450 mg). 
1
H NMR (500 MHz, 
acetone-d
6
) δ 8.99 (s, 1H, OH), 7.84 (d, J = 2.3 Hz, 1H), 7.73 (dd, J = 8.6, 2.3 Hz, 1H), 7.60 (dd, 
J = 3.0, 2.0 Hz, 1H), 7.55 (d, J = 4.1 Hz, 1H), 7.23 – 7.17 (m, 2H), 7.02 (ddd, J = 9.1, 8.6, 1.9 
Hz, 1H),, 3.97 (s, 3H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.50, 157.07, 154.01, 152.57 (dd, J 
= 240.4, 5.8 Hz), 148.43 (dd, J = 245.7, 7.8 Hz), 142.81, 142.63 (dd, J = 13.0, 3.2 Hz), 138.32, 
128.60, 127.29, 127.28, 125.60, 123.74, 120.27 (dd, J = 9.1, 3.9 Hz), 118.12 (dd, J = 24.0, 19.7 
Hz), 113.93, 112.41 (dd, J = 22.8, 3.9 Hz); MS (ESI): 381.67 (M+H)
+
. 
(5-(3-Chloro-4-hydroxy-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (37). The title compound was prepared by reaction of (5-(3-chloro-4-methoxy-
phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (36) (340 mg, 0.89 mmol) 
and boron tribromide (4.46 mmol, 5.0 equiv) according to method B. The product was purified 
by CC (dichloromethan/methanol 99.5:0.5); yield: 74% (241 mg). 
1
H NMR (500 MHz, acetone-
d
6) δ 9.33 (br., s, 1H), 8.99 (br., s, 1H), 7.82 (t, J = 2.9 Hz, 1H), 7.62 (dd, J = 8.5, 2.3 Hz, 1H), 
7.60-7.58 (m, 1H), 7.52 (d, J = 4.1 Hz, 1H), 7.19 (ddd, J = 9.6, 9.2, 5.4 Hz, 1H), 7.12 (d, J = 8.5 
Hz, 1H), 7.06 – 6.96 (m, 1H).  13C NMR (125 MHz, acetone-d6) δ 180.47, 155.24, 154.39, 
152.56 (dd, J = 240.4, 5.8 Hz), 148.43 (dd, J = 245.6, 7.8 Hz), 142.63 (dd, J = 13.1, 3.2 Hz), 
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142.55, 138.36, 128.67, 127.32, 126.79, 125.30, 122.15, 120.24 (dd, J = 9.1, 3.8 Hz), 118.33, 
118.10 (dd, J = 23.8, 19.6 Hz), 112.39 (dd, J = 22.8, 3.9 Hz); MS (ESI): 367.47 (M+H)
+
. 
(5-(3-Chloro-4-methoxy-phenyl)-4-methyl-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (38). The title compound was prepared by reaction of (5-bromo-4-methyl-thiophen-
2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (IX) (600 mg, 1.81 mmol), 3-chloro-4-
methoxy-phenylboronic acid (507 mg, 2.72 mmol), cesium carbonate (2347 mg, 7.20 mmol) and 
tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was 
purified by CC (DCM); yield: 80% (570 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 8.98 (s, 1H), 
7.62 (d, J = 2.2 Hz, 1H), 7.54 (dd, J = 8.5, 2.3 Hz, 1H), 7.52-7.51 (m, 1H), 7.27 (d, J = 8.6 Hz, 
1H), 7.21-7.19 (m, 1H), 7.02 (ddd, J = 9.1, 8.6, 1.9 Hz, 1H), 3.99 (s, 3H), 2.32-2.30 (m, 3H); 
13
C 
NMR (125 MHz, acetone-d
6) δ 180.54, 156.53, 152.54 (dd, J = 240.3, 5.9 Hz), 148.39 (dd, J = 
245.4, 7.9 Hz), 148.32, 142.60 (dd, J = 13.1, 3.0 Hz), 141.34, 140.62, 136.43, 130.96, 129.76, 
127.35, 123.27, 120.14 (dd, J = 9.2, 3.8 Hz), 118.23 (dd, J = 24.1, 20.1 Hz), 113.71, 112.37 (dd, 
J = 22.8, 3.9 Hz), 56.75, 14.96; MS (ESI): 396.72 (M+2H)
+
. 
(5-(3-Chloro-4-hydroxy-phenyl)-4-methyl-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (39). The title compound was prepared by reaction of (5-(3-chloro-4-methoxy-
phenyl)-4-methyl-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (38) (520 mg, 1.32 
mmol) and boron tribromide (6.58 mmol, 5.0 equiv) according to method B. The product was 
purified by CC (dichloromethan/methanol 99.75:0.25); yield: 82% (413 mg). 
1
H NMR (500 
MHz, acetone-d
6)  δ 9.25 (s, 1H, OH), 8.97 (d, J = 1.4 Hz, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.50 – 
7.48 (m, 1H), 7.41 (dd, J = 8.4, 2.2 Hz, 1H), 7.21 – 7.17 (m, 1H), 7.15 (d, J = 8.4 Hz, 1H), 7.04 – 
6.98 (m, 1H), 2.34 – 2.29 (m, 3H); 13C NMR (125 MHz, acetone-d6) δ 180.52, 154.61, 152.54 
(dd, J = 240.2, 5.9 Hz), 148.69, 148.40 (dd, J = 245.5, 7.8 Hz), 142.60 (dd, J = 13.0, 3.2 Hz), 
141.12, 140.65, 136.21, 130.99, 129.72, 126.78, 121.68, 120.12 (dd, J = 9.1, 3.8 Hz), 118.22 (dd, 
J = 32.7, 28.5 Hz), 118.05, 112.36 (dd, J = 22.8, 3.9 Hz), 15.00; MS (ESI): 381.74 (M+H)
+
. 
(5-(3-Chloro-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (40). The 
title compound was prepared by reaction of (5-bromo-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-
phenyl)-methanone (VIII) (430 mg, 1.35 mmol), 3-chlorophenylboronic acid (253 mg, 1.62 
mmol), cesium carbonate (1756 mg, 5.39 mmol) and tetrakis(triphenylphosphine) palladium (5 
µmol) according to method C1. The product was purified by CC (hexane/ethyl acetate 90:10); 
yield: 74% (350 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 9.02 (s, 1H, OH), 7.84 (tt, J = 2.4, 1.2 
Hz, 1H), 7.78- 7.76 (m, 1H), 7.69 (d, J = 4.1 Hz, 1H), 7.66 (dt, J = 4.1, 0.9 Hz, 1H), 7.52 (td, J = 
7.9, 0.5 Hz, 1H), 7.47 (ddd, J = 8.0, 2.0, 1.1 Hz, 1H), 7.23-7.21 (m, 1H), 7.06-7.04 (m, 1H); 
13
C 
NMR (125 MHz, acetone-d
6) δ 180.77, 153.31, 152.56 (dd, J = 240.6, 5.8 Hz), 148.44 (dd, J = 
245.9, 7.7 Hz), 143.92, 142.68 (dd, J = 12.9, 3.2 Hz), 138.12, 135.80, 135.69, 131.92, 130.20, 
126.96, 126.90, 125.81, 120.42 (dd, J = 9.1, 3.9 Hz), 117.97 (dd, J = 23.9, 19.7 Hz), 112.47 (d, J 
= 22.8 Hz); MS (ESI): 351.63 (M+H)
+
. 
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(5-(3-Chloro-2-methoxy-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (41a). The title compound was prepared by reaction of (5-bromo-thiophen-2-yl)-
(2,6-difluoro-3-hydroxy-phenyl)-methanone (VIII) (300 mg, 0.94 mmol), 3-chloro-2-methoxy-
phenylboronic acid (210 mg, 1.12 mmol), cesium carbonate (1225 mg, 3.76 mmol) and 
tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was used 
in the next step without further purification and without any characterization; yield: 39% (140 
mg). 
(5-(3-Chloro-2-hydroxy-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (41). The title compound was prepared by reaction of (5-(3-chloro-2-methoxy-
phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (41a) (140 mg, 0.37 mmol) 
and boron tribromide (1.84 mmol, 5.0 equiv) according to method B. The product was purified 
by CC (dichloromethan/methanol 99.75:0.25); yield: 76% (102 mg). 
1
H NMR (500 MHz, 
acetone-d
6
) δ 9.32 (s, 1H; OH), 9.11 (d, J = 0.9 Hz, 1H, OH), 7.80 (dd, J = 7.9, 1.5 Hz, 1H), 7.77 
(d, J = 4.2 Hz, 1H), 7.62 (d, J = 4.2 Hz, 1H), 7.45 (dd, J = 7.9, 1.5 Hz, 1H), 7.19 (td, J = 9.4, 5.4 
Hz, 1H), 7.06 – 6.98 (m, 2H); 13C NMR (125 MHz, acetone-d6) δ 181.04, 152.52 (dd, J = 240.2, 
5.9 Hz), 150.46, 150.17, 148.43 (dd, J = 245.6, 7.8 Hz), 143.71, 142.68 (dd, J = 12.9, 3.2 Hz), 
136.63, 131.00, 128.18, 128.00, 123.22, 122.89, 122.13, 120.14 (dd, J = 9.1, 3.9 Hz), 118.45 (dd, 
J = 24.2, 19.9 Hz), 112.34 (dd, J = 22.8, 3.9 Hz); MS (ESI): 367.86 (M+H)
+
. 
(5-(3,5-Dichloro-4-methoxy-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (42). The title compound was prepared by reaction of (5-bromo-thiophen-2-yl)-(2,6-
difluoro-3-hydroxy-phenyl)-methanone (VIII) (300 mg, 0.94 mmol), 3,5-dichloro-4-methoxy-
phenylboronic acid (249 mg, 1.13 mmol), cesium carbonate (1225 mg, 3.76 mmol) and 
tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was 
purified by CC (DCM/petroleum ether 90:10) followed by washing with petroleum ether; yield: 
90% (350 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 8.99 (s, 1H; OH), 7.83 (s, 2H), 7.67 (d, J = 4.1 
Hz, 1H), 7.64 (d, J = 4.1 Hz, 1H), 7.21 (td, J = 9.4, 5.4 Hz, 1H), 7.03 (td, J = 8.9, 1.8 Hz, 1H), 
3.93 (s, 3H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.74, 153.85, 152.57 (dd, J = 240.7, 5.7 Hz), 
151.51, 148.44 (dd, J = 246.0, 7.7 Hz), 144.21, 142.66 (dd, J = 12.9, 3.2 Hz), 138.06, 131.62, 
130.85, 127.68, 127.35, 120.48 (dd, J = 9.1, 3.9 Hz), 117.89 (dd, J = 23.8, 19.6 Hz), 112.47 (dd, 
J = 22.8, 3.9 Hz), 61.32; MS (ESI): 415.73 (M+H)
+
. 
(5-(3,5-Dichloro-4-hydroxy-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (43). The title compound was prepared by reaction of (5-(3,5-dichloro-4-methoxy-
phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (42) (350 mg, 0.84 mmol) 
and boron tribromide (4.12 mmol, 5.0 equiv) according to method B. The product was purified 
by CC (dichloromethan/methanol 99.75:0.25); yield: 84% (285 mg). 
1
H NMR (500 MHz, 
acetone-d
6) δ 9.28 (s, 1H), 8.98 (s, 1H), 7.79 (s, 2H), 7.62 (dt, J = 4.1, 0.8 Hz, 1H), 7.60 (d, J = 
4.1 Hz, 1H), 7.20 (ddd, J = 9.6, 9.2, 5.4 Hz, 1H), 7.02 (ddd, J = 9.1, 8.6, 1.9 Hz, 1H); 
13
C NMR 
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(125 MHz, acetone-d
6) δ 180.58, 152.56 (dd, J = 240.6, 5.8 Hz), 152.50, 151.05, 148.43 (dd, J = 
245.8, 7.8 Hz), 143.32, 142.64 (dd, J = 13.0, 3.2 Hz), 138.19, 127.32, 127.22, 126.30, 123.61, 
120.36 (dd, J = 9.1, 3.8 Hz), 118.01 (dd, J = 23.9, 19.7 Hz), 112.43 (dd, J = 22.8, 3.9 Hz); MS 
(ESI): 402.59 (M+H)
+
. 
2-(3-Chloro-4-methoxy-5-methyl-phenyl)-4,4,5,5-tetramethyl-(1,3,2)dioxaborolane (44a). 5-
bromo-1-chloro-2-methoxy-3-methylbenzene (44b) (5,00 g, 20,2 mmol, 1,00 equiv), 
bis(pinacolato)diboron (8,09 g, 31,8 mmol, 1,50 equiv), potassium acetate (5,95 g, 60,6 mmol, 
3,00 equiv) and 1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride (739 mg, 1,01 
mmol, 0,05 equiv) were dissolved under N2 in 40 ml dry DMSO and the mixture was stirred at 
80 °C for 2h. The reaction was quenched with water, diluted with diethyl ether and filtered over 
celite. The phases were separated and the aqueous layer was extracted two times with diethyl 
ether. The combined organic layers were washed three times with water; one time with brine, 
dried over MgSO4, filtered and concentrated under reduces pressure. The crude product was 
purified by CC (hexane/ethyl acetate 85:15); yield: 88% (4.71 g). 
1
H NMR (500 MHz, acetone-
d
6) δ 7.54-7.56 (m, 1H), 7.48-7.50 (m, 1H), 3.82 (s, 3H), 2.31 (t, J= 0.6 Hz, 3H), 1.33 (s, 12H). 
(5-(3-Chloro-4-methoxy-5-methyl-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (44). The title compound was prepared by reaction of 2-(3-chloro-4-methoxy-5-
methyl-phenyl)-4,4,5,5-tetramethyl-(1,3,2)dioxaborolane (44a) (1000 mg, 3.53 mmol), (5-
bromo-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (VIII) (1000 mg, 3.13 
mmol), cesium carbonate (4000 mg, 12.5 mmol) and tetrakis(triphenylphosphine) palladium (18 
mg, 0.02 mmol) according to method C1. The product was purified by CC (hexane/ethyl acetate 
8:2); yield: 82% (1000 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 8.98 (s, 1H), 7.72 (dd, J= 2.2, 0.6 
Hz, 1H), 7.65-7.60 (m, 2H), 7.60 (d, J= 4.1 Hz, 1H), 7.20 (td, J= 9.4, 5.2 Hz, 1H), 7.03 (td, J= 
8.8, 1.9 Hz, 1H), 3.86 (s, 3H), 2.38 (s, 3H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.7, 156.4, 
153.6, 151.7, 149.5, 149.5, 147.5, 143.5, 142.8, 142.7, 138.3, 135.5, 130.7, 129.3, 128.8, 126.5, 
120.4, 112.6, 112.4, 60.7, 16.5; MS (ESI): 395.28 (M+H)
+
. 
(5-(3-Chloro-4-hydroxy-5-methyl-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-
methanone (45). The title compound was prepared by reaction of (5-(3-chloro-4-methoxy-5-
methyl-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (44) (104 mg, 0.26 
mmol) and boron tribromide (1.05 mmol, 4.0 equiv) according to method B. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 82% (84 mg). 
1
H NMR (500 MHz, acetone-d
6
) 
δ 8.96 (d, J=1.3 Hz, 1H), 8.50 (s, 1H), 7.68-7.66 (m, 1H), 7.60-7.55 (m, 2H), 7.53 (d, J= 4.1 Hz, 
1H), 7.19 (td, J= 9.4, 5.5 Hz, 1H), 7.02 (td, J= 8.8, 1.9 Hz, 1H), 2.34 (s, 3H); 
13
C NMR (125 
MHz, acetone-d
6) δ 180.5, 154.6, 153.6, 153.2, 151.7, 149.5, 147.5, 142.7, 138.4, 128.7, 128.6, 
126.5, 125.8, 125.3, 121.8, 120.3, 118.4, 118.2, 112.5, 112.4, 16.8; MS (ESI): 381.06 (M+H)
+
. 
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(2,6-Difluoro-3-hydroxy-phenyl)-(5-(4-methoxy-3,5-dimethyl-phenyl)-thiophen-2-yl)-
methanone (46). The title compound was prepared by reaction of (5-bromo-thiophen-2-yl)-(2,6-
difluoro-3-hydroxy-phenyl)-methanone (VIII) (500 mg, 1.57 mmol), 4-methoxy-3,5-dimethyl 
phenylboronic acid (338 mg, 1.88 mmol), cesium carbonate (2042 mg, 6.27 mmol) and 
tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was 
purified by CC (hexane/ethyl acetate 90:20); yield: 78% (460 mg). 
1
H NMR (500 MHz, acetone-
d
6
) δ 8.83 (s, 1H, OH), 7.46 (d, J = 4.1 Hz, 1H), 7.37 (d, J = 4.1 Hz, 3H), 7.06 (td, J = 9.4, 5.4 
Hz, 1H), 6.89 (td, J = 8.8, 1.8 Hz, 1H), 3.62 (s, 3H), 2.18 (s, 6H); 
13
C NMR (75 MHz, Acetone) 
δ 179.53, 158.58, 154.86, 150.08 (dd, J = 240.5, 5.9 Hz), 145.81 (dd, J = 245.2, 7.9 Hz), 141.72 
(dd, J = 10.9, 5.4 Hz), 141.65, 137.32, 131.90, 128.40, 126.85, 124.37, 119.27 (dd, J = 9.0, 3.8 
Hz), 117.15 (dd, J = 30.8, 11.1 Hz), 111.47 (dd, J = 22.9, 3.8 Hz), 59.09, 15.27; MS (ESI): 
375.69 (M+H)
+
. 
(2,6-Difluoro-3-hydroxy-phenyl)-(5-(4-hydroxy-3,5-dimethyl-phenyl)-thiophen-2-yl)-
methanone (47). The title compound was prepared by reaction of (2,6-difluoro-3-hydroxy-
phenyl)-(5-(4-methoxy-3,5-dimethyl-phenyl)-thiophen-2-yl)-methanone (46) (400 mg, 1.07 
mmol) and boron tribromide (5.34 mmol, 5.0 equiv) according to method B. The product was 
purified by CC (dichloromethan/methanol 99.5:0.5); yield: 69% (266 mg). 
1
H NMR (500 MHz, 
acetone-d
6) δ 8.82 (br. s, 1H), 7.65 (br. s, 1H), 7.41 (d, J = 4.1 Hz, 1H), 7.30-7.28 (m, 3H), 7.06-
7.05 (m, 1H), 6.87 (td, J = 8.8, 1.8 Hz, 1H), 2.16 (s, 6H); 
13
C NMR (125 MHz, acetone-d
6) δ 
179.30, 155.99, 155.18, 151.66 (dd, J = 240.2, 5.9 Hz), 147.52 (dd, J = 245.3, 7.9 Hz), 141.69 
(dd, J = 13.1, 3.3 Hz), 140.66, 137.47, 126.63, 124.95, 124.42, 123.22, 119.14 (dd, J = 9.1, 3.8 
Hz), 117.57 – 117.07 (m), 111.42 (dd, J = 22.9, 3.9 Hz), 15.66; MS (ESI): 361.91 (M+H)+. 
(2,6-Difluoro-3-hydroxy-phenyl)-(5-(4-difluoromethoxy-3,5-difluoro-phenyl)-thiophen-2-
yl)-methanone (48). The title compound was prepared by reaction of (5-bromo-thiophen-2-yl)-
(2,6-difluoro-3-hydroxy-phenyl)-methanone (VIII) (460 mg, 1.44 mmol), 4-difluoromethoxy-
3,5-diflourophenylboronic acid (387 mg, 1.73 mmol), cesium carbonate (1877 mg, 5.77 mmol) 
and tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was 
purified by CC (DCM); yield: 84% (505 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.01 (s, 1H, 
OH), 7.75 (d, J = 4.1 Hz, 1H), 7.72 – 7.65 (m, 1H), 7.24 – 7.19 (m, 1H), 7.10 (t, J = 72.8 Hz, 
1H), 7.07 – 7.02 (m, 1H); 13C NMR (125 MHz, acetone-d6) δ 180.88, 157.04 (dd, J = 251.3, 4.6 
Hz), 152.56 (dd, J = 240.8, 5.7 Hz), 151.23 (t, J = 2.8 Hz), 148.43 (dd, J = 246.1, 7.6 Hz), 
144.71, 142.68 (dd, J = 12.9, 3.2 Hz), 138.02, 133.47 (t, J = 9.6 Hz), 128.01, 120.54 (dd, J = 9.1, 
3.9 Hz), 117.79 (dd, J = 23.6, 19.5 Hz), 117.36 (t, J = 264.6 Hz), 112.50 (dd, J = 22.7, 3.9 Hz), 
111.64 (d, J = 5.4 Hz), 111.49 (d, J = 5.4 Hz); MS (ESI): 419.72 (M+H)
+
. 
5-(5-(2,6-Difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-2-isopropoxy-benzonitrile (49). The 
title compound was prepared by reaction of (5-bromo-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-
phenyl)-methanone (VIII) (460 mg, 1.44 mmol), 3-cyano-4-isopropoxyphenylboronic acid (387 
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mg, 1.73 mmol), cesium carbonate (1877 mg, 5.77 mmol) and tetrakis(triphenylphosphine) 
palladium (5 µmol) according to method C1. The product was purified by CC 
(dichloromethan/methanol 99.5:0.5); yield: 52% (300 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 
8.99 (s, 1H, OH), 8.13 (d, J = 2.5 Hz, 1H), 8.03 (dd, J = 8.9, 2.4 Hz, 1H), 7.65 – 7.62 (m, 2H), 
7.36 (d, J = 9.1 Hz, 1H), 7.24 – 7.17 (m, 1H), 7.03 (td, J = 8.9, 1.9 Hz, 1H), 4.92 (sep, J = 6.0 
Hz, 1H), 1.41 (d, J = 6.0 Hz, 6H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.58, 161.32, 153.11, 
152.56 (dd, J = 240.7, 5.7 Hz), 148.42 (dd, J = 245.8, 7.9 Hz), 143.18, 142.64 (dd, J = 13.0, 3.1 
Hz), 138.32, 133.34, 132.42, 126.74, 126.07, 120.33 (dd, J = 9.0, 3.9 Hz), 118.04 (dd, J = 24.0, 
19.8 Hz), 116.29, 115.60, 112.43 (dd, J = 22.8, 3.8 Hz), 104.38, 73.09, 22.03; MS (ESI): 400.75 
(M+H)
+
. 
5-(5-(2,6-Difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-2-hydroxy-benzonitrile (50). The title 
compound was prepared by reaction of 5-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-2-
isopropoxy-benzonitrile (49) (220 mg, 0.55 mmol) and boron tribromide (2.75 mmol, 5.0 equiv) 
according to method B. The product was purified by CC (dichloromethan/methanol 99.25:0.75); 
yield: 59% (115 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.67 (br. s, 1H), 8.12 – 8.07 (m, 1H), 
7.93 (dd, J = 8.7, 2.4 Hz, 1H), 7.62 (d, J = 4.1 Hz, 1H), 7.60 (d, J = 4.1 Hz, 1H), 7.24 – 7.17 (m, 
2H), 7.03 (td, J = 8.9, 1.9 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.56, 161.47, 153.44, 
152.56 (dd, J = 240.4, 5.8 Hz), 148.42 (dd, J = 245.7, 7.8 Hz), 142.98, 142.63 (dd, J = 13.0, 3.2 
Hz), 138.33, 133.37, 132.07, 126.34, 125.82, 120.31 (dd, J = 9.1, 3.9 Hz), 118.08, 118.07 (d, J = 
43.7 Hz), 116.41, 112.42 (dd, J = 22.8, 3.9 Hz), 101.91; MS (ESI): 358.81 (M+H)
+
. 
(2,6-Difluoro-3-hydroxy-phenyl)-(5-(4-methoxy-3-(morpholine-4-sulfonyl)-phenyl)-
thiophen-2-yl)-methanone (51). The title compound was prepared by reaction of (5-bromo-
thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone (VIII) (460 mg, 1.44 mmol), 4-
methoxy-3-(morpholine-4-sulfonyl)-phenylboronic acid (521 mg, 1.73 mmol), cesium carbonate 
(1877 mg, 5.77 mmol) and tetrakis(triphenylphosphine) palladium (5 µmol) according to method 
C1. The product was purified by CC (dichloromethan/methanol 99.5:0.5); yield: 56% (400 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.01 (br. s, 1H), 8.18 (d, J = 2.4 Hz, 1H), 8.05 (dd, J = 8.7, 
2.5 Hz, 1H), 7.64 (dt, J = 4.1, 0.9 Hz, 1H), 7.60 (d, J = 4.1 Hz, 1H), 7.39 (d, J = 8.7 Hz, 1H), 
7.22-7.20 (m, 1H), 7.05-7.03 (m, 1H), 4.06 (s, 3H), 3.67 – 3.64 (m, 4H), 3.25 – 3.22 (m, 4H); 13C 
NMR (125 MHz, acetone-d
6) δ 180.52, 158.93, 153.70, 152.55 (dd, J = 240.5, 5.8 Hz), 148.42 
(dd, J = 245.7, 7.7 Hz), 143.06, 142.65 (dd, J = 12.9, 3.2 Hz), 138.33, 133.37, 129.86, 128.17, 
126.22, 125.93, 120.33 (dd, J = 9.1, 3.9 Hz), 118.07 (dd, J = 24.0, 19.6 Hz), 114.83, 112.43 (dd, 
J = 22.8, 3.9 Hz), 67.27, 56.86, 47.01; MS (ESI): 496.74 (M+H)
+
. 
(3-Ethoxy-2,6-difluoro-phenyl)-(5-pyridin-4-yl-thiophen-2-yl)-methanone (52a). The title 
compound was prepared by reaction of 5-bromo-thiophen-2-yl)-(3-ethoxy-2,6-difluoro-phenyl)-
methanone (V) (300 mg, 0.86 mmol), pyridine-4-boronic acid pinacol ester (355 mg, 1.73 
mmol), sodium carbonate (2.5 mL, 2 M) and tetrakis(triphenylphosphine) palladium (5 µmol) 
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according to method C2. The product was purified by CC (dichloromethan/methanol 99.5:0.5); 
yield: 91% (450 mg). The product was used in the next step without any characterization. 
(2,6-Difluoro-3-hydroxy-phenyl)-(5-pyridin-4-yl-thiophen-2-yl)-methanone (52). The title 
compound was prepared by reaction of (3-Ethoxy-2,6-difluoro-phenyl)-(5-pyridin-4-yl-thiophen-
2-yl)-methanone (52a) (450 mg, 1.30 mmol) and boron tribromide (7.8 mmol, 6.0 equiv) 
according to method B. The product was purified by CC (dichloromethan/methanol 9:1); yield: 
24% (100 mg). 
1
H NMR (500 MHz, DMSO-d
6) δ 10.40 (br. s, 1H), 8.64 (d, J = 6.1 Hz, 2H), 
7.91 (d, J = 4.1 Hz, 1H), 7.77 (dd, J = 4.6, 1.5 Hz, 2H), 7.69 (d, J = 4.0 Hz, 1H), 7.16 (td, J = 
9.4, 5.6 Hz, 1H), 7.08 (t, J = 8.6 Hz, 1H); 
13C NMR (125 MHz, DMSO) δ 180.32, 150.66, 
150.49, 150.46 (dd, J = 239.7, 5.6 Hz), 146.88 (dd, J = 246.7, 7.5 Hz), 143.06, 141.92 (dd, J = 
11.8, 2.9 Hz), 139.04, 137.82, 128.13, 120.19, 119.81 (dd, J = 8.9, 3.9 Hz), 116.22 (dd, J = 23.4, 
19.0 Hz), 111.75 (dd, J = 22.3, 3.5 Hz); MS (ESI): 318.94 (M+H)
+
. 
(3-Ethoxy-2,6-difluoro-phenyl)-(5-pyridin-3-yl-thiophen-2-yl)-methanone (53a). The title 
compound was prepared by reaction of 5-bromo-thiophen-2-yl)-(3-ethoxy-2,6-difluoro-phenyl)-
methanone (V) (400 mg, 1.15 mmol), pyridine-3-boronic acid (170 mg, 1.38 mmol), sodium 
carbonate (2.5 mL, 2 M) and tetrakis(triphenylphosphine) palladium (5 µmol) according to 
method C2. The product was purified by CC (dichloromethan/methanol 99.5:0.5); yield: 50% 
(200 mg). 
1
H NMR (300 MHz, acetone-d
6) δ 8.90 (d, J = 2.2 Hz, 1H), 8.50 (dd, J = 4.8, 1.4 Hz, 
1H), 8.04 (ddd, J = 8.0, 2.3, 1.7 Hz, 1H), 7.59 (d, J = 4.1 Hz, 1H), 7.55 (dd, J = 4.0, 0.7 Hz, 1H), 
7.37 (ddd, J = 8.0, 4.8, 0.6 Hz, 1H), 7.22 (td, J = 9.3, 5.3 Hz, 1H), 6.99 (td, J = 8.9, 2.0 Hz, 1H), 
4.06 (q, J = 7.0 Hz, 2H), 1.28 (t, J = 7.0 Hz, 3H); 
13
C NMR (75 MHz, acetone-d
6
) δ 179.71, 
152.23 (dd, J = 241.8, 5.9 Hz), 150.81, 148.70 (dd, J = 241.8, 5.9 Hz), 147.16, 143.95 (dd, J = 
10.6, 3.3 Hz), 143.20, 137.35, 133.48, 128.92, 126.24, 124.03, 117.40 (dd, J = 22.9, 3.2 Hz), 
116.88 (dd, J = 9.3, 3.1 Hz), 111.22 (dd, J = 22.6, 4.2 Hz), 65.44, 14.10; MS (ESI): 347.05 
(M+H)
+
. 
(2,6-Difluoro-3-hydroxy-phenyl)-(5-pyridin-3-yl-thiophen-2-yl)-methanone (53). The title 
compound was prepared by reaction of (3-ethoxy-2,6-difluoro-phenyl)-(5-pyridin-3-yl-thiophen-
2-yl)-methanone (53a) (200 mg, 0.58 mmol) and boron tribromide (3.47 mmol, 6.0 equiv) 
according to method B. The product was purified by CC (dichloromethan/methanol 9:1); yield: 
17% (31 mg). 
1
H NMR (500 MHz, DMSO-d
6
) δ 10.28 (s, 1H, OH), 9.06 (s, 1H), 8.64 (d, J = 4.2 
Hz, 1H), 8.23 (ddd, J = 8.0, 2.4, 1.5 Hz, 1H), 7.81 (d, J = 4.1 Hz, 1H), 7.71 (d, J = 4.1 Hz, 1H), 
7.53 (dd, J = 8.0, 4.8 Hz, 1H), 7.16 (td, J = 9.4, 5.7 Hz, 1H), 7.10 (td, J = 8.9, 1.4 Hz, 1H); 
13
C 
NMR (125 MHz, DMSO) δ 180.06, 150.52 (dd, J = 239.6, 5.7 Hz), 150.43, 150.25, 146.90 (dd, J 
= 246.5, 7.6 Hz), 146.86, 142.30, 141.88 (dd, J = 11.9, 3.0 Hz), 137.98, 133.83, 128.41, 126.98, 
124.25, 119.60 (dd, J = 9.1, 4.0 Hz), 116.43 (dd, J = 23.5, 19.4 Hz), 111.71 (dd, J = 22.4, 3.6 
Hz); MS (ESI): 318.92 (M+H)
+
. 
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(5-(3,5-Dichloro-4-methoxy-phenyl)-thiophen-2-yl)-(3-hydroxy-phenyl)-methanone (54). 
The title compound was prepared by reaction of (5-bromothiophen-2-yl)(3-
hydroxyphenyl)methanone (VII) (1000 mg, 3.53 mmol), 3,5-dichloro-4-methoxyphenylboronic 
acid (936 mg, 4.23 mmol), cesium carbonate (4603 mg, 14.13 mmol) and 
tetrakis(triphenylphosphine) palladium (5 µmol) according to method C1. The product was 
purified by CC (petroleum ether/ethyl acetate 80:20) followed by washing with petroleum ether; 
yield: 67% (900 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 8.77 (s, 1H), 7.83 (s, 2H), 7.72 (d, J = 
4.0 Hz, 1H), 7.68 (d, J = 4.0 Hz, 1H), 7.43 – 7.39 (m, 1H), 7.37 (dt, J = 7.6, 1.4 Hz, 1H), 7.34 
(ddd, J = 2.5, 1.5, 0.4 Hz, 1H), 7.14 (ddd, J = 7.8, 2.6, 1.4 Hz, 1H), 3.94 (s, 3H); 
13
C NMR (125 
MHz, acetone-d
6) δ 187.64, 158.45, 153.53, 149.33, 144.32, 140.01, 136.70, 131.99, 130.78, 
130.65, 127.46, 126.78, 121.16, 120.43, 116.32, 61.30; MS (ESI): 380.84 (M+H)
+
. 
(5-(3,5-Dichloro-4-hydroxy-phenyl)-thiophen-2-yl)-(3-hydroxy-phenyl)-methanone (55). 
The title compound was prepared by reaction of ((5-(3,5-dichloro-4-methoxy-phenyl)-thiophen-
2-yl)-(3-hydroxy-phenyl)-methanone (54) (720 mg, 1.90 mmol) and boron tribromide (9.49 
mmol, 5.0 equiv) according to method B. The product was purified by CC 
(dichloromethan/methanol 90.5:0.5); yield: 20% (140 mg). 
1
H NMR (500 MHz, acetone-d
6
)  δ 
8.00 (s, 2H), 7.77 (s, 94H), 7.69 (d, J = 4.0 Hz, 51H), 7.59 (d, J = 4.0 Hz, 50H), 7.41 – 7.37 (m, 
54H), 7.35 (dt, J = 7.6, 1.3 Hz, 53H), 7.33 – 7.31 (m, 49H), 7.12 (ddd, J = 7.9, 2.6, 1.3 Hz, 
50H).
13
C NMR (125 MHz, acetone-d
6) δ 187.70, 158.38, 150.71, 150.33, 143.37, 140.14, 
136.86, 130.60, 127.53, 127.07, 125.69, 123.54, 121.06, 120.24, 116.19; MS (ESI): 366.61 
(M+H)
+
. 
2-(3-Bromomethyl-5-chloro-4-methoxy-phenyl)-4,4,5,5-tetramethyl-(1,3,2)dioxaborolane 
(56b). 2-(3-chloro-4-methoxy-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (44a) 
(200 mg, 0,71 mmol, 1,00 equiv) and N-bromosuccinimide (113 mg, 0,63 mmol, 0,90 equiv)  
were dissolved under N2 in 17 ml CCl4, followed by a catalytic amount of dibenzoyl peroxide. 
The mixture was stirred under reflux for 1h. The reaction was quenched with water and extracted 
three times with dichloromethane. The combined organic layers were washed two times with 
water, one time with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude product was purified by CC (hexane/ethyl acetate 85:15); yield: 70% (180 mg). 
1
H 
NMR (500 MHz, acetone-d
6
) δ 7.75 (d, J= 1.5 Hz, 1H), 7.68 (d, J= 1.5 Hz, 1H), 4.71 (s, 2H), 
4.00 (s, 3H), 1.33-1.35 (m, 12H). 
1-(4-(3-Chloro-2-methoxy-5-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-benzyl)-
piperazin-1-yl)-ethanone (56a). 2-(3-(bromomethyl)-5-chloro-4-methoxyphenyl)-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane (56b) (180 mg, 0,50 mmo, 1,00 equiv) was dissolved under N2 
in 1 ml dry THF and 1-acetylpiperazine was added. The mixture was stirred for 1 h under reflux. 
The reaction was quenched with water and extracted three times with ethyl acetate. The 
combined organic layers were washed two times with water, one time with brine, dried over 
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MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by CC 
(ethyl acetate /ethanol 8:2), to give the desired product as yellow solid; yield: 70% (198 mg). 
1
H 
NMR (500 MHz, acetone-d
6) δ 7.69 (d, J=1.5 Hz, 1H), 7.65 (d, J=1.5 Hz, 1H), 3.90 (s, 3H), 3.57 
(s, 3H), 2.77 (t, J= 5.2 Hz, 2H), 2.70 (t, J= 5.2 Hz, 2H), 2.47 (t, J= 5.2 Hz, 2H), 2.42 (t, J= 5.2 
Hz, 2H), 2.00 (s, 3H), 1.34 (s, 12H). 
1-(4-(3-Chloro-5-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-2-methoxy-benzyl)-
piperazin-1-yl)-ethanone (56). The title compound was prepared by reaction of 1-(4-(3-chloro-
2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)ethanone (56a) 
(100 mg, 0,24 mmol, 1,00 equiv), (5-bromothiophen-2-yl)(2,6-difluoro-3-hydroxyphenyl)-
methanone (VIII) (77 mg, 0,24 mmol, 1,00 equiv), cesium carbonate (156 mg, 0.48 mmol) and 
tetrakis(triphenylphosphine) palladium (1 mg, 0,001 mmol, 0,005 equiv) according to method 
C1. The product was purified by CC (ethyl acetate/ethanol 8:2); yield: 98% (55 mg). 
1
H NMR 
(500 MHz, DMSO-d
6)  δ 9.53 (br. s., 1H), 8.28-8.26 (m, 2H), 8.10-8.03 (m, 2H), 7.66 (td, J= 9.4, 
5.3Hz, 1H), 7.48 (td, J= 8.9, 2.0 Hz, 1H), 4.38 (s, 3H), 4.10 (s, 2H), 4.03-3.94 (m, 4H), 2.99 (t, 
J= 5.0 Hz, 2H), 2.93 (t, J= 5.0 Hz, 2H), 2.46 (s, 3H).
13
C NMR (125 MHz, DMSO-d
6) δ 180.7, 
169.0, 156.7, 153.5, 151.6, 149.4, 147.4, 143.5, 142.7, 138.2, 135.8, 130.6, 129.6, 128.3, 127.7, 
126.5, 120.4, 118.0, 112.5, 112.3, 61.8, 57.1, 54.0, 53.7, 46.9, 42.0, 21.3; MS (ESI): 521.41 
(M+H)
+
. 
1-(4-(3-Chloro-5-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-2-hydroxy-benzyl)-
piperazin-1-yl)-ethanone (57). The title compound was prepared by reaction of 1-(4-(3-Chloro-
5-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-2-methoxy-benzyl)-piperazin-1-yl)-
ethanone (56) (150 mg, 0.29 mmol) and boron tribromide (0.87 mmol, 3.0 equiv) according to 
method B. The product was purified by using preparative TLC (dichloromethan/methanol 95:5); 
yield: 12% (16 mg). 
1
H NMR (500 MHz, acetone-d
6)  δ 7.86-7.80 (m, 1H), 7.75 (d, J= 2.2 Hz, 
1H), 7.65-7.56 (m, 1H), 7.54-7.49 (m, 1H), 7.24-7.18 (m, 1H), 7.06-6.99 (m, 1H), 3.70-3.60 (m, 
4H), 2.71-2.52 (m, 4H), 2.05 (s, 3H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.7, 169.9, 156.0, 
154.6, 153.5, 153.5, 151.6, 149.5, 147.5, 142.8, 142.5, 138.4, 127.7, 126.7, 125.8, 125.3, 124.9, 
122.1, 120.2, 118.2, 112.5, 112.4, 61.1, 53.5, 52.9, 46.6, 41.8, 21.3 ; MS (ESI): 506.89 (M+H)
+
. 
(5-(3-Chloro-4-methoxy-5-piperazin-1-ylmethyl-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-
hydroxy-phenyl)-methanone (58). 1-(4-(3-chloro-5-(5-(2,6-difluoro-3-hydroxybenzoyl)-
thiophen-2-yl)-2-methoxybenzyl)piperazin-1-yl)ethanone (56) (150 mg, 0.29 mmol, 1.00 equiv) 
was dissolved in 20 ml 3M aqueous HCl and heated to 80 °C for 3 h. The reaction was washed 
two times with ethyl acetate, the aqueous layer was basified to pH 10 with 2 M NaOH and 
washed two times with ethyl acetate. The aqueous layer was neutralized with 2M HCl and 
extracted three times with ethyl acetate. The combined organic layers were washed one time with 
water, one time with brine, dried over MgSO4, filtered and concentrated under reduced pressure 
to give the desired pure product in 40% yield as pale yellow solid. 
1
H NMR (500 MHz, acetone-
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d
6
) δ 7.83-7.79 (m, 2H), 7.67-7.60 (m, 2H), 7.19 (m, 1H), 7.00 (td, J= 9.0, 1.9 Hz, 1H), 3.92 (s, 
3H), 3.59 (s, 2H), 2.89-2.81 (m, 4H), 2.53-2.45 (m, 4H); 
13
C NMR (125 MHz, acetone-d
6) δ 
180.8, 156.8, 153.3, 151.5, 149.4, 147.5, 143.6, 142.9, 142.7, 138.2, 135.4, 130.7, 129.6, 128.4, 
127.9, 126.7, 120.5, 118.1, 112.3, 112.2, 62.0, 56.9, 50.4, 44.3; MS (ESI): 479.22 (M+H)
+
. 
2-(3-Azidomethyl-5-chloro-4-methoxy-phenyl)-4,4,5,5-tetramethyl-(1,3,2)dioxaborolane 
(59c). 2-(3-(bromomethyl)-5-chloro-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
(56b) (800 mg, 2.19 mmol, 1.00 equiv) was dissolved under N2 in 8 ml dry DMF and sodium 
azide (143 mg, 2.19 mmol, 1.00 equiv) was added. The mixture was stirred at room temperature 
overnight. The mixture was quenched with water and extracted three times with ethyl acetate. 
The combined organic layers were washed two times with water, one time with brine, dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by CC 
(hexane /ethyl acetate 8:2); yield: 71% (503 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 7.72 (d, J= 
1.6 Hz, 1H), 7.69 (d, J= 1.6 Hz, 1H), 4.55 (s, 2H), 3.93 (s, 3H), 1.34 (s, 12H) 
(5-(3-Azidomethyl-5-chloro-4-methoxy-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-
phenyl)-methanone (59b). The title compound was prepared by reaction of 2-(3-Azidomethyl-
5-chloro-4-methoxy-phenyl)-4,4,5,5-tetramethyl-(1,3,2)dioxaborolane (59c) (683 mg, 2.16 
mmol, 1.00 equiv), (5-bromothiophen-2-yl)(2,6-difluoro-3-hydroxyphenyl)methanone (VIII) 
(700 mg, 2.16 mmol, 1.00 equiv), cesium carbonate (2000 mg, 6.44 mmol, 3 equiv) and 
tetrakis(triphenylphosphine) palladium (13 mg, 0.01 mmol, 0.005 equiv) according to method 
C1. The product was used in the next step without further purification and without any 
characterization; yield: 84% (785 mg). 
Acetic acid 3-(5-(3-chloro-4-methoxy-5-(1,2,3)triazol-1-ylmethyl-phenyl)-thiophene-2-
carbonyl)-2,4-difluoro-phenylester(59a). (5-(3-(azidomethyl)-5-chloro-4-methoxyphenyl)-
thiophen-2-yl)(2,6-difluoro-3-hydroxyphenyl)methanone (59b) (50 mg, 0.11 mmol, 1.00 equiv), 
was dissolved in 106 µl vinyl acetate and the reaction was heated at 120°C under microwave for 
10 h. The reaction was concentrated under reduced pressure and purified by CC using ethyl 
acetate as eluent; yield: 27% (15 mg). 
1
H NMR (500 MHz, DMSO-d
6
) δ 8.11 (d, J= 0.9 Hz, 1H), 
7.92 (d, J= 2.5 Hz, 1H), 7.70 (d, J= 0.9 Hz, 1H), 7.68-7.66 (m, 1H), 7.64-7.61 (m, 2H), 7.53 (td, 
J= 8.9, 5.5 Hz, 1H), 7.26 (td, J= 8.8, 1.9 Hz, 1H), 5.78 (s, 2H), 3.89 (s, 3H), 2.34 (s, 3H); MS 
(ESI): 504.12 (M+H)
+
. 
(5-(3-Chloro-4-methoxy-5-(1,2,3)triazol-1-ylmethyl-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-
hydroxy-phenyl)-methanone (59). Acetic acid 3-(5-(3-chloro-4-methoxy-5-(1,2,3)triazol-1-
ylmethyl-phenyl)-thiophene-2-carbonyl)-2,4-difluoro-phenylester (59a) (110 mg, 0.24 mmol, 
1.00 equiv) was dissolved under N2 in a degased mixture of 5 ml THF and 600 µl of 2M NaOH. 
The mixture was stirred for 2 h at room temperature. The reaction was acidified to pH 6 with 1 
M HCl and extracted three times with ethyl acetate. The combined organic layers were washed 
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two times with water, one time with brine, dried over MgSO4, filtered and concentrated under 
reduced pressure to give the desired product; yield: 95% (90 mg). 
1
H NMR (500 MHz, acetone-
d
6) δ 9.05 (br. s, 1H), 8.11 (d, J= 0.9 Hz, 1H), 7.91 (d, J= 2.2 Hz, 1H), 7.70 (d, J= 0.9 Hz, 1H), 
7.67 (d, J= 2.2 Hz, 1H), 7.65-7.62 (m, 1H), 7.61-7.58 (m, 1H), 7.21 (td, J= 8.9, 5.5Hz, 1H), 7.03 
(td, J= 8.8, 1.9 Hz, 1H), 5.78 (s, 2H), 3.89 (s, 3H); MS (ESI): 462.15 (M+H)
+
. 
(5-(3-Chloro-4-hydroxy-5-(1,2,3)triazol-1-ylmethyl-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-
hydroxy-phenyl)-methanone (60). The title compound was prepared by reaction of (5-(3-
Chloro-4-methoxy-5-(1,2,3)triazol-1-ylmethyl-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-
phenyl)-methanone (59) (80 mg, 0.16 mmol) and boron tribromide (800 µl, 0.80 mmol, 5.0 
equiv) according to method B. The product was purified by CC (ethyl acetate/ethanol 9:1); yield: 
32% (23 mg). 
1
H NMR (500 MHz, acetone-d
6)  δ  8.74 (d, J= 1.3 Hz, 1H), 8.43 (s, 1H), 8.03-
7.90 (m, 2H), 7.68-7.54 (m, 2H), 7.30 (td, J= 8.8, 5.5 Hz, 1H), 7.01 (td, J= 8.8, 1.9 Hz, 1H), 6.05 
(s, 2H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.7, 153.3, 143.2, 138.3, 130.7, 129.3, 129.2, 
128.8, 127.3, 126.1, 124.6, 123.0, 120.3, 112.4, 52.0; MS (ESI): 448.12 (M+H)
+
. 
(5-(3-Aminophenyl)thiophen-2-yl)(3-ethoxy-2,6-difluorophenyl)methanone (61a). The title 
compound was prepared by reaction of (5-bromothiophen-2-yl)(3-ethoxy-2,6-
difluorophenyl)methanone (V) (450 mg, 1.30 mmol) and 3-aminophenylboronic acid (213 mg, 
1.55 mmol), cesium carbonate (1689 mg, 5.18 mmol) and tetrakis(triphenylphosphine) palladium 
(20 mg, 16 µmol) according to method C1. The product was used directly in the subsequent 
reaction without any characterization; yield: 88% (410 mg). 
(5-(3-Aminophenyl)thiophen-2-yl)(2,6-difluoro-3-hydroxyphenyl)methanone  (61). The title 
compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-yl)-(3-ethoxy-2,6-
difluorophenyl)methanone (61a) (440 mg, 1.22 mmol) and boron tribromide (3.7 mmol) 
according to method B. The product was purified by CC (dichloromethan/methanol 99.5:0.5); 
yield: 50% (200 mg). 
1
H NMR (500 MHz, acetone-d
6
) δ 9.02 (br. s, 1H), 7.45 (dd, J = 7.1, 2.9 
Hz, 1H), 7.33 (d, J = 4.1 Hz, 1H), 7.10 (dd, J = 41.1, 6.5 Hz, 2H), 7.00 – 6.85 (m, 3H), 6.62 
(ddd, J = 8.0, 2.1, 0.8 Hz, 1H), 4.75 (br., 2H, NH2); 
13
C NMR (125 MHz, acetone-d
6) δ 179.48, 
155.98, 152.23 (dd, J = 241.6, 6.1 Hz), 149.34, 148.66 (dd, J = 249.5, 7.7 Hz), 143.90 (dd, J = 
10.7, 3.2 Hz), 137.34, 133.47, 129.97, 125.13, 124.46, 121.00, 116.62 (dd, J = 9.3, 3.0 Hz), 
115.73, 114.65, 111.62, 111.13 (dd, J = 22.7, 4.1 Hz); MS (ESI): 332.12 (M+H)
+
. 
4-Bromo-N-(3-(5-(3-ethoxy-2,6-difluorobenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethoxy-
benzenesulfonamide (62a). The title compound was prepared by reaction of (5-(3-
aminophenyl)thiophen-2-yl)(3-ethoxy-2,6-difluorophenyl)methanone (61a) (210 mg, 0.58 mmol) 
and 4-bromo-2-trifluoromethoxybenzenesulfonyl chloride (198 mg, 0.58 mmol) according to 
method D. The product was sufficiently pure for use in the subsequent reaction; yield: 65% (250 
mg). The product was used in the next step without any characterization. 
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4-Bromo-N-(3-(5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl)-phenyl)-2-trifluoro-
methoxybenzenesulfonamide  (62). The title compound was prepared by reaction of 4-bromo-
N-(3-(5-(3-ethoxy-2,6-difluorobenzoyl-thiophen-2-yl)phenyl)-2-trifluoromethoxybenzene-
sulfonamide (62a) (250 mg, 0.38 mmol) and boron tribromide (2.3 mmol) according to method 
B. The product was purified by CC (dichloromethan/methanol 99.5:0.5); yield: 75% (180 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.35 (br. s, 1H), 8.58 (br. s, 1H), 8.03 (d, J = 8.5 Hz, 1H), 
7.76 (dd, J = 8.5, 1.8 Hz, 1H), 7.74-7.72 (m, 1H), 7.68 – 7.65 (m, 1H), 7.62 (dt, J = 4.1, 0.9 Hz, 
1H), 7.54 (ddd, J = 7.7, 1.8, 1.0 Hz, 1H), 7.52 (d, J = 4.1 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.32 
(ddd, J = 8.1, 2.2, 1.0 Hz, 1H), 7.23-7.21 (m, 1H), 7.03 (ddd, J = 9.1, 8.6, 1.9 Hz, 1H); 
13
C NMR 
(125 MHz, acetone-d
6
) δ 180.68, 154.32, 152.55 (dd, J = 240.6, 5.8 Hz), 148.43 (dd, J = 245.8, 
7.7 Hz), 146.95 (d, J = 1.8 Hz), 143.55, 142.66 (dd, J = 13.0, 3.2 Hz), 138.85, 138.17, 134.88, 
133.83, 131.81, 131.47, 131.34, 129.12, 126.34, 124.92 (d, J = 1.9 Hz), 123.59, 122.15, 120.39 
(dd, J = 9.1, 3.8 Hz), 120.08, 118.80, 118.01 (dd, J = 24.0, 19.7 Hz), 112.44 (dd, J = 22.8, 3.9 
Hz); MS (ESI): 635.43 (M+H)
+
. 
N-(3-(5-(3-Ethoxy-2,6-difluorobenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethoxybenzene-
sulfonamide (63a). The title compound was prepared by reaction of (5-(3-aminophenyl)-
thiophen-2-yl)(3-ethoxy-2,6-difluorophenyl)methanone (61a) (210 mg, 0.58 mmol) and 2-
trifluoromethoxybenzenesulfonyl chloride (152 mg, 0.58 mmol) according to method D. The 
product was sufficiently pure for use in the subsequent reaction; yield: 66% (225 mg). The 
product was used in the next step without any characterization. 
N-(3-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethoxybenzen-
esulfonamide  (63). The title compound was prepared by reaction of N-(3-(5-(3-ethoxy-2,6-
difluorobenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethoxybenzene-sulfonamide (63a) (225 mg, 
0.39 mmol) and boron tribromide (2.3 mmol) according to method B. The product was purified 
by CC (dichloromethan/methanol 99.5:0.5); yield: 44% (142 mg). 
1
H NMR (500 MHz, acetone-
d
6) δ 9.50 (br. s, 1H), 9.04 (br. s, 1H), 8.14 – 8.09 (m, 1H), 7.77 (ddd, J = 8.4, 7.5, 1.7 Hz, 1H), 
7.68 – 7.65 (m, 1H), 7.62 (dt, J = 4.0, 0.8 Hz, 1H), 7.57 – 7.51 (m, 3H), 7.51 – 7.50 (m, 1H), 
7.38 (tt, J = 4.6, 2.3 Hz, 1H), 7.34 – 7.30 (m, 1H), 7.25 – 7.17 (m, 1H), 7.03 (ddd, J = 10.5, 6.9, 
1.9 Hz, 1H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.69, 154.44, 152.55 (dd, J = 240.6, 5.8 Hz), 
148.43 (dd, J = 245.9, 7.8 Hz), 146.82 (d, J = 1.7 Hz), 143.48, 142.66 (dd, J = 12.9, 3.2 Hz), 
139.17, 138.18, 136.37, 134.77, 132.58, 132.25, 131.25, 128.02, 126.26, 123.28, 124.49 – 120.18 
(m), 121.95, 121.53 (d, J = 1.8 Hz), 120.39 (dd, J = 9.1, 3.8 Hz), 118.50, 118.02 (dd, J = 23.9, 
19.7 Hz), 112.45 (dd, J = 22.8, 3.9 Hz); MS (ESI): 556.17 (M+H)
+
. 
N-(3-(5-(3-Ethoxy-2,6-difluorobenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethylbenzene-
sulfonamide (64a). The title compound was prepared by reaction of (5-(3-aminophenyl)-
thiophen-2-yl)(3-ethoxy-2,6-difluorophenyl)methanone (61a) (210 mg, 0.58 mmol) and 2-
trifluoromethylbenzenesulfonyl chloride (143 mg, 0.58 mmol) according to method D. The 
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product was sufficiently pure for use in the subsequent reaction; yield: 68% (225 mg). The 
product was used in the next step without any characterization. 
N-(3-(5-(2,6-Difluoro-3-hydroxybenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethylbenzene-
sulfonamide (64). The title compound was prepared by reaction of N-(3-(5-(3-ethoxy-2,6-
difluorobenzoyl)thiophen-2-yl)phenyl)-2-trifluoromethylbenzenesulfonamide (64a) (230 mg, 
0.41 mmol) and boron tribromide (2.4 mmol) according to method B. The product was purified 
by CC (dichloromethan/methanol 99.5:0.5); yield: 48% (165 mg). 
1
H NMR (500 MHz, acetone-
d
6) δ 9.39 (br. s, 1H), 9.00 (br. s, 1H), 8.30 – 8.25 (m, 1H), 8.03 – 7.98 (m, 1H), 7.87 – 7.82 (m, 
2H), 7.68 – 7.65 (m, 1H), 7.62 (dt, J = 4.1, 0.9 Hz, 1H), 7.55 – 7.51 (m, 2H), 7.42 – 7.37 (m, 
1H), 7.32 (ddd, J = 8.1, 2.2, 1.0 Hz, 1H), 7.23-7.21 (m, 1H), 7.06 – 7.00 (m, 1H); 13C NMR (125 
MHz, acetone-d
6) δ 180.69, 152.54 (dd, J = 240.6, 5.8 Hz), 148.42 (dd, J = 245.8, 7.8 Hz), 
143.51, 142.66 (dd, J = 12.9, 3.2 Hz), 139.14, 139.11, 138.17, 134.83, 134.47, 133.86, 132.78, 
131.32, 129.56 (q, J = 6.4 Hz), 128.41, 128.15, 126.32, 125.06, 123.37, 122.88, 122.14, 120.39 
(dd, J = 9.1, 3.8 Hz), 118.73, 118.02 (dd, J = 24.0, 19.6 Hz); MS (ESI): 540.32 (M+H)
+
. 
Pyridine-3-sulfonic acid (3-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-phenyl)-
amide (65). The title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-
yl)(2,6-difluoro-3-hydroxyphenyl)methanone  (61) (100 mg, 0.30 mmol) and pyridine-3-sulfonyl 
chloride hydrochloride (96 mg, 0.45 mmol) according to method D. The product was purified by 
CC (dichloromethan/methanol 95:5); yield: 35% (50 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 
8.28 (dd, J = 2.4, 0.8 Hz, 1H), 8.10 (dd, J= 4.7, 1.6 Hz, 1H), 7.52-7.49 (m, 1H), 6.96-6.94 (m, 
1H), 6.94-6.91 (m, 1H), 6.88 (d, J= 4.1 Hz, 1H), 6.83 (d, J= 7.6 Hz, 1H), 6.82-6.80 (m, 1H), 6.71 
(t, J= 7.9 Hz, 1H), 6.55-6.47 (m, 2H), 6.41 (td, J= 9.0, 1.6 Hz, 1H); 
13
C NMR (125 MHz, 
acetone-d
6) δ 180.8, 154.6, 154.4, 148.7, 143.6, 139.3, 138.3, 137.0, 135.9, 135.0, 131.5, 126.5, 
125.1, 123.8, 122.8, 120.4, 119.4, 112.6, 112.4; MS (ESI): 473.28 (M+H)
+
. 
1-Methyl-1H-imidazole-4-sulfonic acid (3-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-
yl)-phenyl)-amide (66). The title compound was prepared by reaction of (5-(3-
aminophenyl)thiophen-2-yl)(2,6-difluoro-3-hydroxyphenyl)methanone  (61) (100 mg, 0.30 
mmol) and 1-methyl-1H-imidazole-4-sulfonyl chloride (81 mg, 0.45 mmol) according to method 
D. The product was purified by CC (dichloromethan/methanol 95:5); yield: 72% (103 mg). 
1
H 
NMR (500 MHz, acetone-d
6) δ 9.17 (s, 1H), 9.01 (s, 1H), 7.75-7.72 (m, 2H), 7.64-7.61 (m, 2H), 
7.54 (d, J= 4.1 Hz, 1H), 7.50-7.43 (m, 1H), 7.39-7.34 (m, 2H), 7.21 (td, J= 9.4, 5.5 Hz, 1H), 7.04 
(td, J= 8.8, 1.9Hz, 1H), 3.76 (s, 3H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.7, 155.1, 153.6, 
151.6, 149.5, 147.5, 143.3, 142.7, 140.7, 140.1, 138.3, 134.5, 130.9, 126.2, 122.5, 121.9, 120.4, 
118.4, 112.6, 112.4, 34.2; MS (ESI): 476.21 (M+H)
+
. 
Cyclopropanesulfonic acid (3-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-phenyl)-
amide (67). The title compound was prepared by reaction of (5-(3-aminophenyl)thiophen-2-
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yl)(2,6-difluoro-3-hydroxyphenyl)methanone  (61) (100 mg, 0.30 mmol) and 
cyclopropanesulfonyl chloride (1M in DCM) (63 mg, 0.45 mmol) according to method D. The 
product was purified by CC (dichloromethan/methanol 95:5); yield: 56% (73 mg). 
1
H NMR (500 
MHz, acetone-d
6) δ 9.01 (s, 1H), 8.77 (s, 1H), 7.80-7.78 (m, 1H), 7.65 (dt, J= 4.1, 0.9 Hz, 1H), 
7.61-7.58 (m, 2H), 7.54-7.44 (m, 2H), 7.21 (td, J= 9.5, 5.4 Hz, 1H), 7.04 (td, J= 9.0, 1.9 Hz, 1H), 
2.73-2.67 (m, 1H), 1.07-0.96 (m, 4H); 
13
C NMR (125 MHz, acetone-d
6) δ 188.7, 154.8, 143.5, 
140.6, 138.3 134.9, 131.3, 126.3, 123.1, 122.6, 120.4, 119.2, 112.6, 112.4, 32.4, 5.8; MS (ESI): 
436.25 (M+H)
+
. 
Cyclopropanesulfonic acid (3-bromo-5-methyl-phenyl)-amide (68b). The title compound was 
prepared by reaction of 3-bromo-5-methylaniline (1000 mg, 5.38 mmol, 1 equiv) and 
cyclopropanesulfonyl chloride (1013 mg, 8.07 mmol, 1.5 equiv) according to method D. The 
product was purified by CC (hexane/ethyl acetate 8:2); yield: 77% (1200 mg). 
1
H NMR (500 
MHz, acetone-d
6) δ 8.62 (br. s, 1H), 7.35 (s, 1H), 7.15 (s, 1H), 7.13 (s, 1H), 2.65-2.61 (m, 1H), 
2.30 (s, 3H), 1.00-0.95 (m, 4H). 
Cyclopropanesulfonic acid (3-methyl-5-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-
phenyl)-amide (68a). Cyclopropanesulfonic acid (3-bromo-5-methyl-phenyl)-amide (68b) (800 
mg, 2.76 mmol, 1 equiv) was dissolved in 10mL dry dimethyl sulfoxide under N2 atmosphere. 
Bispinakolatodiborone (1050 mg, 4.14 mmol, 1.5 equiv), potassium acetate (8.28 mmol, 3 equiv) 
and Pd(dppf)Cl2 (0.14 mmol, 0.05 equiv) were added. The reaction mixture was heated to 80°C 
over night. Reaction mixture was cooled down to room temperature, quenched with water and 
diethyl ether, filtered over celite, extracted three times with diethyl ether, washed three times 
with water, washed with brine, dried over magnesium sulphate, filtered and evaporated under 
reduced pressure. Purified by CC (dichloromethane pure to dichloromethane/methanol 8:2); 
yield: 16% (150 mg). The product was used in the next step without any characterization. 
Cyclopropanesulfonic acid (3-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-5-methyl-
phenyl)-amide (68). cyclopropanesulfonic acid (3-methyl-5-(4,4,5,5-tetramethyl-(1,3,2)-
dioxaborolan-2-yl)-phenyl)-amide (68a) (150 mg, 0.45mmol, 1.20equiv), (5-bromo-2-
thienyl)(2,4-difluoro-3-hydroxyphenyl)-methanone VIII (118 mg, 0.37mmol, 1.00equiv), 
ceasium carbonate (263 mg, 1.11mmol, 3.00equiv) and Pd(PPh3)4 (0.002mmol, 0.005equiv) 
were suspended in a degased mixture of 5mL DME and 5mL water. The mixture was heated to 
reflux for 3 days under N2 atmosphere. The mixture was cooled down to room temperature, 
quenched with water, filtered over celite, extracted three times with ethyl acetate, washed one 
time with water, one time with brine, dried over sodium sulphate, filtered and evaporated under 
reduced pressure. The product was purified by MPLC (0% ethyl acetate to 100% ethyl acetate) 
followed by preparative TLC (hexane/ethyl acetate 5:5); yield: 18% (30 mg). 
1
H NMR (500 
MHz, acetone-d
6) δ 8.98 (s, 1H), 8.68 (s, 1H), 7.61 (d, J= 4.0 Hz, 1H), 7.57 (s, 1H), 7.55 (d, J= 
4.0 Hz, 1H), 7.41 (s, 1H), 7.26 (s, 1H), 7.21-7.15 (m, 1H), 7.01 (td, J= 8.8, 1.8 Hz, 1H), 2.70-
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2.65 (m, 1H), 2.38 (s, 3H), 1.02-0.96 (m, 4H); 
13
C NMR (125 MHz, acetone-d
6) δ 180.6, 155.0, 
143.2, 141.3, 140.4, 138.1, 134.6, 126.1, 123.7, 123.1, 120.3, 116.4, 112.3, 29.7, 21.4, 5.7; MS 
(ESI): 449.76 (M+H)
+
. 
Cyclopropanesulfonic acid (3-bromo-5-methyl-phenyl)-methyl-amide (69b). Cyclopropane-
sulfonic acid (3-bromo-5-methyl-phenyl)-amide (68b) (100mg, 0.345mmol, 1equiv) was 
dissolved in 1mL anhydrous dimethyl formamide and cooled to 0°C under N2 atmosphere. 
Sodium hydride (10mg, 0.414mmol, 1.2equiv) was added and the solution was stirred for 10 
min. Methyl iodide (54mg, 0.024mL, 0.380mmol, 1.1equiv) was added slowly, the mixture 
warmed up to room temperature and stirred over night. The mixture was quenched with water, 
extracted three times with diethyl ether, washed 5 times with water, washed with brine, dried 
over sodium sulphate, filtered and evaporated under reduced pressure. No further purification 
was required; yield: 81% (85 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 7.44 (s, 1H), 7.29 (s, 1H), 
7.16 (s, 1H), 3.31 (s, 3H), 2.56-2.54 (m, 1H), 2.33 (s, 3H), 0.99-0.96 (m, 4H). 
Cyclopropanesulfonic acid methyl-(3-methyl-5-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-
yl)-phenyl)-amide (69a). Cyclopropanesulfonic acid (3-bromo-5-methyl-phenyl)-amide (68b) 
(260 mg, 0.86 mmol, 1equiv) was dissolved in 3mL dry dimethyl sulfoxide under N2 
atmosphere. Bispinakolatodiborone (326 mg, 1.28 mmol, 1.5equiv), potassium acetate 
(2.57mmol, 3equiv) and Pd(dppf)Cl2 (0.04 mmol, 0.05equiv) were added. The reaction mixture 
was heated to 80°C over night. Reaction mixture was cooled down to room temperature, 
quenched with water and diethyl ether, filtered over celite, extracted three times with diethyl 
ether, washed three times with water, washed with brine, dried over magnesium sulphate, filtered 
and evaporated under reduced pressure. Purified by CC (dichloromethane pure to 
dichloromethane/methanol 8:2); yield: 50% (150 mg). The product was used in the next step 
without any characterization. 
Cyclopropanesulfonic acid (3-(5-(2,6-difluoro-3-hydroxy-benzoyl)-thiophen-2-yl)-5-methyl-
phenyl)-methyl-amide (69). Cyclopropanesulfonic acid (3-bromo-5-methyl-phenyl)-methyl-
amide (69b) (300 mg, 0.86mmol, 1.00equiv), (5-bromo-2-thienyl)(2,4-difluoro-3-
hydroxyphenyl)-methanone VIII (273 mg, 0.86mmol, 1.00equiv), ceasium carbonate (1113 mg, 
3.42mmol, 4.00equiv) and Pd(PPh3)4 (0.004mmol, 0.005equiv) were suspended in a degased 
mixture of 5mL DME and 5mL water. The mixture was heated to reflux for 3 days under N2 
atmosphere. The mixture was cooled down to room temperature, quenched with water, filtered 
over celite, extracted three times with ethyl acetate, washed one time with water, one time with 
brine, dried over sodium sulphate, filtered and evaporated under reduced pressure. The product 
was purified by CC (hexane/ethylacetate 8:2 to 5:5) followed by preparative TLC 
(dichloromethan/methanol 99:1); yield: 6% (25 mg). 
1
H NMR (500 MHz, acetone-d
6) δ 9.04 (s, 
1H), 7.71 (s, 1H), 7.65-7.63 (m, 2H), 7.58 (s, 1H), 7.30 (s, 1H), 7.23-7.18 (m, 1H), 7.04 (dt, J= 
9.0, 1.9 Hz, 1H), 3.41 (s, 3H), 2.68-2.65 (m, 1H), 2.43 (s, 3H), 1.01-0.90 (m, 4H); 
13
C NMR (125 
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MHz, acetone-d
6) δ 180.7, 154.7, 144.2, 140.9, 138.1, 134.4, 129.3, 126.4, 122.5, 112.4, 38.7, 
21.2, 4.9; MS (ESI): 463.87 (M+H)
+
. 
 
Biological methods. [2,4,6,7-
3
H]-E1 and [2,4,6,7-
3
H]-E2 were bought from Perkin-Elmer, 
Boston. Quickszint Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
Preparation of human 17β-HSD1 and 17β-HSD2. Human 17β-HSD1 and 17β-HSD2 were 
obtained from human placenta according to previously described procedures.
39
 Fresh human 
placenta was homogenized, and cytosolic fraction and microsomes were separated by fractional 
centrifugation. For the partial purification of 17β-HSD1, the cytosolic fraction was precipitated 
with ammonium sulfate. 17β-HSD2 was obtained from the microsomal fraction. 
Inhibition of human 17β-HSD1. Inhibitory activities were evaluated by an established method 
with minor modifications.
39
 Briefly, the enzyme preparation was incubated with NADPH (500 
µM) in the presence of potential inhibitors at 37 
o
C in a phosphate buffer (50 mM) supplemented 
with 20% of glycerol and EDTA (1 mM). Inhibitor stock solutions were prepared in DMSO. The 
final concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was 
started by addition of a mixture of unlabelled- and [2, 4, 6, 7-
3
H]-E1 (final concentration: 500 
nM, 0.15 µCi). After 10 min, the incubation was stopped with HgCl2 and the mixture was 
extracted with diethylether. After evaporation, the steroids were dissolved in acetonitrile. E1 and 
E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 reverse phase 
chromatography column (Nucleodur C18 125/3 100-5, Macherey-Nagel) connected to a HPLC-
system (Agilent 1200 Series, Agilent Technologies). Detection and quantification of the steroids 
were performed using a radioflow detector (Ramona, raytest). The conversion rate was 
calculated after analysis of the resulting chromatograms according to the following equation: 
%conversion = [%E2/(%E2 + %E1)]x100 
Each value was calculated from at least three independent experiments. 
Inhibition of human 17β-HSD2. The h17β-HSD2 inhibition assay was performed similarly to 
the h17β-HSD1 procedure. The microsomal fraction was incubated with NAD+ [1500 µM], test 
compound and a mixture of unlabelled- and [2,4,6,7-
3
H]-E2 (final concentration: 500 nM, 0.11 
µCi) for 20 min at 37 
o
C. Further treatment of the samples and HPLC separation was carried out 
as mentioned above.  
The conversion rate was calculated after analysis of the resulting chromatograms according to 
the following equation: 
%conversion = [%E1/(%E1 + %E2)]x100 
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Preparation of murine and rat 17β-HSD1 and 17β-HSD2. Recombinant mouse and rat 17β-
HSD1 enzyme was produced by transfection of HEK 293 cells with a mouse or rat 17β-HSD1 
expression plasmid [coding sequences NM_010475 (mouse) and NM_012851 (rat) in 
pCMV6Entry vector, OriGene Technologies, Inc.]. 48 hours after transfection cells were 
homogenized by sonication (3 x 10 s) in a buffer containing saccharose (40 mM Tris, 250 mM 
saccharose, 5 mM EDTA, 7 mM DTT, 1 mM PMSF, pH 7.5). Cell lysate was centrifuged (1000 
g, 15 min, 4°C) and 20% glycerol was added to the supernatant before aliquots were frozen and 
stored at -70°C.
47
 Microsomal 17β-HSD2 fractions were obtained from mouse tissues.48 Fresh 
tissue was homogenized and centrifuged. The pellet fraction contains the microsomal 17β-HSD2 
and was used for the determination of E1 formation. 
Inhibition of murine/rat 17β-HSD1. Inhibitory activities of the compounds towards mouse or 
rat 17β-HSD1 were evaluated by an established method with minor modifications.33 The enzyme 
preparation was incubated with inhibitors, NADPH (500 µM) and a mixture of unlabeled- and 
[3H]-E1 (final concentration: 10 nM, 0.15 μCi) for 10 min at 37 oC. Further treatment of the 
samples and HPLC separation was carried out as mentioned above.  
The conversion rate was calculated after analysis of the resulting chromatograms according to 
the following equation: 
%conversion = [%E2/(%E2 + %E1)]x100 
Inhibition of murine and rat 17β-HSD2. The m/r17β-HSD2 inhibition assay was performed 
similarly to the m/r17β-HSD1 procedure. The microsomal fraction was incubated with NAD+ 
[1500 µM], test compound and a mixture of unlabelled- and [2,4,6,7-
3
H]-E2 (final concentration: 
10 nM, 0.15 µCi) for 20 min at 37 
o
C. Further treatment of the samples and HPLC separation 
was carried out as mentioned above.  
The conversion rate was calculated after analysis of the resulting chromatograms according to 
the following equation: 
%conversion = [%E1/(%E1 + %E2)]x100 
ER Affinity 
The binding affinity of selected compounds to ERα and ERβ was determined according to the 
recommendations of the US Environmental Protection Agency (EPA) by their Endocrine 
Disruptor Screening Program (EDSP) using recombinant human proteins. Briefly, 1 nM of ERα 
and 4 nM of ERβ, respectively, were incubated with [3H]-E2 (3 nM for ERα and 10 nM for 
ERβ) and test compound for 16-20 h at 4°C.  
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The potential inhibitors were dissolved in DMSO (5% final concentration). Evaluation of non-
specific-binding was performed with unlabeled E2 at concentrations 100-fold of [3H]-E2 (300 
nM for ERα and 1000 nM for ERβ). After incubation, ligand-receptor complexes were 
selectively bound to hydroxyapatite (83.5 g/L in TE-buffer). The bound complex was washed 
three times and resuspended in ethanol. For radiodetection, scintillator cocktail (Quickszint 212, 
Zinsser Analytic, Frankfurt) was added and samples were measured in a liquid scintillation 
counter (1450 LSC & Luminescence Counter, Perkin Elmer). 
 From these results the percentage of [3H]-E2 displacement by the compounds was calculated. 
The plot of % displacement versus compound concentration resulted in sigmoidal binding 
curves. The compound concentrations to displace 50% of the receptor bound [3H]-E2 were 
determined. Unlabeled E2 IC50 values were determined in each experiment and used as 
reference. The E2 IC50 values accepted were 3±20% nM for ERα and 10±20% nM for ERβ. 
Relative Binding Affinity was determined by applying the following equation: RBA [%] = (IC50 
(E2)/IC50 (compound)) ∙ 100 [*]. This results in an RBA value of 100% for E2.  
After the assay was established and validated, a modification was made to increase throughput. 
Compounds were tested at concentrations of 1000 ∙ IC50 (E2). Compounds with less than 50% 
displacement of [3H]-E2 at a concentration of 1000 ∙ IC50 (E2) were classified as RBA <0.1%. 
Metabolic stability 
For evaluation of phase I and II metabolic stability 1 µM compound was incubated with 1 mg/ml 
pooled mammalian liver S9 fraction (BD Gentest), 2 mM NADPH regenerating system, 1 mM 
UDPGA and 0.1 mM PAPS at 37°C for 0, 15 and/or 60 minutes. The incubation was stopped by 
precipitation of S9 enzymes with 2 volumes of cold acetonitrile containing internal standard. 
Concentration of the remaining test compound at the different time points was analyzed by LC-
MS/MS. For evaluation of phase I metabolic stability the assay was conducted in absence of 
UDPGA and PAPS. 
MTT-Cytotoxicity assay 
The number of living cells was evaluated measuring the reduction of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazoliumbromide (MTT). Experiments were performed in 96-well cell culture 
plates in DMEM supplemented with 10% FCS. Cells were incubated for 66 h with 6.25, 12.50, 
25, 50, and 100 µM of test compound at 37 
◦
C in a humidified atmosphere at 5% CO2. For 
cleavage reaction MTT-solution (5mg/mL in PBS) was added and incubation was continued for 
another 66 h. Reaction stop and cell lysis were carried out by addition of sodium dodecyl 
sulphate (SDS) in 0.01N HCl (10%). The produced blue formazan was quantified 
spectrophotometrically at 590nm as described by Denizot and Lang
49
 with minor modifications. 
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Physicochemical properties determination 
The logP and pKa values were calculated using the ACD/Labs Percepta software. The logarithm 
of partition constant P (logP) was calculated using the “GALAS” method (Global, Adjusted 
Locally According to Similarity). The program predicts clogP by comparing the molecule with 
structural similarity of molecules where experimental data are known.  
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Spplemantary table S1: HPLC Purity Control of Final Compounds 
The purity of the compounds was evaluated by LC/MS. The Surveyor®-LC-system consisted of 
a pump, an auto sampler, and a PDA detector. Mass spectrometry was performed on a TSQ® 
Quantum (ThermoFisher, Dreieich, Germany). The triple quadrupole mass spectrometer was 
equipped with an electrospray interface (ESI). The system was operated by the standard software 
Xcalibur®. A RP C18 NUCLEODUR® 100-5 (3 mm) column (Macherey-Nagel GmbH, 
Dühren, Germany) was used as stationary phase. All solvents were HPLC grade. In a gradient 
run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) was increased from an 
initial concentration of 0% at 0 min to 100 % at 15 min and kept at 100 % for 5 min. The 
injection volume was 15 µL and flow rate was set to 800 µL/min. MS analysis was carried out at 
a needle voltage of 3000 V and a capillary temperature of 350 °C. Mass spectra were acquired in 
positive mode from 100 to 1000 m/z and UV spectra were recorded at the wave length of 254 
nm. 
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Spplemantary table S1: HPLC Purity Control of Final Compounds 
Comd Rt 
(min) 
HPLC purity 
(≥ %) 
Comd Rt 
(min) 
HPLC purity 
(≥ %) 
Comd Rt 
(min) 
HPLC purity  
(≥ %) 
1 7.90 98 2 8.27 95 3 11.57 97 
4 13.37 95 5 11.53 97 6 11.84 95 
7 13.69 96 8 11.96 98 9 11.71 98 
10 10.98 95 11 10.93 95 12 10.96 95 
13 11.99 99 14 12.00 95 15 12.15 97 
16 12.20 97 17 12.35 97 18 11.85 96 
19 12.23 96 20 12.07 96 21 12.88 97 
22 13.12 97 23 11.44 96 24 12.05 99 
25 10.70 97 26 12.32 99 27 13.06 98 
28 11.75 96 29 10.57 95 30 13.07 98 
31 13.80 95 32 13.66 95 33 12.83 96 
34 12.96 98 35 11.28 99 36 13.20 95                                                                                                                                                                                                                         
37 11.09 98 38 13.60 95 39 11.45 99 
40 12.77 95 41 11.67 97 42 14.28 97 
43 11.97 96 44 12.04 95 45 13.94 95 
46 13.82 95 47 11.90 95 48 12.61 99 
49 12.88 99 50 8.60 99 51 10.98 96 
52 7.29 95 53 7.92 96 54 15.55 97 
55 12.93 97 56 9.26 98 57 8.83 95 
58 13.99 98 59a 12.73 95 59 10.56 95 
60 9.93 97 61 8.48 99 62 13.11 99 
63 12.38 99 64 12.18 99 65 10.75 95 
66 12.54 98 67 11.33 97 68 11.59 95 
69 13.75 95       
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4 Discussion and Conclusions 
 
17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is a promising target for the treatment 
of estrogen-dependent diseases (EDD) such as breast cancer and endometriosis. The aim of this 
thesis was to obtain more insight in the structural activity relationships (SAR) of bicyclic 
substituted hydroxyphenylmethanone compound class (BSHs), one of the most potent 17β-HSD1 
inhibitor classes described by the Hartmann group (figure 1). 
SO R1
HO
R1, R2: e.g. H, OH, O-alkyl, CN, hetaryl
R2
 
Figure 1. Bicyclic substituted hydroxyphenylmethanones: General structure. 
In order to obtain a suitable candidate which could be used to conduct a proof of principle 
(PoP) study in an animal (rodent) disease model for EDD, the biological properties of the most 
interesting compounds were further investigated aiming at preferably low affinity to the estrogen 
receptors α and β (ERα and β), metabolic stability (S9 fraction), and inhibition of rodent 17β-
HSD1 enzyme. 
Chapter 3.I reports about the elucidation of SAR in the class of BSHs. This chapter describes 
design, synthesis, and biological evaluation of a series of 28 compounds. Furthermore, 
computational methods were used in order to elucidate the binding modes of the novel inhibitors 
with two linker functions. 
Starting point for the design of these compounds were our conceptions concerning the binding 
mode of BSHs (figure 2). 
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Figure 2. Schematic H-bond interactions of BSHs with 17β-HSD1 
Modifications have been made in several positions of the inhibitor in order to evaluate the 
structure activity relationships in this compound class (figure 3, modifications a-c). Moreover, to 
establish additional interactions to Tyr218 and Ser222 a second linker function was introduced 
between the heterocycle and the hydroxyphenyl moiety (ring C). 
SO
R1 = H, CH3, Cl, COOCH3, COOH,
        NHR2 (R2: e.g. H, acyl, sulfonyl, alkyl)
X Y Y
S S
O
O
HO
Compounds I.1-I.16
Modification (a)
Modification (b)
A
B C
X = S, CH2 Y = H, F
R1
R3 = 3-CH2OH, 4-CH2OH, 3-O-alkyl
Compounds I.21-I.24
Compounds I.17-I.20
Compounds I.25-I.28
Modification (d)
Modification (c)
R3
 
Figure 3. Design of potential inhibitors I.1-I.28. 
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In modification a, an appropriate replacement of the hydroxy-group at the benzoyl moiety 
(ring A), which bears the risk to lead to phase II metabolism issues, were investigated. The 
substituents were chosen (H, CH3, Cl, CO2CH3, CO2H and NH2; Compounds I.1-I.6 
respectively) taking into account the Craig plot (variation of the size, lipophilicity, and electronic 
properties). Unfortunately, these compounds were inactive or showed only marginal inhibition of 
h17β-HSD1 compared to the reference compounds A or B (figure 4). From this series, compound 
I.6 showed 24 % inhibition @ 1 µM of h17β-HSD1 enzyme. Therefore, attempts were made to 
enhance the inhibitory activity of compound I.6 by modulating the hydrogen bond donating 
properties of the amino group (compounds I.7-I.16). Probably due to the bulkiness of the 
introduced group, a complete loss of activity obtained. 
In contrast to the OH-group of the benzoyl moiety (ring A), replacement of the OH-group of 
the phenyl ring C by different small or bulky groups (compounds I.21-I.24, modification c) led 
to highly active compounds (IC50 values = 90 to 157 nM). 
S
HO
O S
HO
O
O
% inhibition @ 1 µM 
     (h17-HSD1 )
S
HO
O
OH
A, 80 %                                     B, 88 %                                                    C, 89 %
 
Figure 4. Reference compounds of modifications a-d. 
 
To complete the SAR and estimate the validity of the docking results, we replaced the keto-
linker function by different linker groups, namely CF2, C=S, CH2, C=CH2 (modification b, 
compounds I.17-I.20. This modification had a strong impact on biological activity, depending on 
the nature of the linker group. Only the thioketo-analog I.18 showed comparable activity (75 % 
inhibition @ 1 µM of h17β-HSD1 enzyme) to the reference compound A (figure 4). The 
biological data obtained for compounds I.17-I.20 is in agreement with former molecular docking 
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studies which suggest a bifurcated H-bond between the carbonyl group and the OH-groups of 
Ser142 and Tyr155. 
A second linker containing oxygen was selected to possibly establish additional hydrogen 
bond interactions with the OH groups of Tyr218 and Ser222 (compounds I.26 and I.28, 
modification d). Compounds bearing an additional linker group (I.25 and I.26, figure 5), showed 
comparable IC50-values (IC50 = 104 and 275 nM, respectively) for the inhibition of h17β-HSD1. 
 
S
S
HO
O
HO
S
S
HO
O
HO
O
O
I.25 I.26  
Figure 5. Structures of compounds I.25 and I.26 
 Docking results suggested a different binding mode for the sulfone I.26 compared to the 
BSHs class which precludes the establishment of these hydrogen bond interactions (figure 6). 
Interestingly, in contrast to most of the compound classes described by us, compound I.25 turned 
to be an inhibitor of murine 17β-HSD1 (20 % inhibition @ 1 µM; C: 10%). 
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Figure 6. Compounds I.25 and I.26, docked into human 17β-HSD1 (PDB: 1FDT). Upper left: 
Cofactor NADPH. 
In contrast to most other classes of 17β-HSD1 inhibitors described by us, both BSHs and the 
thioether classes contain members which not only are strong inhibitors of the human enzyme but 
also showed inhibition of the murine ortholog (unpublished results). Since BSHs showed better 
selectivity over m17β-HSD2 compared to the thioether class, we focused on the former for 
further optimization (chapter 3.II) in order to obtain a suitable candidate which could be used to 
conduct a PoP study in an animal disease model for EDDs. 
Basically, existing BSHs have two important drawbacks: a) low m17β-HSD1 inhibition and b) 
low metabolic stability (phase I and/or phase II). Thus, the aim of this part was to obtain a 
potent, selective, and metabolically stable (S9 fraction) h/m 17β-HSD1 inhibitor. In addition, the 
establishment of favorable in vitro ADME parameters (lipophilicity, solubility) was taken into 
account. 
Starting point in the design of this part were BSHs I and II (figure 7). 
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Figure 7. Design of Synthesized Compounds II.1 – II.69 
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Design step I 
Variations in ring C of the lead compound I led to introduction of the sulfonamide moiety in 
the m-position (e.g. compound II.7) which is clearly favored over the p-position (e.g. compound 
II.4), indicating that there is no space in the p-position for bulky groups. Furthermore, the 
presence of the sulfonamide group (compound II.10) led to slightly increased inhibitory activity 
towards h17β-HSD1 compared to its carbonic acid amide analog (compound II.11), table 1. 
Table 1. Inhibition of human/murine 17β-HSD1 and human 17β-HSD2 by compounds 
II.1, II.2, II.4, II.7, II.10 and II.11. 
II.1, II.2 II.4, II.7, II.10
1
2 3
4
56
A
II.11
SO
HO
SO
HO
SO
HO
NH
O
HO
NH
S
O
O
R
R
B C
D
1
2 3
4
56
 
Comd Ring C R IC50 [nM]
a
 SF
d
 % Inhibition 
@ 1 µM
a
 
h17β-
HSD1
b
 
h17β-
HSD2
c
 
m17β-HSD1e 
II.1 - 4-NH2 145  120  0.8  4 
II.2 - 3-NH2 77 %
f
 68 %
f
 - n.d 
II.4 4 4-Br-2-OCF3 169 716 4.2 n.d 
II.7 3 4-Br-2-OCF3 8 199  25.0  21 
II.10 3 3-OH 16  88  5.4  26 
II.11 - H 33 159  4.8  26 
a
 Mean value of three determinations, standard deviation less than 15%. 
b
 Human placenta, 
cytosolic fraction, substrate [
3
H]-E1, 500 nM, cofactor NADH, 500 µM. 
c
 Human placenta, 
microsomal fraction, substrate [
3
H]-E2, 500 nM, cofactor NAD
+
, 1500 µM. 
d
 Selectivity factor: 
IC50(17β-HSD2) / IC50(17β-HSD1). 
e
 Mouse recombinant enzyme, expressed in HEK 293, 
substrate [
3
H]-E1, 10 nM, cofactor NADH, 500 µM. 
f
 Inhibition @ 1µM (inhibitor concentration).
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 In addition to low metabolic stability and low m17β-HSD1 inhibition, e.g. compound II.7 (% 
remaining after 15 min = 47, S9 fraction) and (% inhibition @ 1 µM = 21), the high molecular 
weight sulfonamide compounds (ABCD ring system, fig. 7) did not show advantage over the 
small molecules (ABC ring system). This was a motivation for us to focus on the three ring 
compounds in an attempt to improve both m17β-HSD1 inhibition and s9 metabolic stability. 
 
Design step II 
From our previous work, it was known that only minor structural variations in ring A (fig. 7) 
are tolerated by the enzyme. Therefore, we introduced fluorine as an electron withdrawing group 
(EWG) or methyl as a bulky group in an attempt to decrease the liability of this OH-group - 
which is very important for activity inhibitory and could not be replaced (see chapter 3.I) - 
against phase II metabolism.  
In contrast to the methyl group, which led to a strong decrease in h17β-HSD1 inhibition and 
reversed the selectivity over type 2 enzyme, fluorine showed a strong increase of activity 
inhibitory towards the type 1 enzyme, though with the expense of losing selectivity over h17β-
HSD2 (e.g. compounds II.30-II.34, table 2). 
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Table 2. Inhibition of human/murine 17β-HSD1 and human 17β-HSD2 by 
compounds II.30-II.34. 
 
II.30-II.34
SO
HO
R1
R2
R3
F
F
 
 
Comd R1 R2 R3 IC50 [nM]
a
 SF
d
 % Inhibition 
@ 1 µM
a
 
17β-
HSD1
b
 
17β-
HSD2
c
 
m17β-HSD1e 
II.30 H H H 213
g
 177
g
 
0.8 
n.d 
II.31 CH3 H H 3427 299 0.09 5 
II.32 CH3 H CH3 20 %
 f
 66 %
 f
 - n.d 
II.33 F H H 11
h
 8
h
 0.7 n.d 
II.34 F F H 3.5 9 2.5 41 
a-f
 See table 1. 
g
 Calculated IC50(IC50(Logit)) = test concentration ((100-%inh.)/%inh.). 
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This may be explained by the effect of the fluorine on the hydrogen bonding properties of the 
OH-group or by interacting with carbon atoms of carbonyl groups of the target. 
Concerning ring C, which was investigated in the next step, we found that the OH-group in p-
position is important to enhance the selectivity over the type 2 enzyme. Therefore, we shielded 
this OH-group by bulky and/or EWGs in an attempt to protect it against phase II metabolism. By 
applying this strategy, we obtained the most potent non-steroidal h17β-HSD1 inhibitors 
described so far (IC50-values in the picomolar range, e.g. compounds II.42-II.47). On other hand, 
this series showed a significant increase in m17β-HSD1 inhibition. (Table 3) 
Table 3. Inhibition of human/murine 17β-HSD1 and human 17β-HSD2 by 
compounds II.42-II.47, II.54, II.55 
 
II.42-II.51
SO
HO
F
F
R2
II.54, II.55
SO
HO
R1
Cl
R1
R3
Cl
 
 
Comd R1 R2 R3 IC50 [nM]
a
 SF
d
 % Inhibition 
@ 1 µM
a
 
17β-
HSD1
b
 
17β-
HSD2
c
 
m17β-HSD1e 
II.42 Cl OCH3 Cl 0.5 41 82 43 
II.43 Cl OH Cl 2.4 39 16 23 
II.44 Cl OCH3 CH3 0.3 7 23 32 
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II.45 Cl OH CH3 0.2 6 30 43 
II.46 CH3 OCH3 CH3 0.9 18 20 59 
II.47 CH3 OH CH3 0.4 7 20 77 
II.54 OCH3 - - 6.0 247 40.4 n.d 
II.55 OH - - 31
g
 255
g
 8.3 n.d 
a-e
 See table 1. 
g
 Calculated IC50(IC50(Logit)) = test concentration ((100-%inh.)/%inh.). 
Apparently, the approach to enhance metabolic stability by introducing fluorine (in ring A, 
fig. 7) and by shielding the OH-group (ring C, fig. 7) by two chlorine atoms as EWG and bulky 
groups was successful as evidenced by the biological data of compounds II.42-II.47 and II.55 
(table 4). 
Table 4. Metabolic stability of selected compounds using human 
hepatic S9-fraction or liver microsomes. 
Comd % remaining after 
15 min             60 min 
Comd % remaining after 
15 min 60 min 
 S9
a
 S9
a
  S9
a
 Phase I
b
 
II.42 56 40 II.46 29 - 
II.43 91 72 II.47 6 61 
II.44 49 13 II.55 21 - 
II.45 7     
a
 human hepatic S9 fraction: (1 mg/mL mixture of microsomes and cytosol of 
hepatocytes) supplemented with NADPH, UDPGA and PAPS. 
b
 Phase I: 
supplemented only with NADPH. 
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Design step III 
Biological data suggested that both the presence of the sulfonamide moiety (design step I) and 
a fluorinated A ring (design step II, fig. 7) are beneficial for inhibition of mouse 17β-HSD1. 
Combining design steps I and II in design step III, in which fluorinated-sulfonamide type 
inhibitors synthesized, led to the most active m17β-HSD1 inhibitors in this study (compounds 
II.61-II64, table 5). 
Table 5. Inhibition of human/murine 17β-HSD1 and human 17β-HSD2 by 
compounds II.61-II64 
 
II.61
SO
HO
NH2
II.62-II.64
SO
HO
NH
SO
O
F
F
F
F
R2
R1
 
 
Comd R1 R2 IC50 [nM]
a
 SF
d
 % Inhibition 
@ 1 µM
a
 
17β-
HSD1
b
 
17β-
HSD2
c
 
m17β-HSD1e 
II.61 - - 10 25 2.5 30 
II.62 OCF3 Br 1.7  17 10.0 71 
II.63 OCF3 H 3.1 13 4.1 91 
II.64 CF3 H 2.3 6 2.5 97 
a-e
 See table 1.  
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Last step in the design was the improvement of the ADME parameters concerning solubility 
and lipophilicity. The tolerance of the target protein towards substitution of the phenyl ring (ring 
C, fig. 7) allowed for the introduction of different hydrophilic heterocyclic substituents (e.g. 
compounds II.56-II.60, table 6).  
Table 6. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds II.56-II.60 
and II.59a. 
II.56-II.58
SO
HO
F
F
R1
Cl
N
N
R2
II.59a, II.59, II.60
SO
O
F
F
R1
Cl
N
N
N
R2
 
Comd R1 R2 IC50 [nM]
a
 SF
d
 LogP
f
 LogD@ 
pH7.4
e
 
17β-HSD1b 17β-HSD2c 
II.56 OCH3 COCH3 1.4 21 15.0 3.21 3.1 
II.57 OH COCH3 2.1 11 5.2 2.63 2.2 
II.58 OCH3 H 4.7 26 5.5 3.41 1.7 
II.59a OCH3 COCH3 26
f
 21
f
 0.8 3.34 3.3 
II.59 OCH3 H 2.1 8.8 4.2 3.44 3.3 
II.60 OH H 17
f
 26
f
 1.5 2.86 2.3 
a-d
 See table 1. 
e
 Calculated LogP and LogD@ pH 7.4 data. 
f
 Calculated 
IC50(IC50(Logit)) = test concentration ((100-%inh.)/%inh.). 
Discussion and Conclusions 
166 
 
Selected compounds were submitted to further biological evaluation in attempt to identify a 
suitable candidate for PoP study. Parameters under evaluation included: affinity to the estrogen 
receptors α and β, inhibition of rat 17β-HSD1 and cytotoxicity. Compound II.47 seems to be a 
possible candidate for PoP study with metabolic stability drawback. Therefore, this compound 
should be submitted to further optimization as a lead compound. 
In conclusion, a sharp SAR for BSHs is obtained, one of the most active classes of non-
steroidal 17β-HSD1 inhibitors. Through this investigation, the most potent 17β-HSD1 inhibitors 
up to date with good selectivity towards the type 2 enzyme and no or little affinity to ER α and β 
were designed. In addition, we could significantly increase the activity in both murine and rat 
17β-HSD1 enzyme, which is essential for a PoP study in rodents. Furthermore, compound II.43 
(IC50 = 2.5 nM, SF = 16) showed a very good metabolic stability (human S9 fraction) issue with 
72 % remaining after 60 min. 
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